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Abstract 
At present, cisplatin (cis-diamminodichloroplatinum(II)) is one of the most largely employed 
anticancer drugs, used especially for the treatment of testicular cancer and, in combination with other 
drugs, of ovarian, small cell lung, bladder, brain, and breast tumors. Anyway, despite its high 
effectiveness, it exhibits severe drawbacks, as normal tissue toxicity (in particular, nephrotoxicity) 
and intrinsic or acquired resistance to the treatment. To overcome these problems, new Pt- and other 
metal-based complexes were designed and tested as anticancer drugs. In particular, since gold-based 
complexes were linked for centuries to the treatment of rheumatoid arthritis (due to their 
antiinflammatory and immunosuppressive properties), they were also tested for their antiproliferative 
properties..  
In the last decade in our research group, some Au(III)-dithiocarbamato derivatives were synthesized, 
characterized and tested, showing outstanding antiproliferative activity on human cancer cells.  
Starting from the promising results obtained both in vitro and in vivo for the “first generation" 
compounds of formula [AuIIIX2(dtc-L)] (X= Cl, Br; dtc=dithiocarbamato; L= dimethylamine, 
pyrrolidine, N-methyl glycine (Sar) esters), a "second generation" of complexes was designed to 
improve bioavailability, selectivity and cellular uptake. In particular, the dithiocarbamato moiety was 
functionalized with different oligopeptides of general formula [AuIIIX2(dtc-Sar/Aib-(AA)n)] (AA= 
different aminoacids), to be recognized and uptaken by specific peptide transporters called PEPTs 
(PEPT1 and PEPT2), predominantly present in epithelial cells of small intestine, mammary glands, 
lung, choroid plexus and kidney, and overexpressed in some tumor types. A unique feature of these 
transporters is their capability for sequence-independent transport of most possible di- and 
tripeptides, thus representing excellent targets for the delivery of pharmacologically-active 
peptidomimetics such as β-lactam antibiotics and some angiotensin converting enzyme (ACE) 
inhibitors. Interestingly, these complexes demonstrate high capability to strongly inhibit tumor cells 
growth by exploiting a mechanism of action different from the clinically-established platinum drugs, 
overcoming drawbacks without any observed cross-resistance. 
In this PhD thesis work, new Au(III)-peptidodithiocarbamato complexes were synthesized and fully 
characterized, mainly by means of elemental and X-ray analysis, mono- and bidimensional NMR, 
FT-IR and UV-Vis spectroscopy. 
The water-insoluble compounds, previously dissolved in DMSO, showed high reactivity in aqueous 
conditions, generally undergoing hydrolysis of the bromido ligands which leads to the formation of 
the water insoluble dihydroxo derivative. Nevertheless, when analyzing more complex environments, 
as cell culture medium, a stabilizing effect seemed to be exerted by the components of the medium 
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itself (e.g., proteins, organic molecules), as confirmed by interaction studies with the serum carrier 
protein BSA (Bovine Serum Albumin). 
The antiproliferative activity of the complexes was tested on different human cancer cell lines, 
representative of different cancer types (e.g. lung, ovary, breast), showing promising 
cytotoxicproperties. Furthermore, their antitumor activity was confirmed in vivo on breast MDA-MB-
231 human xenografts, while their toxicological profile, preliminary evaluated ex vivo, was similar to 
the "first generation" compounds. 
To overcome the solubility problem in aqueous conditions and to avoid the intrinsic toxicity of 
DMSO (normally used as primary solvent), new solubilizing methods were explored. In particular, 
micelles based on Pluronic F127 and liposomes based on DPPC phospholipids were prepared, 
characterized and tested in vitro. These systems were proved to stabilize the compounds in 
physiological conditions, without affecting their antiproliferative activities. Moreover, micelles 
functionalized with CCK8 octapeptide were tested as targeting moieties to be selectively delivered to 
cancerous cells overexpressing the CCK-receptors. In this case, the GI50 values of the encapsulated 
compounds were improved of one order of magnitude. 
To achieve more information about their mechanism of action, the interaction in vitro with some 
purified enzymes was performed, confirming that the complexes inhibit all the three enzymatic 
functions of the proteasome, together with the activity of PARP-1 enzyme.  
More detailed studies, taking into account the kinetics of gold uptake by cells and the real-time 
inhibition of cell growth and adhesion, suggested that the complexes probably exert their cytotoxic 
effect on cells in the 4-5 h after administration, acting probably at the membrane level. 
All together these results highlight the promising properties of the complexes as anticancer agents, 
and put the basis for the pursuance of the preclinical characterization, including deeper studies of 
their pharmacological properties and biological activity. 
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Riassunto 
Il cisplatino (cis-diamminodicloroplatino(II)) è tuttora uno dei farmaci antitumorali più utilizzati, 
impiegato in particolare per il trattamento del tumore al testicolo e, in combinazione con altri 
chemoterapici, per la cura del cancro all'ovaio, al polmone a cellule piccole, alla vescica, al cervello e 
alla mammella. Nonstante la sua efficacia, il suo utilizzo viene fortemente limitato dall'insorgenza nei 
pazienti di effetti collaterali molto gravi, come l'elevata tossicità verso i tessuti sani (in particulare 
nefrotossicità) oltre che da meccanismi di resistenza al trattamento o acquisiti dopo alcuni cicli di 
terapia. 
Per superare questi inconvenienti, sono stati sintetizzzati e testati come potenziali farmaci 
antitumorali nuovi complessi sia a base di platino che di altri metalli di transizione.  
In particolare, alcuni composti di oro, già utilizzati da molti anni per la cura dell'artrite reumatoide 
(grazie alle loro proprietà anti-infiammatorie e immunosuppressive) sono stati testati per le loro 
proprietà antiproliferative, aprendo la strada a una nuova classe di potenziali composti antitumorali. 
Da circa un decennio nel nostro gruppo di ricerca sono stati sintetizzati, caratterizzati e testati nuovi 
complessi ditiocarbammici di oro(III), che hanno dimostrato promettenti proprietà antiproliferative su 
diverse linee cellulari tumorali umane. I promettenti risultati ottenuti sia in vitro che in vivo per 
alcuni composti di “prima generazione” del tipo [AuIIIX2(dtc-L)] (X= Cl, Br; dtc=ditiocarbammato; 
L= dimetilammina, pirrolidina, esteri della N-metilglicina (Sar)), hanno portato al design di una 
nuova serie di complessi di "seconda generazione", al fine di aumentarne la biodisponibilità, la 
selettività e l'uptake cellulare.  
A questo scopo, sono stati preparati complessi ditiocarbammici funzionalizzati con diversi 
oligopeptidi, aventi formula generale [AuIIIX2(dtc-Sar/Aib-(AA)n)] (AA = diversi amminoacidi), 
affinchè potessero essere riconosciuti e trasportati da specifici trasportatori di membrana denominati 
PEPT (PEPT1 and PEPT2). Queste proteine risultano prevalentemente espresse nelle cellule epiteliali 
dell'intestino tenue, nella mammella, nel polmone, nel plesso coroideo e nei reni, e vengono in 
particolare sovraespresse in alcuni tipi di cellule tumorali. La principale caratteristica di queste 
biomolecole è la loro capacità di trasportare la maggior parte dei di- e tri-peptidi naturali, 
indipendentemente dalla loro sequenza, dimostrandosi quindi degli eccellenti target per il 
riconoscimento ed il trasporto selettivo di composti peptido-mimetici farmacologicamente attivi, 
quali ad esempio antibiotici β-lattamici ed alcuni inibitori di enzimi convertitori dell'angiotensina 
(ACE).  
I complessi sintetizzati hanno mostrato ottime proprietà antiproliferative, esercitando un meccanismo 
d'inibizione della crescita tumorale diverso da quello normalmente descritto per i farmaci a base di 
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platino comunemente utilizzati in chemoterapia clinica, superandone anche i tipici effetti collaterali e 
i problemi di resistenza crociata al trattamento. 
In questo lavoro di tesi sono stati sintetizzati nuovi complessi di Au(III) con leganti 
peptidoditiocarbammici, i quali sono stati ampiamente caratterizzati attraverso analisi elementare e di 
diffrazione a raggi-X su monocristallo, NMR mono- e bidimensionale, FT-IR e spettroscopia Uv-Vis.  
I complessi non-idrosolubili (previa dissoluzione nella minima quantità di DMSO) si sono dimostrati 
molto reattivi in soluzioni acquose caratterizzate da diverse condizioni di pH o di composizione 
salina. Generalmente essi tendono ad idrolizzare, scambiando con l'acqua un legante bromuro e 
portando alla formazione del di-idrosso derivato, insolubile in acqua. Andando però ad analizzare 
ambienti più complessi, come ad esempio il mezzo di coltura cellulare, è stato notato un effetto 
stabilizzante derivante probabilmente dalla presenza di particolari componenti del mezzo stesso (e.g. 
proteine, molecole organiche), come confermato anche da studi di interazione con la proteina del 
siero BSA (Bovine Serum Albumin). 
L'attività antiproliferativa dei complessi è stata testata su diverse linee cellulari di tumori umani, 
rappresentative di diversi tipi tumorali (e.g. polmone, ovaio, mammella), mostrando promettenti 
attività citotossiche. La loro attività antitumorale è stata ulteriormente confermata in vivo sul tumore 
xenografico umano alla mammella MDA-MB-231, mentre una valutazione preliminare del profilo 
tossicologico effettuata ex vivo ha messo in luce un'analogia con i risultati ottenuti per uno degli 
analoghi composti di "prima generazione". 
Per superare il problema della scarsa solubilità in soluzioni acquose, oltre che per evitare la tossicità 
intrinseca del DMSO (normalmente utilizzato per sciogliere i complessi), sono stati valutati nuovi 
metodi di dispersione. In particolare, sono state preparate, caratterizzate e testate in vitro sia micelle a 
base di Pluronico F127 che liposomi costituiti da fosfolipidi DPPC. Questi sistemi si sono dimostrati 
in grado di solubilizzare e stabilizzare i complesi in condizioni fisiologiche, senza tuttavia alterarne le 
proprietà antiproliferative. Inoltre, micelle funzionalizzate con l'octapeptide CCK8 sono state testate 
come nanosistemi per il trasporto selettivo verso le cellule tumorali che sovraesprimono il recettore 
specifico CCK-R. In questo caso i valori di GI50 registrati sono risultati di un ordine di grandezza 
inferiori rispetto allo stesso sistema non funzionalizzato.  
Per ottenere maggiori informazioni sul meccanismo d'azione dei complessi, ne è stata in seguito 
valuatata la capacità di inibire in vitro alcuni enzimi selezionati per la loro rilevanza nell'attivazione 
della risposta apoptotica nelle cellule tumorali. I composti si sono dimostrati in grado di inbire tutte e 
tre le funzioni del proteasoma, inibiendo contemporaneamente anche l'attività dell'enzima PARP-1.  
Studi più dettagliati hanno in seguito riguardato la cinetica di uptake dei complessi di oro da parte 
delle cellule tumorali, e la valutazione in tempo reale del profilo dell'inibizione della crescita 
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cellulare. I risultati ottenuti hanno suggerito che i complessi esplicano la loro attività citotossica nelle 
prime 4-5 h dalla somministrazione, agendo probabilmente a livello della membrana cellulare. 
Questi risultati sottolineano le promettenti proprietà dei composti come potenziali agenti 
antitumorali, e gettano le basi per il proseguimento della loro caratterizzazione preclinica, la quale 
prevede una più approfondita valutazione delle loro proprietà farmacologiche e della loro attività 
biologica. 
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Aim of the work 
The present work is mainly focused on the synthesis of new gold(III)-oligopeptide-dithiocarbamato 
derivatives for anticancer therapy, with the evaluation of their biological activity and stability in 
physiological conditions. In addition, we tried to gain insights in the understanding of their 
mechanism of action. 
The rationale of this research project springs from previous results obtained in our research group on 
analogous gold(III)-dithiocarbamato aminoacid derivatives. Indeed, "first generation" compounds of 
type [AuIIIX2(dtc)] (X=Cl, Br; dtc= various dithiocarbamates) were previously analyzed, showing 
promising antiproliferative activity both in vitro on a large panel of cancer cell lines, and in vivo on 
xenograft tumors1,2. Moreover, the toxicity profiles detected in vivo for these compounds resulted 
very promising if compared with cisplatin reference drug3. 
To improve their selectivity and their therapeutic effectiveness, a new "second generation" series of 
complexes was designed to specifically target membrane receptors overexpressed in cancerous cells.  
In particular, the dithiocarbamato ligand was specifically functionalized with di/tripeptides in order to 
target PEPT receptors, which are present in humans in two isoforms (PEPT1 and PEPT2). They are 
proton-coupled integral membrane proteins that cotransport H+ and substrates (as di- and tripeptides) 
across cell membranes. The driving force for the accumulation of the substrate in the cell against its 
concentration gradient is provided by an inwardly directed proton gradient. They are expressed in 
different tissues like small intestine, kidney, pancreas, bile duct, liver, mammary glands, lung and 
choroid plexus and are overexpressed in tumor cells, so they can be targeted for specific delivery of 
the therapeutic agents into the tumor site.  
In addition to their physiological substrates, PEPTs are also responsible for membrane transport of 
many pharmacologically active peptidomimetic drugs and prodrugs, such as β-lactam antibiotics, 
angiotensin-converting-enzyme (ACE) inhibitors, renin inhibitors, thrombin inhibitors, or the 
anticancer drug bestatin, owing to their structural resemblance to di- and tri-peptides4,5. 
Starting from this rational, the experimental work mainly focused on the synthesis and the evaluation 
of the biological behavior of some new gold(III) dithiocarbamato derivatives of dipeptide ligands, for 
the selective targeting of PEPT receptors (IT01-05, Figure I), in comparison with a platinum-based 
reference drug and some "first generation" gold compounds (cisplatin, AuL12, Figure I). 
Considering the possible application as anticancer compounds, their stability was analysed in 
different aqueous conditions (after dissolving the compounds in DMSO), starting from distilled water 
to saline solution NaCl 0.9%, and from PBS buffer pH=7.4 to cell culture medium. 
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Figure I: molecular structures of cisplatin and gold(III)-dithiocarbamato derivatives analyzed in this project.  
 
The ability of the compounds to interact with blood transport proteins was further evaluated, 
choosing the BSA (Bovine Serum Albumin, homologous of the human isoform) as a model for the 
studies. The interaction was analyzed by means of different spectroscopic techniques, in order to 
assess the presence of a stabilizing interactions between the protein and our compounds, which can 
eventually account for an enhanced stability of the complexes in the blood stream, accompanied by 
an increased bioavailability.  
The in vitro antiproliferative activity of the compounds was screened on a large panel of human 
cancer cell lines, representative of different tumor types. In addition, toxicological studies were 
performed through an ex vivo set of experiments, to evaluate the toxicity on healthy rat tissues from 
liver, kidney and colon, along with preliminary in vivo experiments on human xenografts. 
Because of the very poor solubility of the dithiocarbamato gold(III) complexes in physiological 
conditions, all the experiments were carried out pre-dissolving the compounds in DMSO, as above 
mentioned. This procedure is normally adopted also for the in vitro testing, keeping the DMSO 
concentration down below the 1% v/v to avoid effects deriving from the intrinsic toxicity of the 
organic solvent. However, for the forthcoming in vivo tests, a more biocompatible system to 
solubilize our compounds has been studied.  
To overcome the complexes solubiliy problems, micellar and vesicular systems based on non- or 
low-toxic amphiphilic components were prepared and tested on cancer cell lines, allowing the 
exclusion of possible drawbacks deriving from the use of organic solvents.  
Aim of the work 
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In particular, micelles based on Pluronic F127 (EO98PO57EO98; EO= ethylene oxide; PO=propylene 
oxide) were prepared and tested in comparison with vesicular systems derived from DPPC 
(dipalmitoylphosphatidylcholine) phospholipids. 
After preparation and characterization of the different dipersant systems, the stability of the loaded 
compounds and their cytotoxic activity were tested. Furthermore, targeted delivery of a "first 
generation" gold(III) dithiocarbamato complex was exploited through the functionalization of 
micelles with the CCK8 peptide, specifically recognized by CCK receptors overexpressed in 
cancerous cells. 
Moreover the reactivity towards the selected biomolecules PARP-1 and proteasome was investigated 
in order to obtain more insights into the mechanism of action of the gold compounds.  
Finally, we performed some kinetic studies to determine the time-dependance of the cell growth 
inhibition by our compounds and their cellular uptake. 
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Abbreviations and acronyms 
ACE angiotensin-converting-enzyme  
BER/SSB  Base Excision Repair/Single Strand Break 
BSA Bovine serum albumin 
DCM dichloromethane 
DEDT diethyldithiocarbamato 
DIPEA N,N-Diisopropylethylamine 
DLS Dynamic Light Scattering 
DMAP 4-dimethylaminopyridine 
DMEM Dulbecco's Modified Eagle Medium 
DMDT N,N-dimethyldithiocarbamate 
DMF Dimethylformamide 
DMSO dimethysulfoxide 
DPPC dipalmitoylphosphatidylcholine 
dtc dithiocarbamato 
EDCl 1-ethyl-3-(3-dimethylamminopropyl)-
carbodiimide hydrochloride 
EO Ethylene oxide 
ES Ethylsarcosine 
ESDT Ethylsarcosine dithiocarbamato 
FCS Fetal Calf Serum 
Fmoc Fluorenylmethyloxycarbonyl 
GI50 Growth Inhibition concentration 
HMBC Heteronuclear multiple bond correlation 
HMQC Heteronuclear multiple quantum correlation 
HSA Human Serum Albumin 
HSQC Heteronuclear single quantum correlation 
HoBt 1-hydroxy-1H-benzotriazole 
ICP-AES Inductive Coupled Plasma - Atomic Emission 
Spectroscopy 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide 
NMM N-methylmorpholine 
NMR Nuclear Magnetic Resonance 
PF127 Pluronic F127 
PARP Poly (ADP ribose) polymerase 
PEG Polyethylene glycol 
PO Propylene oxide 
PyBOP benzotriazol-1-yl-
oxytripyrrolidinophosphonium 
hexafluorophosphate 
RPMI Roswell Park Memorial Institute 
TDM 4,4'-tetramethyldiaminodiphenylmethane 
TEA trietilamine 
TEG-OH Triethylene glycol monomethyl ether 
TFA Trifluoroacetic acid 
TIS Triisopropylsilane 
TMS tetramethylsilane 
WME Williams Medium E 
Z carboxybenzyl 
Abbreviations and acronyms 
xii 
 
ZOSu N-(benzyloxicarbonyloxy)succinimide 
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Introduction 
 
Cancer is today considered a leading cause of mortality worldwide since it accounted for 7.6 million 
deaths (13% of all deaths; WHO, World Health Organization) in 2008, projected to continue rising 
with an estimated 13.1 million deaths in 2030 (Figure 1)6. 
 
 
Figure 1: estimated crude mortality rate over 100000 people in 5 years (both sexes, all cancer types except melanoma) 
 
The most diffuse cancer types are currently lung (1.37 million deaths), stomach (736 000 deaths), 
liver (695 000 deaths), colon (608 000 deaths), breast (458 000 deaths) and cervical cancer (275 000 
deaths), with incidences that differ between men and women (word projection in 5 years, Figure 2)7. 
The main risks (nearly 30%) of developing a malignancy is connected to wrong behavioral and 
dietary habits: high body mass index, low fruit and vegetable consumption, lack of physical activity, 
tobacco use, alcohol use. In particular, it was proved that tobacco use is the most important risk 
factor for cancer causing 22% of global cancer deaths and 71% of global lung cancer deaths. In the 
low-income countries, chronic infections from hepatitis B (HBV), hepatitis C virus (HCV) and some 
types of Human Papilloma Virus (HPV) are leading risk factors for cancer.  
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Ageing is another fundamental factor for the development of cancer, and the incidence of cancer rises 
dramatically with age, combined with the tendency for cellular repair mechanisms to be less effective 
when a person grows older. 
 
Hallmarks of cancer 
The progression of a normal cell into a cancer cell can be described as a multi-step process. New 
achievements in anticancer research recently led to the definition of six hallmarks characteristic of all 
cancer types, as summarized in Figure 3. 
 
Figure 3: of six hallmarks characteristic of all cancer types. 
 
1. Sustaining proliferative signaling 
The most fundamental trait of cancer cells is their ability to sustain chronic proliferation. Contrarily 
to normal cells, the malignant counterparts lose the control on the production and release of growth-
promoting signals, thus entering into and progressing through the cell life cycle in an unregulated 
way. The unbalanced homeostasis is largely due to the release of mitogenic signals and the 
conveyance of growth factors to neighboring cells. In the extracellular matrix, growth factors bind 
to cell-surface receptors, which trigger intracellular signaling pathways involved in cell growth and 
function. Likewise, this stimuli may be sent to normal cells within the supporting cancer-associated 
stroma, which reciprocate by supplying the neoplastic cells with several growth factors. 
Interestingly, some somatic mutations are known to enhance receptor signaling by either up-
regulating the receptor proteins at the cancer cell surface or structurally changing the receptor 
molecule, thus making such cells hyper-responsive to growth factors8,9. 
2. Evading growth suppressors 
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To induce and sustain positive growth-stimulatory signals, tumor cells must also circumvent 
programs that negatively regulate cell proliferation. Dozens of tumor suppressors which operate in 
various systems to limit cell growth and proliferation have been discovered in different cancers, 
regulated by the expression of specific genes. Two prototypical oncosuppressor genes encode in 
particular for TP53 (tumor protein 53) and RB (retinoblastoma-associated).  
RB protein is involved in the regulation of the cell growth-and-division cycle, and it is known in to 
in particular inhibit the cell from replicating damaged DNA, by preventing its progression along the 
cell cycle through G1 (first gap phase) into S (synthesis phase). When the genes encoding for these 
protein are mutated, the protein is dysfunctional, causing a persistent cell proliferation10. 
TP53 is, similarly, a tumor suppressor protein that plays a crucial role in regulating cell cycle, and 
has been also described as "the guardian of the genome" because of its role in conserving stability 
by preventing genome mutation functioning, thus acting as a tumor suppressor. 
 
3. Resisting cell death 
Functional studies conducted over the last decades proved apoptosis to be a natural barrier to cancer 
development in normal cells11. Various physiological stresses that cancer cells experience during 
their tumorigenesis or as a result of anticancer therapy, trigger apoptosis. The main apoptosis-
inducing stresses derive from signals imbalances as result of high levels of oncogene signaling and 
DNA damage associated with hyperproliferation. The apoptotic machinery is composed by both 
upstream and downstream effector components, whilst the regulators can be divided in those 
receiving and processing extracellular death-inducing signals (extrinsic apoptotic pathway, 
involving for example Fas ligand/receptor) and those sensing and integrating a variety of signals of 
intracellular origin (the intrinsic program)10.  
 
4. Enabling replicative immortality 
Normal cells are able to pass only through a defined number of subsequent cell growth and division 
cycles. Then, the cell enters into a phase of senescence, characterized by the entrance in a non-
proliferative but viable state, and ultimately passes to a crisis condition, which results in cell death. 
Nonetheless, it is possible that cells, when in the crisis phase, revert to a proliferating state with an 
unlimited replicative potential. This transition is called immortalization10 and depends strictly from 
the action of telomeres, hexanucleotide repeats protecting the ends of chromosomes12,13. In normal 
cells they serve as "clocking" device, since are progressively shorten during duplication until 
leaving chromosomal DNA unprotected from end-to-end fusions, thus triggering apoptosis. In 
neoplastic cells this control is lost, since they are able to maintain telomeric DNA long enough to 
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5 
 
avoid the induction of senescence or of apoptosis, usually upregulating the expression of 
telomerase. This enzyme is almost absent in normal cells, but was found expressed at functionally 
significant levels in cancer cells. By lengthening telomeric DNA, the tumor cell will not experience 
the progressive telomere erosion.  
 
5. Inducing angiogenesis 
The sprouting of new blood vessels from existing ones is normally associated with the need of 
cancer cells to absorb more oxygen and nutrients, as well as discharging metabolic wastes and 
carbon dioxide. In normal adult cells, angiogenesis is activated transiently only for wound healing 
and female reproductive function cycle. Instead, during malignancy the angiogenesis is always 
activated and consists in the continuous developing of new vessels from the existing vasculature14.  
 
6. activating invasion and metastasis 
The process of invasion and metastasis comprehends a series of discrete biological changes, starting 
with local invasion, intravasation of malignant cells into neighboring blood and lymphatic vessels 
and transit of neoplastic cells through the lymphatic and circulatory systems. These processes are 
followed by escape of cells from the lumina of such vessels into the parenchyma of distant tissues 
(extravasation), formation of small nodules of cancer cells (micrometastases) and ultimately by 
growth of micrometastatic lesions to yield macroscopic tumors (colonization)10. 
 
Anticancer metallodrugs 
From the historical point of view, a large number of metal compounds have been used in medicine, 
even if their toxicity has often prompted alternative options. Some of these compounds have been 
developed and used for specific diseases, including lithium compounds to treat hyperactivity, gold 
compounds in arthritis treatment, barium sulfate in gastrointestinal diagnostic strategies as imaging 
agent or contrast medium; some other have been used for more common applications such as 
antacids, fluoride as tooth decay preventative and zinc oxide for protection against sunburn15,16. 
The use of metal-based drugs can be dated in prehistoric times and through the age of alchemists, 
since empirical and, more often, pseudoscientific preparations were used for the treatment of a wide 
variety of diseases. For instance, gold salts were used in the late 19th century to treat alcoholism, 
opium addiction and neurasthenia, although modern medicine finds no value for such treatments. In 
some cases, metal ions were combined with other substances, including herbal extracts such as 
gentian or cinchona, organic medicines such as quinine, strychnine and opium, cod liver oil and even 
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red wine17. The German physicians Paul Ehrlichmann and Robert Koch made pioneering 
contributions to modern medicine, including scientific approaches to the development of arsenicals 
and gold compounds, respectively, for the treatment of various diseases. In particular, Robert Koch’s 
research on the antibacterial activity of K[Au(CN)2] for the treatment of tuberculosis led to the 
successful use of gold thiolates for treating rheumatoid arthritis. 
Until the 1960s, research on metal ions in biochemistry and medicine attracted the attention mostly of 
clinical medicine, nutritional science and toxicology. Notably, in the 1960s, more powerful 
physicochemical methods of characterization became available to study the role of metal ions in 
biological systems, allowing a well-aware use of metal ions in biochemistry and medicine. The 
enhanced knowledge of metal ion biological activity, as well as the progressive unraveling of their 
structure/activity relationships, has led in the last decades to the development of a wide variety of 
new metal-based drugs suitable for the treatment of specific pathological diseases18-20. The design 
and development of new and more effective metal complexes has been further boosted by the recent 
identification and characterization of a huge number of proteins (e.g. serum albumin, metallothionein 
and transferrin), able to modify oxidation state and bioavailability of metal ions, as well as by the 
discovery of crucial details on the metabolism of small molecules, such as ligands or redox active 
species. 
Despite the scientific progress, few compounds achieved the approval by national drug agencies; in 
addition, the mechanisms of activity and of toxicity of most of these complexes still remains 
ambiguous, as in the case of cisplatin introduced in therapy by FDA (Food and Drug Administration) 
in 1970s21. 
 
Cisplatin: the archetype of metal-based anticancer drugs 
Cisplatin was firstly synthesized by Michele Peyrone in 184522 and only 50 years later Alfred Werner 
proposed a square planar geometry for this compound and distinguished between the cis- and trans- 
isomers, namely cisplatin {cis-[PtCl2(NH3)2]} and transplatin {trans-[PtCl2(NH3)2]} (Figure 
4)21,23,24. The capability of cisplatin, but not its trans-isomer, to inhibit cellular division was 
serendipitously discovered only in 1960s by Barnett Rosenberg, during an experiment on the effects 
of electric fields on bacterial cell division. Nowadays cisplatin is one of the best drugs for the 
treatment of testicular cancer, resulting very effective also against melanoma, non-small-cell lung 
carcinoma and, in combination with other anticancer drugs such as paclitaxel, against ovarian 
cancer25. 
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Figure 4: Cisplatin and transplatin chemical structures. 
 
Although its mechanism of action remains still elusive, it is generally believed that cisplatin carries 
out its anticancer activity by forming adducts with DNA, which induce programmed cell death 
(apoptosis)26. In these adducts, the two chlorido ligands are lost (by hydrolysis), whereas the two 
ammonia groups remain coordinated to the metal center. Upon endovenous administration, the 
relatively high extracellular chloride concentration (approximately 100 mM) reduces the possibility 
for cisplatin to undergo hydrolysis of the metal-bound halogen before entering the cells. Early studies 
suggested that cisplatin passes intact through the cell membrane mainly by passive diffusion27. More 
recently, experimental evidences have pointed out the existence of active transport mechanisms 
which exploit Cu-transporting proteins28. Once inside the cell, the lower intracellular chloride 
concentration (~4-20 mM), induces a partial solvolysis of the drug which replaces one of the 
chlorine-ligands with a water molecule. The mono-aquo species is responsible for at least 98% of the 
platinum binding to DNA within the cell nucleus29. 
Mono-aquo cisplatin forms a monofunctional adduct with nucleobases30, followed by ring closure to 
give a bifunctional adduct, usually guanine-guanine31, either directly or subsequently to the 
solvolysis of the second cis-chlorido-ligand (Figure 5)32. The final adduct induces significant 
distortion to the DNA structure, leading some DNA-binding proteins to initiate signal pathways of 
apoptosis. The biological ineffectiveness of transplatin can be explained by the inability of the trans 
isomer to form similar adducts with DNA33. 
In spite of its efficacy, it has been estimated that only about 1% of intracellular cisplatin is able to 
reach the nucleus and explicate its cytotoxic activity, because of the presence of many extracellular 
(serum albumin and other proteins containing cysteine and methionine amino acids) and intracellular 
S-donor molecules (mainly glutathione and metallothionein). In fact, the soft metal center Pt(II) 
shows high affinity towards soft S-donor ligands, this resulting in displacement of harder ligands (Cl-
), cisplatin sequestration and deactivation34. 
In addition, the effectiveness of cisplatin treatment is strongly limited by the development of tumor 
resistance. This phenomenon includes a decreased intracellular drug accumulation, an increased 
capability of cells to repair or tolerate the DNA damage caused by cisplatin and higher levels of 
cytoplasmic thiols able to scavenge the DNA adducts by coordinating the metal center32. 
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Figure 5: main adducts form upon interaction of cisplatin with DNA. 
 
For these reasons, the research has been focusing its efforts on the design of new and more effective 
Pt-based drugs (second generation drugs) with improved clinical performances, aimed at reducing 
side-effects associated with cisplatin treatment (i.e. toxicity to kidneys and nervous system, hearing 
difficulties, nausea, vomiting)35. Rosenberg and coworkers developed carboplatin (Figure 6), less 
active than cisplatin but with less severe side-effects36. In fact, in carboplatin bidentate dicarboxylate 
leaving group determines a higher ligand-metal bond stability than the chlorido groups in cisplatin, 
due to the chelate effect; this results in a slower reactivity and, hence, a reduced toxicity with respect 
to cisplatin37. Another second-generation Pt-based drug, oxaliplatin, has a broader activity spectrum 
and a better safety profile than cisplatin (Figure 6)38. It has also shown lack of cross-resistance with 
cisplatin or carboplatin, likely resulting from the chemical and steric features of its DNA-adducts38. 
From 1970s onwards, several cisplatin analogues, more tumor-specific or less prone to resistance 
development, have been reported in literature. In addition, other biologically active platinum 
complexes with trans-geometry or containing multiple platinum centers have been recently under 
extensive investigation39,40. 
 
The issue to overcome cisplatin limitations, to enlarge the activity spectrum of the drug and, in this 
context, the failure of several Pt-based candidates, has led many researchers to focus on non-Pt 
coordination compounds for cancer treatment41. Among the most promising drug candidates, Ru-, 
Cu- and Au-based complexes have shown interesting cytotoxic activity against some solid tumors 
and constitute a subject of intensive studies aimed at clarifying their mechanism of action and 
toxicological profiles42. 
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Figure 6: most popular platinum-based anticancer agents: (a) cisplatin, (b) carboplatin, (c) picoplatin, (d) satraplatin, (e) 
oxaliplatin. 
 
Gold and its history 
Gold was the first pure element known to early man; since early ages it was found in stream beds and 
other geological formations and was visually attractive and easily workable. Medical uses from 
ancient civilizations in Egypt, China and Greece included this metal for the treatment of a wide 
variety of diseases43. These ancient civilizations attributed magical and healing powers to items 
fashioned from gold or to preparations containing the powdered metal44. 
The modern use of gold in medicine, known as chrysotherapy (χρυσός, gold), traces its scientific 
origins to the above-mentioned pioneering work of Dr. Robert Koch, who studied the antibacterial 
properties of potassium aurocyanide, K[Au(CN)2], while screening potential metal-based drugs 
against tubercle bacilli. This led to the clinical, but ultimately unsuccessful, use of other gold 
compounds to treat tuberculosis in the late 19th and early 20th centuries40. In 1930s, the physician 
Jacque Forestier observed beneficial effects of gold compounds on the rheumatoid arthritis of some 
patients, thus prompting their use for the cure of the disease. Since the early 1970s, an oral gold 
preparation, Auranofin (2,3,4,6-tetraacetyl-β-1-D-thioglucopyranosato-S-(triethyl-phosphine) 
gold(I)), was developed and finally approved in the late 1980s45. In modern medicine, gold 
compounds are clinically used to treat rheumatoid arthrite and, at present, are studied for their 
antitumor, antiparasitic and antiviral activities. 
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Gold and its chemistry 
Gold is most “noble” metal and has peculiar features due to its position in the periodic table. The 
physical properties conferred by its crystal structure (cubic close packed), such as ductility, high 
melting point (1064°C) and density (specific gravity 19.32 g⋅cm-3 with respect to water), are easily 
matched by other metals as silver. Nevertheless, the bright and yellow color of gold represents a rare 
exception in the bright silvery appearance of many other metals, where only copper and a small 
number of alloys (e.g. common brass) show a different color16. 
The chemical behavior of gold contributes to make this element unique as well46. Because of its 
“noble” character, gold at the elemental state (electron configuration [Xe]4f145d106s1) is not easily 
combined or mixed with other elements, even after long exposure to extremely aggressive conditions, 
making possible the existence of pure gold veins in the earth’s superficial layers. 
Most of the applications of gold and its compounds, until the early 1980s47, exploited the inertness of 
the metal to give lasting protection of materials against degradation by chemicals or light (for 
example, astronauts’ gold mirrored visors or non-corrodible electrical conductors at very small 
dimensions). The durability and ductility of the metal allowed the production of extremely thin films 
(gold foils, gold leaves) and wires for technological applications by simple mechanical procedures, 
even though deposition techniques from gaseous precursors (including gold vapors) or from solutions 
of gold chemicals (by electrolysis, electroplating or electroless methods) are also available and easy 
to carry out48. 
Until the last century, gold-based coordination compounds have played a minor role if compared with 
gold at metal state. In fact, these compounds were used as intermediates in the recovery process of 
gold from ores. The most important species are the gold cyanide complexes formed in the cyanide 
leaching and extraction processes, in which finely crushed ores are treated with sodium cyanide in 
the presence of oxygen. Typically, the resulting sodium gold cyanides (Na[Au(CN)2]) are then 
adsorbed on high affinity carbon-in-pulp coal and, after re-extraction, depleted of gold by various 
reductive processes to yield gold metal49. For further conversion, gold metal can be taken up again in 
cyanide or in aqua regia (nitric and hydrochloric acids in a volume ratio 1:3) that is the only acidic 
medium able to dissolve it. In this process, one among the very few thermodynamically stable gold 
compounds, tetrachloroauric acid, is formed; this acid and its derivative salts are used for the 
preparation of other gold-based chemicals, whose the overwhelming majority is thermodynamically 
labile and has been proved to decompose into metallic gold and side-products. 
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Therefore, it is not surprising that gold chemistry, which is clearly dominated by the metallic state, 
has remained undeveloped for so long as it was merely regarded as an art aimed at recovering and 
converting the metal into possible forms for decorative, monetary, anticorrosive or electrical usages. 
Since the 1980s, gold chemistry has been characterized by innovative approaches and by 
unprecedented branches of research interests. New ways of recovering the metal were explored in 
view of the environmental hazard deriving from the traditional amalgam and cyanide-based 
processes, as for the use of non-toxic and biologically degradable thiourea to recover gold from 
electronic scrap48. Biomass, prepared from algal cells, constitutes an efficient binding medium for 
gold salts in aqueous solution; this bio-absorption process may provide a lucrative alternative for 
gold recovery from mining effluents50.  
Studies on stereochemistry51-53, bioinorganic and medicinal chemistry54 application of gold 
coordination compounds55,56 are very attractive, in particular for gold compounds in unusual 
oxidation states as well as for gold clusters or complexes with exceptional gold-gold or gold-metal 
bonds57. Since the last decade, many researches have been focusing on the use of gold nanoparticles 
in different application fields (e. g. drug delivery, catalysis, photovoltaics, sensors). 
Au(I) and Au(III) are the most common and stable oxidation states that dominate the aqueous 
chemistry of gold. The aquated ions are unstable and rapidly undergo reduction, even though many 
complexes are stabilized by a large variety of “soft” ligands. 
Gold(I) is characterized by the electronical configuration [Xe]4f145d10 and it can form linear, 
trigonal-planar or tetrahedral complexes. Gold(I) is a very “soft” metal ion and the stability constants 
for some of its complexes (determined in acetonitrile solutions, where disproportion of gold(I) does 
not basically occur) follow the reported series58: 
1. anionic complexes [AuX2]-: CNO-< CNS- ~ Cl-< Br-< I-<< CN-; 
2. cationic complexes [AuL2]+: Ph3PO < Me2S <Py< Ph3As < NH3<< Ph3P ~ ArNC<MeNC< 
Ph2PMe < PhPMe2; 
3. neutral complexes [AuXL]: Me2O << Me2S < Me2Se < Ph3Sb <ArNC ~ Ph3As < Me2Te 
<MeNC ~ Ph3P < Ph2PMe < PhPMe2. 
In case of complexes with potentially bidentate ligands, gold(I) binds almost invariably the softer end 
of the ligand; for example, the ligands NCO-, S2O32- and SO32- will be bound through N or S rather 
than O atoms. Similarly, SCN- is normally bound through S rather than N atom, although the 
equilibrium between N- and S-bonded species in [AuL(SCN)] complexes depends on the nature of 
the ligand L59. An example of a trigonal-planar complex is [Au(SCN)(PPh3)2] with S-bonded 
thiocyanate60. 
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The electron configuration of the “less soft” gold(III) ion, is [Xe]4f145d8. All the gold(III) complexes 
are diamagnetic with a low-spin configuration. Although it forms a larger number of complexes with 
“hard” ligands with respect to gold(I), it has been argued that gold(III) displays a higher selectivity 
for “soft” ligands such as sulfur61. The wide majority of these complexes are square-planar, but 
penta- or hexa- coordinated derivatives with distorted square-pyramidal and tetragonally distorted 
octahedral structures, respectively, are also reported in literature62. Gold(III) can readily form square-
planar complexes with a variety of bidentate sulfur-donor ligands such as toluene-1,2-dithiolate, 
maleonitriledithiolate and dithiocarbamate.  
In their most common stereochemistry, gold(I) and gold(III) centers have 14 and 16 valence 
electrons, respectively. Thus, most gold complexes are coordinatively unsaturated and can undergo 
ligand addition, usually proceeding through five-coordinated intermediates. However, the number of 
characterized 5-coordinate complexes reported is limited, and typically show a chelating bidentate 
ligand with the first donor atom coordinated on the plane and the second, more distant, in apical 
position. 
The “noble” character of gold is originated by its high reduction potential, which makes it inert by 
nature. Indeed, gold is the most electronegative among all the metals (2.54 on Pauling scale going 
from 0.7 estimated for francium to 3.98 of fluorine) and can easily be reduced. The value of its 
standard electrochemical potential (E0) is the highest of any other metal: 
Au3+ Au+ Au 
Au3+ Au 
According to these values, any Au cationic form will virtually undergo reduction by accepting 
electrons from any reducing agent, to form neutral gold atoms and, consequently, metal gold 
aggregates in bulk. As a rule, the values of reduction potentials for Au ions may be lowered by ligand 
coordination53. 
 
Gold and its use in medicine: antiarthritic therapy 
In 1922, Landé was the first to report on the use of gold(I) compounds, in particular aurothioglucose 
(Solganol), to treat various diseases, including rheumatic fever63. In 1935, Forestier proposed the use 
of aurothiopropanolsulfonate (allocrysin), aurothiomalate (myocrysin) and aurothiosulfate 
(sanocrysin) (Figure 7) for the treatment of rheumatoid arthritis, an autoimmune disease in which the 
synovial tissues that line and lubricate the joints are under attack by the immune system64. 
All of these gold(I) compounds are characterized by linear -S-Au-S- geometries and appear to be 
polymeric. A full trial started only in 1957 and, few years later, the reports showed myocrysin 
 → V29.1  → V68.1
 → V42.1
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effectiveness against rheumatoid arthritis65. These gold drugs are referred to as “disease modifying 
anti-rheumatic drugs”, able to retard and sometimes to cause remission of the disease stage66. 
However, the use of these compounds has some adverse effects, such as skin rashes, diarrhea and 
kidney inflammation; in addition, patients widely differ in their tolerance. For this reason, its use is 
usually postponed until failure of safer alternative methods67. 
Among second-generation gold-based drugs, auranofin (2,3,4,6-tetraacetyl-β-1-D-thiogluco-
pyranosato-S-(triethylphosphine)gold(I)) (Figure 7) is the only one approved for use against arthritis 
by oral administration. This compound is a monomeric species with a linear geometry, able to cross 
the cell membrane due to the lipophilic phosphine ligand. In vivo, the tetraacetylthioglucose ligand is 
rapidly displaced by ligand-exchange reactions, whereas the phosphine is removed more slowly by 
the same process after 24 hours, causing fewer toxic side effects than its conventional forerunner 
agents. Nevertheless the slow reactivity also influences the efficacy of the drug, which results 
generally reduced with respect to the other compounds, i.v. administered68. 
 
 
 
Figure 7: most popular gold(I)-based anticancer agents: (a) solganal, (b) miocrisin, (c) sanocrisin, (d) allocrisin, (e) 
auranofin. 
 
The most important recognized effect of chrysotherapy is the anti-inflammatory activity; additional 
effects have been reported on the inhibition of various enzymes (thiol-containing proteins), 
antimicrobial activity, reduction of antibody-mediated system, effects on lymphocytes, monocytes or 
neutrophils (especially inhibition of T-cell proliferation and of polymorphonuclear monocyte 
activation). Multiple concerted mechanisms of action have been hypothesized for chrysotherapy, but 
for any of them there is a wide acceptance of one particular as primary biological action46,69. 
Gold and its use in medicine: anticancer chemotherapy 
Gold compounds have been extensively tested to assess their antitumor activity in cell cultures and, 
in the case of the more promising species, also in animal models70. 
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Some antiarthritic gold-based drugs (e.g., the 6-mercaptopurine and cyclophosphamide) have been 
initially tested as anticancer agents, due to their well-known immune-suppressive and anti-
inflammatory actions71. In addition, two rationales have been accounted for the investigation of gold 
compounds as antitumor agents: similarities between gold(III) square-planar complexes and their 
platinum(II) analogues and the possibility to synthesize gold(I) and gold(III) complexes with active 
organic chemotherapy agents as ligands, in order to modulate or confer new properties to the metal 
ion. However, as gold(III) compounds may be expected to be reduced in vivo to gold(I) or metallic 
gold, due to the generally reducing physiological environment, a proper selection of the right type of 
ligand enhances the stabilization of the metal center, by lowering its reduction potential. 
Early investigations of gold-based Auranofin analogues for antitumor activity were not fruitful. The 
first attempts suggested that a less toxic action and an enhanced delivery of gold would have been 
achieved with less labile ligands than the currently used monodentate thiolates provided with 
antiarthritic action. Successively, the screening of numerous Auranofin analogues with variations on 
the phosphine and thiolate ligands has led to the development of a promising antitumor agent. 
[Au(DPPE)2]Cl (DPPE = bis(diphenylphosphino)ethane) was identified as a stable metabolite of the 
dinuclear gold compound (µ-DPPE)(AuCl)2[Au(DPPE)2]+ by Berners-Price72. However, the 
development of a treatment based on this compound was prevented by the discovery of significant 
cardiovascular toxicity caused by inhibition of mitochondrial functions. In contrast, the complexes 
(dimethylaminomethylphenyl)-dichloro-gold(III) and its acetato- analogue showed interesting 
properties. From a chemical point of view, these compounds are strongly stabilized by the chelating 
C,N donor ligand that generates a neutral complex and stabilizes the gold(III) against reduction in 
vivo. The two complexes showed promising activity, with a different mechanism of action compared 
to cisplatin, but clinical trials have not been undertaken, because of their low solubility55. 
In last decades, various classes of cytotoxic gold(III) compounds were developed in few laboratories 
worldwide and were found to exhibit very attractive biological profiles73,74. Other than chlorides, 
these complexes exhibit N-, O- and P- donor ligands coordinated. The most representative ones have 
N-donor ligands, such as complexes with aldiminate derivatives, porphyrins, aliphatic amines and 
heteroaromatic rings. 
Recently, a group of thirteen structurally different gold(III) complexes, including the dithiocarbamato 
complex AuL12 (see following Section), has been tested in vitro at the German Biotech Company 
Oncotest GmbH, according to a specific comparative strategy for the development of new anticancer 
agents. Among all, AuL12 turned out to be the second best performer with GI50 (concentration which 
leads to 50% Growth Inhibition of cancer cells) values in the low micromolar range on all the 
screened 36 human tumor cell lines, in particular against ovary and brain cancers, and showed an 
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excellent degree of selectivity (17%). Intriguingly, from a comparative analysis by 110 reference 
substances with known modes of action, AuL12 proved to be the only gold(III) complex whose 
mechanism of action did not resemble that of any other reference compound75. 
 
Research on gold(III)-based anticancer compounds 
In principle, gold(III) shows more chemico-physical similarities with platinum(II) than the gold(I) 
counterpart. Gold(III) shares with platinum(II) the same d8 configuration, forming complexes with 
square-planar geometry and similar chemico-physical properties. These properties suggested that 
gold(III) could be a better candidate in replacing platinum(II) in anticancer compounds, to achieve 
similar mechanisms of action but with reduced toxicity55,76. Anyway, the high redox potentials of 
gold in the oxidation state +3, limit their utilization in physiological conditions. 
In the last decades, a series of gold(III) complexes were synthesized owing to the suitable choice of 
stabilizing ligands presenting in particular sulfur- and nitrogen-donating groups. 
The compounds developed by different scientists can be divided in four groups, differing 
substantially for the nature of coordinating ligands77:  
 
i) mononuclear gold(III) complexes: belong to this class gold(III) complexes with square-planar 
geometry characterized by nitrogen-donating and halogens ligands (Figure 8). The nitrogen-
donating ligands act as stabilizers with respect to gold(III) reduction, whist the halogen ligands 
can be, almost in principle, exchanged in physiological conditions with water molecules, 
rendering the metal center available to interact with target biomolecules, as for cisplatin41.  
 
 
Figure 8: Principal gold(III) complexes with N-donating ligands: (a) [Au(en)2]Cl3, (b) [AuCl(dien)]Cl, (c) 
[Au(cyclam)]Cl(ClO4)2, (d) [AuCl(terpy)]Cl2, (e) [AuCl2(phen)]Cl. 
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ii) porphyrinic gold(III) derivatives: these complexes (Figure 9) result particularly stable with 
respect both to the reduction to gold(I) and to the de-metallation of the ligand. Their 
antiproliferative activity seems to be connected to the intercalation of the porphyrine to DNA but 
also to the alteration of normal mithocondrial functions78. 
 
 
Figur e 9: porphyrinic derivatives of gold(III). 
 
iii) gold(III) organometallic compounds: in this promising class of gold(III) complexes the 
presence of one or more direct metal-carbon bonds owns an high stabilization of the metal 
center towards reduction in physiological conditions (Figure 10)76,79. 
 
 
Figure 10: organometallic derivatives of gold(III): (a) [Au(OH)(bipyc-H)](PF6), (b) [Au(AcO)2(pydmb-H)], (c) 
[Au(bipydmb-H)(2,6-xylidinyl-H)](PF6). 
N N
Au
HO
CH3
CH3
(PF6)
(a)
N
Au
CH3
CH3
(b)
O
H3C
O
H3C
N N
Au
HN
CH3
CH3
(PF6)
(c)
H3C
CH3
Introduction 
17 
 
 
iv) dinuclear complexes of gold(III): are mainly characterized by the presence of N-donating 2.2'-
bipyridine derivatives ligands and bridging oxygen atoms between two gold(III) centers. The 
peculiar characteristic is the presence of a "diamond core" Au2O2, which, along with the 
bypiridinic ligands, defines a square-planar geometry around the metal center (Figure 11).  
 
Figure 11: dinuclear complexes of gold(III): (a) [{Au(bipy)}2(µ-O)2](PF6)2; (b) [{Au(6-Mebipy)}2(µ-O)2](PF6)2; (c) 
[{Au(6-CH2CMe3bipy)}2(µ-O)2](PF6)2. 
 
The introduction of substituents on 6 and 6' positions influences weakly the overall structure of 
the complexes, determining indeed a strong variation of the metal center reactivity80. 
 
 
Gold(III)-based dithiocarbamato complexes: state of the art of our researches 
Among the mononuclear complexes an important example of gold(III) complexes designed for 
anticancer therapy is represented by dithiocarbamato derivatives.  
As previously mentioned, nephrotoxicity (i.e., kidney toxicity) limits the use of cisplatin and 
related platinum-based therapeutics. This side-effect may be induced by platinum binding to 
thiol-containing renal enzymes, which leads to their consequent inactivation81. The high affinity 
of Pt(II) ion for sulfur-containing biomolecules, such as cysteine, methionine, glutathione, 
metallothionein and albumin, plays a central role in platinum toxicity as well as in its 
deactivation82,83. In this case, the adducts formed upon the irreversible binding to S-donor 
biomolecules are further metabolized and, successively, excreted through urine or bile (faeces). 
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Since sulfur is involved in the whole metabolic process of platinum drugs, a large number of 
sulfur-containing nucleophiles has been tested as chemoprotectants to modulate cisplatin 
nephrotoxicity84. 
The selective protection of non-tumor cells, together with reduced systemic toxicity, are two 
critical issues for the development of novel and efficient chemoprotectants. Many sulfur-based 
molecules have been designed and tested (Figure 12), some of them showing encouraging 
properties in the perspective of clinical use. However, the selective protection of normal tissues 
without inhibition of the anticancer activity still remains a challenging objective85,86. 
In this context, positive outcomes were achieved with sodium diethyldithiocarbamate (NaDEDT), 
that provides protection against renal, gastrointestinal and bone marrow toxicity induced by 
cisplatin without decreasing its antitumor activity87. 
The chemoprotective effect results from the capability to remove platinum from the thiol groups 
of proteins, without any reversal of platinum-DNA adducts responsible for its antitumor activity. 
Interestingly, platinum-DNA adducts (1,2-intrastrand cross-links) were shown to decrease by ca. 
50% upon treatment with NaDEDT soon after cisplatin administration, causing a loss of 
therapeutic effect, whereas no change in anticancer activity was observed when NaDEDT was 
administered 3 h after the drug. This behavior can be ascribed to NaDEDT-cisplatin reaction, 
resulting in the inactivation of the drug, when diethyldithiocarbamate is administered soon after 
cisplatin. In particular, this reaction is 40,000-fold faster than hydrolysis, leading to the direct 
chloride substitution. Conversely, when NaDEDT is administered 3 h later, the drug has already 
started to react with DNA. In this case the dithiocarbamate is not able to cleave platinum-DNA 
adducts, wherein chlorides have been replaced by guanine residues, but it can remove platinum 
centers from a variety of other sulfur-containing molecules and, as a consequence, increase the 
amount of drug available to interact with DNA. Hence, the accurate use and dosing of NaDEDT 
as chemoprotectant reduces nephrotoxicity of cisplatin chemotherapy without decreasing the 
antitumor properties. Furthermore, few data showed DEDT ability to significantly reduce other non-
renal toxicities, particularly the cumulative neuropathies, associated with cisplatin treatment. 
Nevertheless, the overall benefits of NaDEDT are somewhat limited by the acute inherent 
toxicity of dithiocarbamates themselves that excludes the possibility to treat patients with a dose-
intensive program86. In fact, potential health hazards associated with free (i.e., not coordinated) 
dithiocarbamates are still under investigation, including genotoxicity. However, clinical use of 
chemoprotectants has been forsaken and replaced by aggressive hydration, together with antiemetic 
prophylaxis during cisplatin treatment. In the meantime, a continuous effort is still being made by 
researchers in order to reduce cisplatin-induced toxicity. 
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Figure 12: Cisplatin modulatory sulfydryls and peptide derivatives: glutathione (GSH, a), the GSH-depleting 
antimetabolite L-buthioninesulfoximine (L-BSO, b), the sulfydryl metabolite of disulfiramdiethyldithiocarbamate 
(DEDT, c), the parent disulfide disulfiram (antabuse, d), N-acetyl-L-cysteine (L-NAC, e), S-
mercaptoethanesulfonatesodium salt (mesna, f), sodium thiosulfate (g), the phosphothiolamifostine (WR-2721) and its 
active metabolite actifostine (WR-1065) formed by alkaline phosphatase activity (h), and the melanocortin-
derivedpeptide ORG-2766 (i). 
 
On the basis of these considerations, our research group has been designing novel 
dithiocarbamato complexes potentially able to combine the cytotoxic activity of the related metal 
centers (e.g. Pt(II), Pd(II), Au(III), Ru(III), Ru(II), Zn(II), Cu(II)) with the lack of nephrotoxicity 
due to the inherent chemoprotective action of the ligand88,89. The rationale of our strategy is 
based on the chemical features possessed by the dithiocarbamato moiety (−NCSS-). 
Dithiocarbamates are bidentate ligands that can form very stable complexes, due to the chelating 
effect; thus, the possible decomposition with subsequent loss of the dithiocarbamato ligand is 
unlikely to occur. Moreover, the solubility properties of the metal-dithiocarbamato derivatives 
may be, at least in principle, modulated by modifying the organic chain of the dithiocarbamato 
ligand. 
Interestingly, the presence of a chelating dithiocarbamato ligand in a square-planar complexes 
should prevent from the coordination of additional S-donor ligands (e.g., methionine and cysteine 
residues) in trans position with respect to the −NCSS- moiety, due to the strong trans effect of 
the dithiocarbamato sulfur atoms; this peculiarity potentially avoids any interaction of the metal 
center with thiol-containing renal enzymes and, consequently, reduces the risks of nephrotoxic 
side-effects. 
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To date, the toxicological profile and the anticancer activity of compounds points out the success 
of our design strategy, both in stabilizing the heavy metal center and in avoiding the non-specific 
reactivity of the compound, responsible of systemic toxicity. The most promising results were 
obtained with gold(III)-dithiocarbamato derivatives [AuIIIX2(dtc)] (X = Cl, Br; dtc = 
dithiocarbamato-derivatives ligands), whose design aimed to reproduce as much as possible the 
main features of cisplatin. All the compounds have been fully characterized by means of several 
techniques, confirming that coordination of the metal ion by the dithiocarbamato ligand takes 
place in a near square-planar geometry through the two sulfur-donating atoms in a bidentate 
symmetrical fashion. The two remaining coordination positions are occupied by two cis-halogen 
atoms which may undergo hydrolysis. When X-ray structures were not available, density 
functional calculations were performed, confirming the structural conclusions deduced by other 
characterization techniques90.  
In addition, the inherent electrochemical properties of our gold(III) compounds have been studied in 
a physiological-like solution by cyclic voltammetry, showing that both N,N-dimethyldithiocarbamate 
(DMDT) (AuL10 and AuL14) and sarcosine ethyl ester (ESDT) (AuL12 and AuL13) derivatives 
(Figure 13) undergo irreversible stepwise reduction processes, leading to the corresponding 
dinuclear gold(I) species [AuI(DMDT)]2 and [AuI(ESDT)]2, at ca. -300 mV and -180 mV (vs. 
saturated calomel electrode, SCE), respectively. Remarkably, these reductions occur at potentials 
considerably lower than the typical values for the Au(III)/Au(I) couple known for the 
corresponding K[AuX4] (X = Cl, Br) precursors (ca. +1.29 V)91. Therefore, coordination by 
dithiocarbamates induces a large stabilization of the metal ion in the +3 oxidation state, owing to 
the electron-donating capability and the stabilizing chelate effect of the dithiocarbamato moiety. 
 
 
Figure 13: Selected Au(III)-dithiocarbamato derivatives. 
 
Concerning their solution properties, these gold(III) complexes hydrolyze in a physiological-like 
environment, by delivering two moles of halide per mole of starting complex, leading to the 
corresponding Au(III)-diaquo counter-parts within 30-40 min. Intriguingly, the hydrolyzed 
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species were proved to be reasonably stable in physiological solution, reduction to gold(I) 
occurring after 12-24h. 
From comparative in vitro cytotoxicity studies on our Pt(II)-, Pd(II)-, and Au(III)-MSDT derivatives 
on human squamous cervical adenocarcinoma (HeLa) cells and human leukemic promyelocytes 
(HL60), gold(III) complexes resulted to be significantly more active (GI50 ca. 1 µM) than cisplatin 
(GI50 ca. 2 µM) and with respect to Pt(II) and Pd(II)-dtc counter-parts (GI50 >15 and 5 µM, 
respectively) under the same experimental conditions, inducing apoptosis especially in HL60 cells92. 
[AuIIIX2(MSDT)]-type compounds were also tested on a panel of acute myelogenous leukemia cell 
lines, representing different French-American-British subtypes, and toward the Philadelphia-positive 
(K562) cells93. In this case, the gold complexes showed to inhibit cell growth in the tested myeloid 
cell lines with GI50 values ca. ten-fold lower than the reference drug91.  
Moreover, after short exposure (18 h), they induced strong and rapid apoptosis by down-regulating 
the antiapoptotic molecule Bcl-2 and up-regulating the proapoptotic molecule Bax, whereas cisplatin 
did not. Finally, after long exposure (72 h), they were proved to induce only modest cell cycle 
perturbations but high DNA fragmentation, whereas classical platinum(II) complexes are known to 
promote characteristic cell cycle alterations resulting in increased G2M cell fraction. G2M is an 
important DNA cell cycle check-point which prevents cells from initiating mitosis before they 
have a chance to repair damaged DNA after replication26,94. Therefore, [AuIIIX2(MSDT)]-type 
complexes are able to promote early apoptosis and membrane damage to a much greater extent 
than cisplatin, suggesting a different mechanism of action underlying its biological activity. 
Within the family of [AuIII(dtc)X2] complexes, the derivatives AuL10, AuL14, AuL13 and 
AuL12, turned out to be much more cytotoxic in vitro than cisplatin, even toward human tumor 
cell lines intrinsically resistant to the Pt-based drug itself, such as Daudi, MeWo, LoVo and A549 
cells, for which they have shown activity levels comparable to those recorded on the 
corresponding cisplatin-sensitive parent cell lines, ruling out the occurrence of cross-resistance 
phenomena (Table 1). As a whole, our complexes proved to be much more potent than cisplatin 
even at nanomolar concentrations, with GI50 values up to five orders of magnitude lower than the 
reference drug95. 
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Table 1: In vitro cytotoxic activity of Au(III)-dithiocarbamato derivatives [AuIIICl2(DMDT)] (AUL10), 
[AuIIIBr2(DMDT)] (AUL14), [AuIIICl2(ESDT)] (AUL13) and [AuIIIBr2(ESDT)] (AUL12) compared to the reference 
metallodrug cisplatin toward different established human cancer cell lines: human squamous cervical adenocarcinoma 
(HeLa), human leukemic promyelocytes (HL60), human Burkitt's lymphoma (Daudi), human malignant melanoma 
(MeWo), human colon adenocarcinoma (LoVo), human non-small cell lung adenocarcinoma (A549), human ovarian 
carcinoma cisplatin-sensitive (2008) and cisplatin-resistant (C13*), human epidermoid carcinoma cisplatin-sensitive 
(A431) and cisplatin-resistant (A431-R), human osteosarcoma cisplatin-sensitive (U2OS) and cisplatin-resistant (U2OS-
R) cells. 
 GI50±st.dev. (µM) 
Cell line 
Compound 
AUL10 AUL14 AUL13 AUL12 cisplatin 
HeLa 2.10±0.01 3.5±0.01 8.2±0.2 7.6±0.2 15.6±0.4 
HL60 (0.80±0.01).10-2 (0.70±0.01).10-2 0.43±0.09 0.14±0.02 25.6±0.3 
Daudi (0.10±0.01).10-2 (0.10±0.01).10-2 4.65±0.09 5.8±0.2 95±1 
MeWo 2.0±0.3 (0.10±0.01).10-2 12.4±0.9 10.0±0.9 48±2 
LoVo (2.40±0.04).10-2 3.8±0.1 7.6±0.2 7.9±0.1 56±2 
A549 (0.35±0.01).10-2 0.41±0.03 4.73±0.04 9.6±0.2 35±1 
2008 (0.20±0.01).10-2 30.0±0.1 49.3±0.1 16.5±0.4 43.2±0.4 
C13* (0.10±0.01).10-2 21.8±0.2 23.8±0.1 (0.10±0.01).10-2 556±3 
A431 (1.20±0.01).10-2 1.8±0.1 0.29±0.01 (1.50±0.01).10-2 77.4±0.4 
A431-R (0.20±0.01).10-2 2.8±0.2 0.43±0.03 (0.10±0.01).10-2 382±3 
U2OS 4.8±0.3 18±1 5.8±0.4 0.49±0.09 35±2 
U2OS-R 6.4±0.1 13±1 5.2±0.2 0.24±0.09 84±3 
 
It is worth to highlight that usually in vitro anticancer activity of gold compounds is not confirmed 
by subsequent in vivo studies96. On the other hand, the in vivo antitumor activity of our gold(III)-
dithiocarbamato derivatives, evaluated against human tumors implanted on immunodepressed 
nude mice (xenografts), was fully consistent with in vitro data. For example, treatment of MDA-
MB-231 breast tumor-bearing nude mice with AuL14 resulted in significant inhibition of the 
tumor growth (ca. 50% inhibition after 29 days of daily treatment at 1 mg kg–1 body weight 
subcutaneous, s.c., compared to control). Interestingly, during the treatment, no toxicity was 
observed, and mice did not display signs of weight loss, decreased activity or anorexia97. 
Similarly, administration of 1 mg kg–1 s.c. every second day of AuL10 caused an overall 85% 
reduction of PC3 human prostate tumor implanted in nude mice after a 19-day treatment 
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(compared to control untreated mice). Again, chemotherapy was well tolerated by the treated 
animals which suffered from minimal systemic toxicity only, and histology showed no detectable 
damage to the main organs93,94. Among all, the Au(III)-dithiocarbamato derivative AuL12 has 
been selected for additional in vivo studies due to its overall favorable solubility, stability and 
antitumor properties. Thus, in vivo nephrotoxicity studies were also carried out with AuL12 by 
measuring some specific biomarkers in both urines (total urinary proteins (TUP), N-acetyl-β-D-
glucosaminidase (NAG) and glutamine synthetase (GS)) and renal tissues (p-aminohippuric acid 
(PAH) and GS) of the treated rats3. In this investigation, cisplatin administration induced a 
significant increase of all the urinary biomarkers and a significant inhibition of GS activity in 
renal cortical slices, whereas the gold(III)-dithiocarbamato derivative caused negligible changes 
compared to untreated control rats (mainly observable at the higher dose, 20 mg kg–1 body 
weight), accounting for a substantial lack of nephrotoxic side-effects. The favorable toxicity 
profile was also confirmed by the LD50 value of 30 mg kg–1 recorded for AuL12 that is, as far as 
we know, among the higher ever reported for gold-based therapeutics (cisplatin LD50 = 11.4 mg 
kg–1). Subsequent investigations showed that no significant histologically detectable toxicity 
involving treated animals’ organs was observed. SEM (scanning electron microscopy) evaluation 
of the surface of all tissues examined was considered compatible with normal conditions, when 
compared to control animals. Surprisingly, no gold was detected in the investigated tissues, thus 
ruling out the accumulation of the metal in any of the organs taken into account (i.e., heart, liver, 
spleen, kidneys, testicles, pancreas, lungs and brain). Accumulation around the injection site (i.e., 
peritoneal area) was also excluded. These results together with excretion studies, suggest that 
gold is quickly cleared from the body (within 48 h), the large majority being excreted through the 
feces (>89%) and only about 10% via the urinary system98. This result is extremely positive 
when compared with the data reported in literature concerning the renal toxicity induced by gold 
derivatives. For instance, it is well known that the anti-arthritic drugs, auranofin and 
myochrysine, induce proteinuria and kidney dysfunctions and gold nanoparticles are able to 
penetrate renal cells causing nephrotoxicity99. 
 
 
Second Generation gold(III) dithiocarbamato complexes.  
To improve the therapeutic effectiveness of the complexes and increase their cellular uptake, a 
"second generation" of gold(III)-dithiocarbamato complexes was designed100,101. Since cancer cells 
are known to overexpress specific biomarkers and receptors needed for carcinogenesis and tumor 
growth, targeted chemotherapies actually aim at blocking cancer cells proliferation exploiting such 
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specific upregulated biomolecules. This led to the development of efficient and innovative delivery 
systems in which conjugated drugs incorporating a tumor targeting group, can selectively reach the 
tissue of interest and deliver the cytotoxic agent directly into the tumor cells102. In particular specific 
peptide transporters (PEPTs), characterized by different tissue distributions (small intestine, kidney, 
lung, etc.), were selected as potential targets, because of their upregulation in various cancerous 
cells103. In particular, owing to their capability to promote cellular uptake of potentially all 
physiologically occurring di- and tripeptides, they represented an excellent target also for the delivery 
of some pharmacologically-active compounds (as β-lactam antibiotics and ACE inhibitors), and 
might have a central role also in the recognition and transport of our compounds. 
According to the in vitro cytotoxicity studies, the complexes [AuBr2(dtc-SarGlyOtBu)] (AuD6) and 
[AuBr2(dtc-SarAibOtBu)] (AuD8) (Figure 14) resulted the most effective not only toward the 
evaluated human tumor cell lines (Table 2), but also in preliminary in vivo tests on xenografts, and 
were thus selected for further studies104.  
 
 
Figure 14: chemical structure of [AuIIIBr2(dtc-SarGlyOtBu)] (AuD6) and [AuIIIBr2(dtc-SarAibOtBu)](AuD8) compounds 
 
AUD8, up to now the better characterized, showed no cross-resistance with cisplatin and was proved 
to inhibit tumor cell proliferation with different mechanism of action compared to clinically-
established platinum drugs100. All the obtained results account for the interest in continuing the 
preclinical studies on AUD8 and other Au(III)-peptidodithiocarbamato derivatives, evaluating the 
possibility for these complexes to approach to phase I clinical trials. 
 
Table 2: in vitro cytotoxic activity of AuD6 and AuD8 on established human cancer cell lines: human prostate cancer 
(PC3 and DU145), ovarian adenocarcinoma cisplatin-sensitive (2008) and cisplatin-resistant (C13*) and Hodgkin's 
lymphoma (L540) cells compared to the reference metallodrug, cisplatin. 
Cell line 
GI50 ± st.dev. (µM) 
AuD6 AuD8 Cisplatin 
PC3 1.3±0.1 0.8±0.1 3.3±0.3 
DU145 4.5±0.9 1.4±0.1 4.5±0.1 
2008 18±2 4.5±0.2 19±1 
C13* 12±1 3.7±0.3 117±9 
L540 2.1±0.2 1.5±0.2 2.5±0.1 
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General materials and methods 
Instrumentation 
Elemental analysis  
Elemental analysis of carbon, nitrogen and hydrogen were obtained with a CARLO ERBA mod 1108 
CHNS-O microanalyzer.  
 
Termogravimetric analysis 
Thermogravimeter analysis were carried out using a thermoanalyzer NETZSCH mod. STA42 in the 
range 25-1200°C in alumina crucibles, with an heating rate of 5°C/min under air, with a flow rate of 
30 cm3/min, using alumina as reference substance. 
 
Thin layer chromatography 
Silica gel 60 F254 (Merck) or Alugram® Sil G UV 254 (Macherey-Nagel) on aluminium foil was 
used to follow the reactions. Silica gel 60 F254 (Merck) on glass was used for TLC characterization. 
Retention factors (Rf) have been measured using three different solvent mixtures as eluents. 
Rf1: CHCl3/EtOH 9:1; Rf2: BuOH/AcOH/H2O 3:1:1; Rf3: PhMe/EtOH 7:1. 
Products were detected either by UV lamp irradiation, or with exposition to I2 vapours or by warming 
with a heat gun and spraying firstly with a 1.5 % NaClO solution and then with a ninhydrin-TDM 
solution. 
 
Flash chromatography 
For flash chromathography (FC) purifications silica gel 60 Merck (40-63 µm diameter, mesh 230-
400) was used. For the various purifications, the crude product was directly loaded on top of the 
column, after been dissolved in a small amount of the eluent used for the purification. 
 
Polarimetric measurements 
Optical rotations were measured on a Perkin-Elmer model 241 polarimeter with an Haake model D8 
thermostat at the mercury line wavelength, using a cell with an optical pathlength of 10 cm. 
Concentrations are expressed in g/100 mL. [α] are calculated using the formula [α] = α/(c·l), where 
"c" is the concentration (in g/mL) and "l" is the optical path (in dm). Spectrophotometric grade 
MeOH was used as solvent. 
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IR Spectroscopy 
FT-IR spectra were recorded in nujol on a Nicolet Nexus 870 spectrophotometer (1000 scans, 
resolution 2 cm-1) for the range 50-600 cm-1, and in solid KBr on either a Nicolet 55XC or a Perkin-
Elmer 580B spectrophotometer (32 scans, resolution 2 cm-1) for the range 400-4000 cm-1. Data 
processing was carried out using OMNIC version 5.1 (Nicolet Instrument Corp.). 
 
NMR Spectroscopy  
All NMR spectra were acquired in the appropriate deuterated solvent at 298 K on a Bruker Avance 
DRX 300 spectrometer using a BBI [1H,X] probe-head equipped with z-field gradients. Data 
processing was carried out using MestReNova version 6.2 (Mestrelab Research S.L.). 
Typical acquisition parameters for 1D 1H NMR spectra (1H: 300.13 MHz): 16 transients, spectral 
width 7.5 kHz, using 32k data points and a delay time of 5.0 s. Spectra were processed using 
exponential weighting with a resolution of 0.5 Hz and a line-broadening threshold of 0.1 Hz. 
Typical acquisition parameters for 1D 13C{1H} NMR spectra (13C: 75.48 MHz): 8k transients, 
spectral width 18.8 kHz, using 32k data points and a delay time of 7.0 s. Sequences were optimized 
for 1J(13C,1H) = 145 Hz, and 1H decoupling was achieved by using WALTZ16 pulse sequence. 
Spectra were processed using exponential weighting with a resolution of 2.0 Hz and a line-
broadening threshold of 2.8 Hz. 
Typical acquisition parameters for 2D [1H,13C] HMQC NMR spectra (1H: 300.13/13C: 75.48 MHz): 
512 transients of 32 scans/block, spectral width 7.5/18.8 kHz, 1k/1k data points and a delay time of 
2.0 s. Sequences were optimized for 1J(13C,1H) = 145 Hz, and 1H decoupling was achieved by using 
GARP pulse sequence. Spectra were processed by using cosine-square weighting with a resolution of 
1.0/3.0 Hz and a line-broadening threshold of 0.3/1.0 Hz. 
Typical acquisition parameters for 2D [1H,13C] HMBC NMR spectra (1H: 300.13/13C: 75.48 MHz): 
512 transients of 16 scans/block, spectral width 7.5/18.8 kHz, 1k/1k data points and a delay time of 
2.0 s. Sequences were optimized for 1J(13C,1H) = 145 Hz/nJ(13C,1H) = 5 Hz with no 1H decoupling. 
Spectra were processed by using sine-square weighting with a resolution of 0.3/1.0 Hz and a line-
broadening threshold of 0.3/1.0 Hz. 
Typical acquisition parameters for 2D [1H,15N] HSQC NMR spectra (1H: 300.13/15N: 30.41 MHz): 
512 transients of 16 scans/block, spectral width 7.5/12.1 kHz, 1k/1k data points and a delay time of 
2.0 s. Sequences were optimized for 1J(15N,1H) = 70 Hz, and 1H decoupling was achieved by using 
WALTZ16 pulse sequence. Spectra were processed by using cosine-square weighting with a 
resolution of 2.2/3.7 Hz and a line-broadening threshold of 0.7/1.0 Hz. 
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Typical acquisition parameters for 2D [1H,15N] HMBC NMR spectra (1H: 300.13/15N: 30.41 MHz): 
512 transients of 16 scans/block, spectral width 7.5/12.1 kHz, 1k/1k data points and a delay time of 
2.0 s. Sequences were optimized for 1J(15N,1H) = 70 Hz/ nJ(15N,1H) = 3 Hz with no 1H decoupling. 
Spectra were processed by using sine-square weighting with a resolution of 2.2/3.7 Hz and a line-
broadening threshold of 0.7/1.0 Hz. 
1H and 13C chemical shifts were referenced to TMS at 0.00 ppm via internal referencing to the 
residual peak of the deuterated solvent employed, and 15N to external 15NH4Cl (1.5 M in 1 M HCl in 
90% H2O/10% D2O) at 0.00 ppm. 
 
UV-Vis spectroscopy 
Electronic spectra were recorded using a Cary 100 Spectrophotometer (Agilent Technologies) in the 
range 200–800 nm (230-800 for aqueous samples containing DMSO), at a scan rate of 300 nm min-1 
and a resolution of 2 nm. Sample temperature was kept constant at 37°C through a Varian Dual Cell 
Peltier device. Data processing was performed with Cary WINUV version 4.2 (Varian Inc.).  
 
Circular Dichroism  
CD measurements were registered at 25°C with a Jasco J-715 spectropolarimeter (scan rate: 50 nm 
min-1) using Hellman quartz cells of 0.01 and 0.1 cm path length, respectively in the range 193–260 
and 240–350 nm. Spectra (each being the average of eight subsequent accumulations) were recorded 
at standard sensitivity (100 mdeg) with a data-pitch of 1 nm in the continuous mode and a resolution 
of 2 nm. Data processing was carried out using SPECTRA MANAGER version 1.52 (Jasco Inc.), 
and values expressed in terms of total molar ellipticity [θ] (deg·cm2.dmol-1). 
 
Fluorescence Spectroscopy 
Emission spectra were recorded at room temperature on a Perkin Elmer LS50B Luminescence 
Spectrometer in 1 cm quartz cuvettes. The emission of BSA was measured in the range ∆em=300-400 
nm with an excitation wavelength of 288 nm. The excitation and emission slits were fixed at 5 nm, 
scanning speed 40 nm/min (10 accumulations). 
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Chapter 1  
Design, synthesis and characterization of gold(III) peptidomimetics 
 
The enhancement of the therapeutical effectiveness of drugs can be achieved by increasing their 
bioavailabilty and cellular uptake, which is usually limited by their capacity to pass the plasma 
membrane. In order to overcome this issue, carrier-mediated strategies were adopted to suitably 
modify drugs in order to be recognizable by specific transporters, thus enhancing the amount of 
compound entering the cell without losing their pharmacological activity. Moreover, since cancer 
cells are known to overexpress specific biomarkers and receptors needed for carcinogenesis and 
tumor growth, targeted chemotherapies aim at blocking cancer cells proliferation by exploiting such 
specific upregulated biomolecules. This led to the development of efficient and innovative delivery 
systems in which conjugated drugs incorporating a tumor targeting group can selectively reach the 
tissue of interest and deliver the cytotoxic agent directly into the tumor cells.  
Starting from promising in vitro and in vivo antiproliferative activities of some gold(III)-
dithiocarbamato complexes designed in our reasearch group, we carried out further functionalization 
with specific oligopeptides to exploit their recognition and transport by specific peptide transporters.  
In particular, transporters named PEPTs were selected as potential targets for our compounds. They 
are integral membrane proteins expressed in mammals in two different isoforms, PEPT1 and PEPT2, 
which are known to promote cellular uptake of all physiologically occurring L-enantiomers of di- and 
tripeptides, regardeless sequence, size, charge and hydrophobicity. They are present predominantly in 
epithelial cells of small intestine, bile duct, mammary glands, lung, choroid plexus and kidney, but 
are also localized in other tissues (e.g. pancreas, liver, gastrointestinal tract) and are interestingly 
upregulated in different cancer cells105. Owing to their specificity in recognition and transport, they 
represented an excellent target for the delivery of some pharmacologically-active peptidomimetics 
(e.g. β-lactam antibiotics and ACE inhibitors), and might have a central role also in the uptake of our 
gold(III) peptide derivatives. 
Recently we reported about the synthesis, characterization and biological evaluation of new gold(III)-
dithiocarbamato complexes functionalized with short oligopeptides, of the type [AuIIIX2(dct-Sar-
AA)] (X = Br, Cl; Sar = sarcosine, N-methylglycine; AA=different aminoacids). These complexes 
were tested on a large panel of cancer cell lines representatives of different cancer types, recording 
GI50 in the lower micromolar range, with values up to 5-times lower than the reference drug cisplatin. 
Interestingly they showed no cross-resistance with cisplatin and were proved to inhibit tumor cell 
Chapter 1. Design, synthesis and characterization of gold(III) peptidomimetics 
30 
 
proliferation with a different mechanism of action if compared to clinically-established platinum 
drugs100,101,106. 
Since PEPTs are known to transport selectively only L-occuring natural aminoacids, the possibiity to 
enhance the cellular uptake of the complexes by using different chiral aminoacids was also explored.  
 
Experimental 
Chemicals and solvents 
Acetone-d6, DMSO-d6, dichloromethane-d2, chloroform-d1, methanol-d4, 4-dimethylaminopyridine 
(DMAP), triethylene glycol monomethyl ether (TEG-OH) (Sigma Aldrich); 1-hydroxy-1H-
benzotriazole (HOBt), phosphoric anhydride P2O5, H-D-AlaOH, H-D-ProOH (Acros-Janssen); 
potassium tetrabromoaurate(III) dihydrate (Alfa Aesar); potassium hydrogen carbonate NaHCO3, 
potassium hydrogen sulfate KHSO4, sodium carbonate dodecahydrate, sodium hydroxide, sodium 
hypochlorite, sodium sulphate anhydrous, triethylamine (TEA, Carlo Erba); isobutene (Siad); 
isobutylchloroformiate (Lancaster); N-methylmorpholine (NMM), palladium (10% on carbon), 
HSarOH (Fluka); 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDCl), N-
(benzyloxycarbonyloxy)succinimide (ZOSu, Iris Biotech); Z-Aib-OH, Z-L-Ala-OH, Z-L-Pro-OH, Z-
Sar-OH (synthesized in Prof. Formaggio laboratory, University of Padua)  
All other reagents and solvents were used as purchased without any further purification. 
 
Synthesis. The purity of all the synthesized compounds was ≥95%, as determined by elemental and 
thermogravimetric analysis (vide infra). 
 
General synthetic route for tert-Butyl- or TEG-esterified dipeptide hydrochlorides and related 
intermediates. ZSarOH, Z-L-ProOH, Z-L-AlaOtBu, Z-L-AibOtBu) were prepared according to 
literature methods107,108. For the synthesis of Z-L-AibOTEG, 1 eq. of ZAibOH (15 mmol) was 
dissolved in CH2Cl2 and cooled to 0°C with ice bath. To the solution were subsequently added: 1.2 
eq. of HOBt; 0.3 eq. of DMAP; 1.2 equiv. di EDCl; 2 eq. of TEG-OH, and the mixture was stirred for 
48h. The solvent was evaporated at reduced pressure; the product was extracted with ethylacetate and 
washed with KHSO4 and NaHCO3 aqueous solutions. After removing water traces by treating with 
Na2SO4, the organic portion was dried obtaining a yellow oil which was purified by flash 
chromatography (eluent: petroleum ether/ethyl acetate 3:2 and subsequently 4.5:0.5, on silica). 
Yellow oil; yield: 92%; Rf1: 0.94; Rf2: 0.74; Rf3: 0.43.  
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1H NMR (300.13 MHz, DMSO-d6, 298 K, TMS): 1.55 (s, 6H, ß-CH3 Aib); 3.68 (s, 3H, O-CH3 
TEG); 3.50-3.55, 3.60-3.68, 4.25-4.29 (m, 12H, -CH2 TEG); 5.08 (s , 2H, -CH2 Z); 5.44 (s, 1H, N-H 
Aib); 7.27-7.36 (m, 5H, CH Z). 
FT-IR (KBr): ν =3341 (ν, N-H); 2984/2929/2877 (ν, C-H); 1739 (ν, C=O ester); 1721 (ν, amide I); 
1523 (ν, amide II); 1157 (ν, (TEG)-O).  
For the aminoacids coupling reaction, generally, a THF solution (15–20 mL) of Z-Sar-OH (or Z-L/D-
ProOH) was treated with NMM (22 mmol), cooled to −15 °C and then treated with isobutyl 
chloroformiate (22 mmol) under continuous stirring109. After 10 min, a cold CHCl3 (10–35 mL) 
suspension of H-L/D-Ala-OtBu (or H-Aib-OtBu), H-Aib-OTEG; 22 mmol110 was added, adjusting 
the pH to ca. 8 by adding NMM.  
After stirring overnight at room temperature, the reaction mixture was concentrated under reduced 
pressure and the residue was dissolved with AcOEt, washed subsequently with 10% KHSO4, H2O, 
5% NaHCO3, H2O, and dried over Na2SO4. The organic layer was then concentrated to dryness and 
purified by flash chromatography using AcOEt/petroleum ether 1:1 as eluent, in order to obtain the 
corresponding Z-protected dipeptides esters (yield = 70–90%). 
Each Z-AA1-AA2-OR (AA1= Pro, Sar; AA2= Aib, Ala; R= tBu, TEG) intermediate was then Z-
deprotected by catalytic hydrogenation over Pd/C (20% w/w) in MeOH. The H-AA1-AA2-OR 
compound was dissolved in dry diethylether and dropwise treated with 1 equivalent of a dilute ether 
solution of HCl (0.2 mM) under vigorous stirring, leading to the formation of a white precipitate 
corresponding to the hydrochloride form of the dipeptide, HCl·H-AA1-AA2-OR (AA1= Pro, Sar; 
AA2= Aib, Ala; R= t-Bu, TEG). 
 
HCl·H-Sar-D-Ala-OtBu (P1) 
White powder; yield: 65%. Rf1: 0.13; Rf2: 0.23; Rf3: 0.04; m.p.: 148-150°C; [α]20D= 38.67° (c=0.5, 
MeOH); 1H NMR (300.13 MHz, DMSO-d6, 298 K, TMS): δ=9.00 [br, s, 2H, NH2+ Sar]. 8.88 [d, 1H, 
NH Ala], 4.17 [m, 1H, α-CH Ala], 3.70 [s, 2H, N-CH2 Sar], 2.53 [s, 3H, N-CH3 Sar], 1.40 [s, 9H, 
CH3 t-Bu], 1.28 ppm [d, 3H, β-CH3 Ala]; 13C{1H} NMR (75.48 MHz, DMSO-d6, 298 K, TMS): δ= 
171.22 (C=O Ala), 164.87 (C=O Sar), 80.55 (-C(CH3)3 t-Bu), 48.52 (N-CH2 Sar), 48.29 (α-C Ala), 
32.41 (N-CH3 Sar), 27.28 (CH3 t-Bu), 16.76 ppm (β-CH3 Ala); FT-IR (KBr): ν =3332 (ν, N-H); 
2978/2960/2936 (ν, C-H); 2763 (νa, NH2+);2701 (νs, NH2+), 1735 (ν, C=O ester); 1669 (ν, amide I); 
1564 (ν, amide II); 1266 (ν, amide III); 1221 (ν, C-O(t-Bu)); 1165 cm-1 (ν, t-Bu-O). 
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HCl·H-Sar-L-Ala-OtBu (P2) 
White powder; yield: 82%; Rf1: 0.13; Rf2: 0.23; Rf3: 0.04; m.p.: 147-150°C; [α]20D = -39.1° (c = 0.5, 
MeOH) 
1H NMR (300.13 MHz, DMSO-d6, 298 K, TMS): δ = 9.12 [br, s, 2H, NH Sar], 8.96 [d, 1H, NH Ala], 
4.16 [m, 1H, α-CH Sar], 3.69 [s, 2H, N-CH2 Sar], 2.52 [s, 3H, N-CH3 Sar], 1.40 [s, 9H, CH3 t-Bu], 
1.27 ppm [d, 3H, β-CH3 Ala]; 13C{1H} NMR (75.48 MHz, DMSO-d6, 298 K, TMS): δ =171.27 
(C=O Ala), 164.86 (C=O Sar), 80.58 (-C(CH3)3 t-Bu), 48.53 (N-CH2 Sar), 48.29 (α-C Ala), 32.40 (N-
CH3 Sar), 16.75 (β-CH3 Ala); 27.36 ppm (CH3 t-Bu); FT-IR (KBr): ν =3332 (ν, N-H); 
2978/2963/2939 (ν, C-H); 2766 (νa, NH2+); 2699 (νs, NH2+); 1735 (ν, C=O ester); 1669 (ν, amide I); 
1564 (ν, amide II); 1266 (ν, amide III); 1220 (ν, C-O(t-Bu)); 1166 cm-1 (ν, t-Bu-O). 
 
HCl·H-D-Pro-Aib-OtBu (P3) 
White powder; yield: 49%; Rf1: 0.15; Rf2: 0.30; Rf3: 0.06; m.p.: 104-108°C; [α]20D = -32.8° (c = 0.6, 
MeOH);   
1H NMR (300.13 MHz, DMSO-d6, 298 K, TMS): δ=9.34 [s, br, 2H, NH2+ Pro]; 8.94 [s, 1H, NH 
Aib], 4.14 [m, 1H, CH2 Pro], 3.16 [m, 2H, CH25 Pro], 2.29 [m, 1H, CH3’ Pro], 1.83 [m, 3H, CH3’’ 
Pro e CH24 Pro], 1.36 [s, 9H, CH3 t-Bu], 1.33, 1.37 ppm [2 s, 6H, β-CH3 Aib]; 13C{1H} NMR (75.48 
MHz, DMSO-d6, 298 K, TMS): δ = 172.06 (C=O Aib), 167.15 (C=O Pro), 79.65 (-C(CH3)3 t-Bu), 
58.07 (CH2 Pro), 55.69 (C(CH3)2 Aib), 45.32 (CH25 Pro), 29.59 (CH23 Pro), 27.13 (CH3 t-Bu), 24.00, 
24.77 (CH3 Aib), 23.28 ppm (CH24 Pro); FT-IR (KBr): ν =3437 (ν, N-H); 2979/2935 (ν, C-H); 2743 
(νa,s, NH2+); 1733 (ν, C=O ester); 1678 (ν, amide I); 1551 (ν, amide II); 1256 (ν, amide III); 1219 (ν, 
C-O(t-Bu)); 1146 cm-1 (ν, t-Bu-O).  
 
HCl·H-L-Pro-Aib-OtBu (P4) 
White powder; yield: 49%; Rf1: 0.15; Rf2: 0.30; Rf3: 0.06; m.p.: 104-108°C. [α]20D = -31.2° (c = 0.7, 
MeOH) 
1H NMR (300.13 MHz, DMSO-d6, 298 K, TMS): δ= 9.80 [s, br, 2H, NH2+ Pro], 8.92 [s, 1H, NH 
Aib], 4.11 [m, 1H, CH2 Pro], 3.15 [m, 2H, CH25 Pro], 2.27 [m, 1H, CH3' Pro], 1.83 [m, 3H, CH3'' 
and CH24 Pro], 1.32, 1.36 ppm [2 s, 15H, β-CH3 Aib and CH3 t-Bu]; 13C{1H} NMR (75.48 MHz, 
DMSO-d6, 298 K, TMS): δ = 172.15 (C=O Aib), 167.75 (C=O Pro), 79.71 (C(CH3)3 t-Bu), 58.26 
(CH2 Pro), 55.70 (C(CH3)2 Aib), 45.55 (CH25 Pro), 29.67 (CH23 Pro), 27.19 (CH3 t-Bu), 24.08, 24.78 
(CH3 Aib), 23.56 ppm (CH24 Pro); FT-IR (KBr): ν = 3430 (ν, N-H); 2980/2936 (ν, C-H); 2744 (νa,s, 
NH2+); 1733 (ν, C=O ester); 1678 (ν, amide I); 1551 (ν, amide II); 1256 (ν, amide III); 1219 (ν, C-
O(t-Bu)); 1146 cm-1 (ν, (t-Bu)-O). 
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HCl·H-Sar-Aib-OTEG (P5) 
Pale-yellow oil; yield: 97%; Rf1: 0.92; Rf2: 0.69; Rf3: 0.33;  
1H NMR (300.13 MHz, DMSO-d6, 298 K, TMS): δ = 9.04 [s, 3H, NH Aib e NH2+ Sar], 4.10-4.13 
[m, 2H, CH21 TEG], 3.66 [s, 2H, N-CH2 Sar], 3.57-3.60 [m, 2H, CH22 TEG], 3.41-3.54 [m, 8H, 
CH23,4,5,6 TEG], 3.24 [s, 3H, O-CH3 TEG], 2.51 [s, 3H, N-CH3 Sar], 1.39 ppm [s, 6H, β-CH3 Aib]; 
13C{1H} NMR (75.48 MHz, DMSO-d6, 298 K, TMS): δ =172.52 (C=O Aib), 163.80 (C=O Sar), 
68.8-70.7 (CH23,4,5,6 TEG), 67.44 (CH22 TEG), 63.19 (CH21 TEG), 57.26 (O-CH3 TEG), 54.77 
(C(CH3)2 Aib), 47.94 (N-CH2 Sar), 31.84 (N-CH3 Sar), 23.39 (β-CH3 Aib); FT-IR (KBr): ν =3193 (ν, 
N-H); 2985/2937/2872 (ν, C-H); 2762 (νa,s, NH2+); 1739 (ν, C=O ester); 1684 (ν, amide I); 1554 (ν, 
amide II); 1256 (ν, amide III); 1217 (ν, C-OTEG); 1159 (ν, (TEG)-O). 
 
General route for the synthesis of the complexes. The compound HCl·H-AA1-AA2-OR (AA1= Sar, 
L/D-Pro; AA2= L/D-Ala, Aib; 0.7 mmol) was dissolved in water and the solution was kept at 0°C 
with a water/ice bath. Under continuous stirring, cold CS2 (1.4 mmol) and sodium hydroxide (0.7 
mmol) were added to the solution. The variation of pH from 9 to 6 confirms the reaction of the 
dipeptide with CS2 and the consequent formation of the dithiocarbamato derivative. The ligand 
solution was then added, under vigorous stirring, to an ice-cold water solution of K[AuIIIBr4] (0.35 
mmol), leading to the formation of a ocher-brown precipitate. The solid was separated from the 
mother liquor and washed several times with ice-cold water before drying under reduced pressure 
with P2O5. 
  
[AuIIIBr2(SSC-Sar-L-Ala-OtBu)] (ITØ1) 
Ocher powder; yield: 86%; 1H NMR (300.13 MHz, acetone-d6, 298 K, TMS): δ=7.93 (d, 1H, NH 
Ala), 4.69,4.72 (s, 2H, NCH2 Sar), 4.37 (m, 1H, CH Ala), 3.52, 3.55 ( s, 3H, NCH3 Sar), 1.45 (s, 9H, 
CH3 tBu), 1.36 ppm (d, 3H, CH3 Ala); 1H NMR (300.13 MHz, DMSO-d6, 298 K, δ/ppm, TMS): 8.79 
(m, 1H, NH Ala), 4.53 (m, 2H, NCH2 Sar), 4.18 (m, 1H, CH Ala), 3.36, 3.38 ( s, 3H, NCH3 Sar), 
1.40 (s, 9H, CH3 tBu), 1.23 ppm (d, 3H, CH3 Ala); 13C{1H} NMR (75.48 MHz, acetone-d6, 298 K, 
TMS): δ =196.49, 200.40 (CSS), 172.54 (C=O Ala), 164.48, 164.72 (C=O Sar), 82.36 (C(CH3)3 
tBu), 54.99, 55.97 (NCH2 Sar), 50.35 (CH Ala), 40.08, 41.06 (NCH3 Sar), 28.35 (CH3 tBu), 18.34 
(CH3 Ala); IR (KBr): ν =3317 (ν, N-H); 2979/2932 (ν, C-H); 1733 (ν, C=O ester); 1668 (ν, amide I); 
1564 (n, N-CSS+amide II); 1219 (ν, C-O(tBu)+amide III); 1149 (ν, (tBu)-O); 1003 cm-1 (νa, S-C-S). 
FT-IR (nujol): ν =567 (νs, S–C–S); 419 (νa, S–Au–S); 380 (νs, S–Au–S); 251 (νa, Br–Au–Br); 229 
cm-1 (νs, Br–Au–Br). Elemental analysis: calcd (%) for C11H19AuBr2N2O3S2 (648.19 g mol-1): C, 
20.38; H, 2.95; N, 4.32; S, 9.89%; found: C, 20.52; H, 2.93; N, 4.41; S, 9.90%. 
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[AuIIIBr2(SSC-Sar-D-Ala-OtBu)] (ITØ2) 
Ocher powder; yield: 86%; 1H NMR (300.13 MHz, acetone-d6, 298 K, TMS): δ=7.94 (d, 1H, NH 
Ala), 4.68, 4.72 (s, 2H, NCH2 Sar), 4.37 (m, 1H, CH Ala), 3.52, 3.55 ( s, 3H, NCH3 Sar), 1.45 (s, 9H, 
CH3 tBu), 1.36 (d, 3H, CH3 Ala); 1H NMR (300.13 MHz, DMSO-d6, 298 K, TMS): δ =8,79 (m, 1H, 
NH Ala), 4.53 (m, 2H, NCH2 Sar), 4.17 (m, 1H, CH Ala), 3.36 ( s, 3H, NCH3 Sar), 1.41 (s, 9H, CH3 
tBu), 1.28 (d, 3H, CH3 Ala); 13C{1H} NMR (75.48 MHz, acetone-d6, 298 K, TMS): δ=195.83, 
199.74 (CSS), 171.88 (C=O Ala), 163.57, 163.81 (C=O Sar), 81.70 (C(CH3)3 tBu), 54.33, 55.30 
(NCH2 Sar), 49.68 (CH Ala), 39.42, 40.40 (NCH3 Sar), 27.69 (CH3 tBu), 17.67 (CH3 Ala); FT-IR 
(KBr): ν =3311 (ν, N-H); 2979/2933 (ν, C-H); 1732 (ν, C=O ester); 1668 (ν, amide I); 1563 (ν, N-
CSS+amide II); 1218 (ν, C–O(tBu)+amide III); 1149 (ν, (tBu)-O); 1003 (νa, S-C-S). IR (nujol): ν
=566 (νs, S–C–S); 419 (νa, S–Au–S); 380 (νs, S–Au–S); 251 (νa, Br–Au–Br); 228 cm-1 (νs, Br–Au–
Br). Elemental Analysis calcd (%) for C11H19AuBr2N2O3S2 (648.19 g mol-1): C, 20.38; H, 2.95; N, 
4.32; S, 9.89%; found: C, 19.96; H, 2.86; N, 4.55; S, 9.89%. 
 
[AuIIIBr2(SSC-L-Pro-Aib-OtBu)] (ITØ3) 
After the synthetic procedure described above, the complex was further purified by re-precipitation in 
water from a concentrated acetone solution, obtaining the compound as a dark-orange powder. Yield: 
76%.; 1H NMR (300.13 MHz, acetone-d6, 298 K, TMS): δ=8.01 (s, br, 1H, NH Aib), 4.91-4.95 ( m, 
1H, CH2 Pro), 3.97-4.02 (m, 2H, CH25 Pro), 2.57-2.64 (m, 1H, CH3' Pro), 2.25-2.39 (m, 3H, CH24 + 
CH3 Pro), 1.44 (s, 9H, CH3' tBu), 1.43, 1.47 ppm (s, 6H, CH3 Aib); 1H NMR (300.13 MHz, DMSO-
d6, 298 K, TMS): δ=8.71-8.78 (m, 1H, NH Aib), 4.75-4.78 (m, 1H, CH2 Pro), 3.85-3.89 (m, 2H, 
CH25 Pro), 2.41 (m, 1H, CH3' Pro), 2.08 (m, 3H, CH24 + CH3 Pro), 1.38 (s, 9H, CH3' t-Bu), 1.31, 
1.34 ppm (s, 6H, CH3 Aib); 13C{1H} NMR (75.48 MHz, acetone-d6, 298 K, TMS): δ=190.22 (-CSS), 
172.84 (C=O Aib), 166.69 (C=O Pro), 80.98 (C(CH3)3 tBu), 64.87 (CH2 Pro), 57.28 (C(CH3)2 Aib), 
52.10 (CH25 Pro), 30.84 (CH23 Pro), 28.00 (CH3 t-Bu), 24.56, 25.51 (CH3 Aib), 23.09 (CH24 Pro); IR 
(KBr): ν =3341 (ν, N-H); 2979/2931 (ν, C-H); 1730 (ν, C=O ester); 1680 (ν, amide I); 1553 (ν, N-
CSS amide II); 1247 (ν, C-O(tBu)+amide III); 1147 (ν, (tBu)-O); 1000 cm-1 (νa, S-C-S). FT-IR 
(nujol): ν =535 (νs, S–C–S); 410 (νa, S–Au–S); 376 (νs, S–Au–S); 252 (νa, Br–Au–Br); 222 cm-1 (νs, 
Br–Au–Br). Elemental Analysis calcd (%) for C14H23AuBr2N2O3S2 (688.26 g mol-1): C, 24.43; H, 
3.37; N, 4.07; S, 9.32%; found: C, 24.59; H, 3.47; N, 4.14; S, 8.98%.  
 
[AuIIIBr2(SSC-D-Pro-Aib-OtBu)] (ITØ4) 
Dark-orange powder; obtained as described for the synthesis of IT03. Yield: 25%; 1H NMR (300.13 
MHz, acetone-d6, 298 K, TMS): δ=8.00 (s, br, 1H, NH Aib), 4.91-4.94 ( m, 1H, CH2 Pro), 3.97-4.02 
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(m, 2H, CH25 Pro), 2.54-2.64 (m, 1H, CH3' Pro), 2.28-2.38 (m, 3H, CH24 + CH3'' Pro), 1.44 (s, 9H, 
CH3 tBu), 1.43, 1.47 (s, 6H, CH3 Aib); 1H NMR (300.13 MHz, DMSO-d6, 298 K, TMS): δ=8.78 (s, 
br, 1H, NH Aib), 4.75-4.78 (m, 1H, CH2 Pro), 3.83-3.91 (m, 2H, CH25 Pro) 3.83-3.91 (m, 2H, CH25 
Pro), 2.41 (m, 1H, CH3' Pro), 2.07-2.12 (m, 3H, CH24 + CH3'' Pro), 1.34 (s, 9H, CH3 t-Bu), 1.24, 
1.31 (s, 6H, CH3 Aib). 13C{1H} NMR (75.48 MHz, acetone-d6, 298 K, TMS): δ=190.21 (-CSS), 
23.16 (CH24 Pro); 172.96 (C=O Aib), 166.94 (C=O Pro), 81.10 (C(CH3)3 tBu), 64.92 (CH2 Pro), 
57.44 (C(CH3)2 Aib), 52.08 (CH25 Pro), 30.80 (CH23 Pro), 27.97 (CH3 tBu), 24.67, 25.21 ppm (CH3 
Aib); IR (KBr): ν =3363 (ν, N-H); 2982/2927 (ν, C-H); 1732 (ν, C=O ester); 1680 (ν, amide I); 1549 
(ν, N-CSS+amide II); 1241 (ν, C-O(tBu)+amide III); 1147 (ν, (tBu)-O); 991 cm-1 (νa, S-C-S). FT-IR 
(nujol): ν =533 (νs, S–C–S); 410 (νa, S–Au–S); 376 (νs, S–Au–S); 251 (νa, Br–Au–Br); 222 cm-1 (νs, 
Br–Au–Br). Elemental analysis calcd (%) for C14H23AuBr2N2O3S2 (688.26 g mol-1): C, 24.43; H, 
3.37; N, 4.07; S, 9.32%; found: C, 24.30; H, 3.64; N, 4.06; S, 9.02%. 
 
[AuIIIBr2(SSC-Sar-Aib-OTEG)] (ITØ5) 
After the general synthetic procedure previously described, the compound was further purified to 
eliminate the presence of hydrolyzed compound at the ester function, by dissolving the product in 
dichloromethane and washing it with a water solution of KHCO3 5%. 
Dark-brown powder, Yield: 56%. 1H NMR (300.13 MHz, acetone-d6, 298 K, TMS): δ=8.05 (s, br, 
1H, NH Aib), 4.62, 4.65 (s, 2H, NCH2 Sar), 4.19-4.22 (m, 2H, CH21 TEG), 3.65-3.68 ( m, 2H, -CH22 
TEG), 3.50,3.53 (s, 3H, NCH3 Sar), 3.47-3.62 (m, 8H, CH23,4,5,6 TEG), 3.29 (s, 3H, OCH3 TEG), 
1.50 ppm (s, 6H, CH3 Aib);1H NMR (300.13 MHz, DMSO-d6, 298 K, TMS): δ=8.83 (s, br, 1H, NH 
Aib), 4.47 (s, 2H, NCH2 Sar), 4.10-4.11 (s, br, 2H, -CH22 TEG), 3.36-3.58 (m, 13H, CH21,3,4,5,6 TEG, 
NCH3 Sar), 3.24 (s, 3H, OCH3 TEG), 1.39 (s, 6H, CH3 Aib); 13C{1H} NMR (75.48 MHz, acetone-d6, 
298 K, TMS): δ=195.38, 199.21 (CSS), 173.63 (C=O Aib), 163.54 (C=O Sar), 72.35 (CH2 TEG), 
70.8-71.2 (CH23,4,5 TEG), 69.25 (CH22 TEG), 64.52 (CH21 TEG), 58.52 (OCH3 TEG), 57.00 
(C(CH3)2 Aib), 54.34, 55.17 (NCH2 Sar), 39.36, 40.38 (NCH3 Sar), 24.86 (CH3 Aib); FT-IR (KBr): ν
=3290 (ν, N-H); 2909/2872 (ν, C-H); 1735 (ν, C=O ester); 1683 (ν, amide I); 1576 (ν, N-CSS); 1549 
(ν, amide II); 1253 (ν, amide III); 1210 (ν, C–OTEG); 1159 cm-1 (ν, TEG-O). IR (nujol): ν =569 (νs, 
S-C-S); 412 (νa, S-Au-S); 390 (νs, S-Au-S); 250 (νa, Br-Au-Br); 226 cm-1 (νs, Br-Au-Br). Elemental 
analysis calcd (%) for C15H27AuBr2N2O6S2 (752.30 g mol-1): C, 23.95; H, 3.62; N, 3.72; S, 8.52%; 
found: C, 24.40; H, 3.55; N, 3.70; S, 8.57%. 
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X-ray Crystallography 
Single crystal data were collected with a Bruker Smart Breeze area detector diffractometer, Mo Kα: λ 
= 0.71073 Å. The unit cell parameters were obtained using 60 ω-frames of 0.5° width and scanned 
from three different zone of reciprocal lattice. The intensity data were integrated from several series 
of exposures frames (0.3° width) covering the sphere of reciprocal space111. An absorption correction 
was applied using the program SADABS111 with min. and max. trasmission factors of: 0.676-1.000. 
The structures were solved by direct methods (SIR2004111) and refined on F2 with full-matrix least 
squares (SHELXL-97112), using the WinGX software package113.  
For IT05, the crystals were of poor quality and of small size, and this affected the overall quality of 
the data. For this reason, only the atoms comprising the coordination sphere were refined 
anisotropically, whereas the remaining atoms were refined isotropically. The hydrogen atoms were 
placed at their calculated positions. In the lattice, solvent molecules of crystallization (pentane) were 
found but could not be properly modelled during the refinement, and they were treated with the 
SQUEEZE program114. According to the residual electron density, the crystal lattice contained 
approximately one molecule of pentane per complex molecule. Graphical material was prepared with 
the ORTEP3 for Windows115 and Mercury CSD 3.1116. 
 
Chromatography 
Separation of the two forms of complex AuL23 was accomplished by preparative layer 
chromatography on silica gel Merck Kieselgel 60F254 precoated glass plates (2 mm thick) in 
dichloromethane/ethanol 97:3. Retention factors (Rf) of 0.9 and 0.3 were measured for the major and 
the minor species, respectively. Once detached from the plate, each fraction was washed with fresh 
dichloromethane, filtered and evaporated to dryness under reduced pressure. 
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Results and discussion 
The synthesis of the esterified dipeptides HCl.Sar-L/D-AlaOtBu (respectively P1, P2), HCl.L/D-
ProAibOtBu (respectively P3, P4), HCl.SarAibOTEG (P5) was performed in solution starting from 
the single protected amino acids, by using proper coupling agents. The synthesis in solution was 
preferred over the solid phase route since the preparation of the oligopeptides require a reasonable 
number of synthetic steps, moreover allowing the obtainment of higher amounts of products. The 
general procedure followed is described in Scheme 1.1. 
 
Scheme 1.1: schematic general synthetic route for the synthesis of hyrochloride dipeptides esters P1-P5 (R= OtBu, 
OTEG; AA1= Sar, L/D-Pro; AA2=L/D-Ala, Aib). 
 
Briefly, the C-terminal aminoacid was first esterified to protect the carboxylate function. The tert-
butyl function was introduced by reacting under pressure the Z-protected amino acid with isobutane 
for 1 week, while the TEG fraction was coupled to the Z-protected amino acid using as coupling 
agents EDCI/HOBt.  
The esterified amino acid was then deprotected at the N-terminus through catalytic hydrogenation 
over Pd/C (10%) in organic solution, and then coupled to the Z-protected C-ter amino acid. Particular 
attention was paid in the choice of the coupling reagents in this step, since the use of 
isobutylchloroformiate usually causes racemization at the C-ter amino acid as a consequence of a 
mixed anhydride formation (Figure 1.1). This is not relevant when Sar is used as first amino acid in 
the oligopeptide sequence, but must be taken into account when chiral L/D-Pro are either used (e.g., 
for the synthesis of P2 and P3) as the optical purity of the amino acid must be conserved. For this 
reason, in such case a different method is adopted and EDCI/HOBt is rather used (Figure 1.2). In this 
way the racemization of the aminoacid is prevented due to the formation of an ester between L/D-Pro 
and HOBt, which results less reactive than the mixed anhydride and do not allow racemization. 
After removing the N-ter Z-protecting group by hydrogenation all the dipeptides were transformed in 
their hydrochloride form by reacting the esterified dipeptide with HCl in ether solution.  
(1) (2) 
(3) 
(4) 
(5) 
(6a, 6b) 
OR 
OH 
OR 
OR 
OR 
Z 
Z 
H 
Z 
Z 
HCl.H 
OH 
AA1 AA2 
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Figure 1.1: schematic representation of peptide bond formation using isobutylchloroformiate as coupling reagent. 
 
Figure 1.2: schematic representation of peptide bond formation using HOBt/EDC approach. 
 
The tert-butyl ester was used as C-protecting group (i.e. COOR) since it has been previously shown 
that the COOH-containing derivatives are not active. Screening between -OMe, -OEt and -OtBu 
esters as protecting groups, demonstrated that hydrophobic and sterically hindered ligand would be 
beneficial to the biological activity of the Au(III) complexes, and -OtBu protected complexes are 
much better than the –OMe ester protected counterparts in terms of antitumor activity.  
On the other hand, the more hydrophobic the complexes the less soluble in aqueous medium. This is 
an important issue to take into account when considering the biological application of the synthesized 
compounds. For this reason a complex with TEG-ester functionalization was prepared, enhancing 
water solubility through the presence of ethyloxy-groups, but keeping the hinderance to the C-
terminus of the complex. The properties of the compound IT05 thus prepared was compared to the 
previously prepared -OtBu esterified counterpart AuD8 [AuIIIBr2(dtc-Sar-Aib-OtBu)]101. 
The choice of Sar in P1/P2 was suggested by the stability and the antiproliferative activity of 
previously synthesized compounds, as for example [AuIIIBr2(ESDT)] (AuL12) described in the 
Introduction. Conversely, in P3 and P4 sarcosine was substituted by Pro because it is a chiral N,N-
substituted aminoacid and has also the advantage to be, almost in principle, more easily recognized 
by PEPT transporters, thus possibly enhancing the cellular uptake of the complexes.  
The hydrochloride dipeptides were then used for the synthesis of the corresponding gold(III) 
dithiocarbamato complexes [AuIIIBr2(dtc-Sar-L/D-AlaOtBu)] (IT01 and IT02, respectively), 
[AuIIIBr2(dtc-L/D-Pro-AibOtBu)] (IT03 and IT04, respectively), [AuIIIBr2(dtc-SarAibOTEG)] 
(IT05) (Scheme 1.2, Figure 1.3). In particular, the dithiocarbamato functionalized oligopeptide was 
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prepared in situ, treating the water solution of the hydrocloride dipeptide with NaOH and CS2. When 
the pH of the solution drops from 9 to 6, the reaction proceeds leading to the formation of the ligand, 
which is not sufficiently stable in this conditions and cannot be isolated. Therefore, it is added 
directly to a water solution containing 0.5 eq of KAuBr4, leading to the precipitation of ocher-brown 
powdery solids. In some cases, further purification through flash chromatography was necessary to 
eliminate undesired side-products.  
 
 
Scheme 1.2: schematic general synthetic route for the synthesis of gold(III) dithiocarbamato complexes (IT01/02 R1= 
CH3; R2=H; R3=CH3; R4=H; R5= -tBu. IT03/04 R1+R2= -(CH)(CH2)3-; R3= R4=CH3; R5= -tBu. IT05: R1= CH3; R2=H; 
R3= R4=CH3; R5= -TEG). 
 
 
Figure 1.3: chemical structures of gold(III)-dithiocarbamato complexes IT01-05. 
 
FT-IR analysis was proved useful to characterize the synthesized complexes (Table 1.1).  
Concerning the vibration modes of the peptide chain, the main signals are generated by the ν(N-H) of 
the amide proton at 3550-3200 cm-1 (Amide A band), and by the three characteristic bands referred to 
as amide I, II and III, generated by combination of ν(C=O), δ(N-H) and ν(C-N) characteristic of the 
C(O)NH function. 
In particular, amide I is the combination of the above mentioned modes in 80:10:10 ratios, 
respectively. It can be normally found between 1660-1620 cm-1 when C=O are involved in hydrogen 
bonds, and between 1710-1660 cm-1 when not. The amide II band is characterized by a contribution 
of δ(N-H) and ν(C-N) in a 60:40 ratio respectively, and can be either found at 1570-1540 cm-1 when 
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the N-H group is involved in the formation of H-bonds and at 1520-1500 cm-1 when the N-H group is 
"free" (the more the proton is involved in H-bonding, the more high the wavenumber of the vibration 
mode). The amide III is similarly constituted by a 40:30 contribution of δ(N-H) and ν(C-N), and is 
normally found in 1300-1240 cm-1 range, with a shift to higher wavenumber when the proton of the 
amide is involved in H-bonds.  
The most diagnostic regions to verify the formation of the gold(III) dithiocarbamato complex are 
principally three:  
• the 1580-1450 cm-1 region, primarily associated with the “thioureide” band of the ν(N-CSS) 
vibration;  
• the 1060-940 cm-1 region, associated with ν(S-C-S) vibrations;  
• the 420-350 cm-1 region, associated with ν(M-S) vibrations. 
Upon complex formation, the deprotonation of the free dipeptide to form the corresponding 
dithiocarbamato moiety causes the disappearance of the signal at 2766-2743 cm-1 generated by the 
νa/s(NH2+) vibration mode, and the appearance of both the ν(N-CSS) band at 1580-1450 cm-1 
(somewhat overlapped to amide II band) and the νa(S-C-S) band at 1060-940 cm-1. 
As described by Chatt et al.117, the dithiocarbamato function is characterized by a strong 
delocalization of electrons in the dithiocarbamate moiety, and can be described by three main 
resonance structures (Figure 1.4). The position of the ν(N-CSS) band recorded for our compounds 
are consistent with the presence of a carbon-nitrogen bond which order lies between a single bond 
(ν=1350-1250 cm-1) and a double bond (ν~=1690-1640 cm-1)118. This is consistent thus with a main 
contribution to the structure deriving from the resonance form III, consisting in a symmetric chelated 
coordination of the dithiocarbamato function to the gold(III) metal center119.  
 
 
Figure 1.4: resonance forms of the dithiocarbamic –NCSS- moiety. 
 
Moreover, following the Bonati-Ugo criterion120, the presence of a single band for the νa(S-C-S) at 
1022-991 and the νs(S-C-S) at 569-533 cm-1 further confirms the presence of a bidentate symmetric 
coordination (Figure 1.5).  
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Figure 1.5: Different ways of metal-sulfur binding in dithiocarbamate complexes: symmetrical bidentate (a), 
asymmetrical bidentate (b) and monodentate (c). 
 
The formation of a symmetrically chelated dithiocarbamato is demonstrated also by the metal-sulfur 
stretching vibrations signals νa/s(S-Au-S) at 419-410/390-376 cm-1, in accordance to previously 
reported data119. Moreover, the vibration of the cis-coordinated halides νa/s(Br-Au-Br) can be rather 
found at 252-250/229-220 cm-1 119,120,121.  
 
Table 1.1: FT-IR frequencies of ligands P1-P5 and corresponding complexes IT01-IT05 
 Vibrational mode [cm-1] 
Comp. ν NH νa/s 
NH2+ 
ν C=O amide 
I 
ν N-
CSS 
Amide 
II 
Amide 
III 
νa/s 
SCS 
νa/s 
SAuS 
νa/s 
XAuX 
P1 3332 2736 1735 1669 - 1564 1266 - - - 
IT01 3317 - 1733 1668 1564a 1219 1003/ 
567 
419/ 
380 
251/ 
229 
P2 3332 2766 1735 1669 - 1564 1266 - - - 
IT02 3311 - 1732 1668 1563 a 1218 1003/ 
566 
419/ 
380 
251/ 
228 
P3 3430 2744 1733 1678 - 1551 1265 - - - 
IT03 3341 - 1730 1680 1553 a 1247 1000/ 
535 
410/37
6 
252/22
0 
P4 3437 2743 1733 1678 - 1551 1256 - - - 
IT04 3363  1732 1680 1549 a 1241 991/ 
533 
410/ 
376 
251/ 
222 
P5 3193 2762 1739 1648 - 1554 1256 - - - 
IT05 3290 - 1735 1683 1576 1549 1253 1022/ 
569 
412/ 
390 
250/ 
226 
a
 ν N-CSS and amide II are overlapped. 
 
All the synthetized dipeptides, P1-P5 and the corresponding gold(III) complexes IT01-IT05 were 
analyzed by means of 1H (Table 1.2) and 13C (Table 1.3) NMR spectroscopy. In general, the proton 
signals of the dipeptide backbone undergo a downfield shift upon complex formation, less evident 
when the distance from the metal center increases as previously reported for similar compounds119. 
The protons located on -NCSS proximal groups undergo a chemical shift increase of about 1 ppm, 
while the amide signal follows an opposite trend, with chemical shift value lowered by 0.1-0.2 ppm 
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in the complex with respect to the free dipeptide. This trend is generally observed also for the 13C 
signals (Table 1.3). The formation of the dithiocarbamato moiety is confirmed by the disappearance 
of the proton amine signal at 9.00-9.80 ppm of the free dipeptide, and by the appearance in the 13C-
NMR spectrum of the signal related to the dithiocarbamato carbon at 190.2-199.2 ppm (Table 1.3), 
in accordance with literature data for complexes with metals in high oxidation states, as 
gold(III)122,123.  
 
Table 1.2: 1H NMR chemical shifts of ligands and complexes in DMSO-d6. 
 δ (1H) [ppm] 
Compound RO AA1 AA2 NH3+ 
 R=OtBu AA1=Sar AA2=L-Ala  
P1 1.40 ((CH3)3C) 2.53 (N-CH3) 1.28 (β-CH3) 9.00 
  3.70 (N-CH2) 4.17 (α-CH)  
   8.88 (NH)  
IT01 1.40 ((CH3)3C) 3.37 (N-CH3) 1.23 (β-CH3)  
  4.53 (N-CH2) 4.18 (α-CH)  
   8.79 (NH)  
  AA1=Sar AA2=D-Ala  
P2 1.40 ((CH3)3C) 2.52 (N-CH3) 1.27 (β-CH3) 9.12 
  3.69 (N-CH2) 4.16 (α-CH)  
   8.96 (NH)  
IT02 1.41 ((CH3)3C) 3.36 (N-CH3) 1.28 (β-CH3)  
  4.53 (N-CH2) 4.17 (α-CH)  
   8.79 (NH)  
  AA1=L-Pro AA2=Aib  
P3 1.32 ((CH3)3C) 1.83(CH3'', CH24) 1.36 (β-CH3) 9.80 
  2.27 (CH3') 8.92 (NH)  
  3.15 (CH2V)   
  4.11 (CH2)   
IT03 1.38 ((CH3)3C) 2.08(CH3, CH24) 1.31, 1.34 (β-CH3)  
  2.41 (CH3') 8.75 (NH)  
  3.85-3.89 (CH25)   
  4.75-4.78 (CH2)   
 
  AA1=D-Pro AA2=Aib  
P4 1.36 ((CH3)3C) 1.83(CH3'', CH24) 1.33, 1.37 (β-CH3) 9.34 
  2.29 (CH3') 8.94 (NH)  
  3.15 (CH25)   
  4.14 (CH2)   
IT04 1.38 ((CH3)3C) 2.07-2.12 (CH
3
'', 
CH24) 1.31, 1.34 (β-CH3) 
  2.41 (CH3') 8.78 (NH)  
  3.83-3.91 (CH25)   
  4.75-4.78 (CH2)   
  AA1=Sar AA2=Aib  
P5 3.24 (O-CH3) 2.51 (N-CH3) 1.39 (β-CH3) 9.04 (NH) 
 3.41-3.54 (CH23,4,5,6) 3.66 (N-CH2) 9.04 (NH2)  
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 3.57-3.60 (CH22)    
 4.10-4.13 (CH1)    
IT05 3.24 (O-CH3) 2.51 (N-CH3) 1.39 (β-CH3)  
 3.36-3.58 (CH21,3,4,5,6) 4.47 (N-CH2) 8.83 (NH2)  
 4.10-4.11 (CH22)    
 4.10-4.13 (CH1)    
 
Table 1.3: 13C NMR chemical shifts of ligands and complexes, in DMSO-d6. 
 δ (13HC) [ppm]  
Compound RO AA1 AA2 C-SS 
 R=OtBu AA1=Sar AA2=L-Ala  
P1 27.36 ((CH3)3C) 32.40 (N-CH3) 16.75 (β-CH3)  
 80.58 ((CH3)3C) 48.53 (N-CH2) 48.29 (β-CH3)  
  164.86 (C=O) 171.27 (β-CH3)  
IT01 28.35 ((CH3)3C) 40.08, 41.06 (N-CH3) 18.34 (β-CH3) 196.49, 200.4 
 82.36 ((CH3)3C) 54.99, 55.97 (N-CH2) 50.35 (α-CH)  
  164.72 (C=O) 172.54 (C=O)  
 R=tBu AA1=Sar AA2=D-Ala  
P2 27.28 ((CH3)3C) 32.41 (N-CH3) 16.76 (β-CH3)  
 80.55 ((CH3)3C) 48.52 (N-CH2) 48.29 (α-CH)  
  164.87 (C=O) 171.22 (C=O)  
IT02* 27.69 ((CH3)3C) 39.42, 40.40 (N-CH3) 17.67 (β-CH3) 195.83, 199.74 
 81.70 ((CH3)3C) 54.33, 55.30 (N-CH2) 49.68 (α-CH)  
  163.81 (C=O) 171.88 (C=O)  
 R=tBu AA1=L-Pro AA2=Aib  
P3 27.19 (-
C(CH3)3) 
23.56 (CH24 ) 24.08, 24.78 
(CH3) 
 
 
79.71 (-
C(CH3)3) 
29.67 (CH23 ) 172.15 (C=O)  
  45.55 (CH25 )   
  58.26 (CH2 )   
IT03* 28.00 (-C(CH3)3) 
23.09 (CH24 ) 24.56, 25.51 
(CH3) 
190.22 
 
80.98 (-
C(CH3)3) 
30.84 (CH23) 57.28 (C(CH3)2) 
 
 
 
52.10 (CH25) 172.84 (C=O)  
 
 
64.87 (CH2) 
  
 R=tBu AA1=D-Pro AA2=Aib  
P4 27.13 (-C(CH3)3) 23.28 (CH24)  172.06 (C=O) 
 
 
 79.65 (-C(CH3)3) 29.59 (CH23)   
  45.32 (CH25)   
 
 58.07 (CH2)   
IT04* 27.97 (CH3 t-Bu) 23.16 (CH24) 24.67, 25.21 (CH3) 190.21 
 81.10 (-C(CH3)3) 30.80 (CH23)   
 
 52.08 (CH25) 57.44 (C(CH3)2)  
 
 64.92 (CH2) 172.96 (C=O)  
 R=TEG AA1=Sar AA2=Aib  
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P5 57.26 (O-CH3)    
 63.19 (CH21) 31.84 (N-CH3) 23.39  (β-CH3)  
 67.44 (CH22) 47.94 (N-CH2) 54.77 (C(CH3)2)  
 
68.8-70.7 
(CH23,4,5,6 ) 
 172.52 (C=O) 
 
IT05* 58.52 (OCH3) 39.36, 40.38 (NCH3) 24.86 (CH3) 195.38, 199.21 
 64.52 (CH21 ) 54.34, 55.17 (NCH2) 173.63 (C=O)  
 69.25 (CH22 )    
 
70.8-71.2 (CH2 
3,4,5) 
   
* acetone-d6 
 
In both the 1H and the [1H,13C]-HMBC spectra of IT01 in acetone-d6 and DMSO-d6 (Figures 1.6, 1.7 
and 1.8 respectively), a set of signals (two singlets) is recorded for the protons of N-CH3 and N-CH2 
groups of the sarcosine residue, and for the dithiocarbamic carbon CSS at nearly 192 ppm (Figure 
1.8).  
This can be explained by the presence in solution of two different isoforms of the compounds, whose 
relative abundance varies depending on the synthetic conditions93. Moreover, as we can see from 
Figure 1.6 and 1.7, the behavior of the compound is quite different in the two solvents, since in 
acetone-d6 (Figure 1.6) the relative intensity of the two isomers changes with time, favouring the 
formation of the major species, while in DMSO-d6 this interconversion does not occur and the 
relative abundance of the isomers does not change significantly even after 48 h (Figure 1.7).  
 
Figure 1.6: 1H-NMR spectra of IT01 in acetone-d6 over 24h. 
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Figure 1.7: 1H-NMR spectra of IT01 in DMSO-d6. 
 
Figure 1.8: [1H,13C]-HMBC spectrum of IT01 in (CD3)2CO. 
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The two species were not resolved since recently, when we were able to separate the two forms of 
one of the most studied and characterized gold(III) dithiocarbamato complexes, AuL23 
[AuIIIBr2(SSC-Sar-OMe)] (Figure 1.9), during the experiments aimed at obtaining high purity 
compounds for the in vitro and in vivo biological evaluations. 
 
 
Figure 1.9: molecular structure of AuL23 forms, Au23-1 (above) and AuL23-2 (bottom). 
 
In Figure 1.10 the 1H NMR spectra over time of crude AuL23 are shown. Similarly to what reported 
for IT01, two proton signals at 3.58/3.61 and 4.79/4.81 ppm were recorded in acetone-d6 for the N-
methyl and N-methylene groups, respectively. The NCH3/NCH2 couples at 3.58/4.79 and 3.61/4.81 
ppm belong to two different species, as confirmed by the mutual long-range couplings observed in 
the [1H,13C] HMBC spectrum (Figure 1.11), thus accounting for the coexistence of two forms for 
complex AuL23. This is confirmed by the presence of two 13C signals recorded for both the C=O and 
the NCSS carbons as well, each giving rise to long-range couplings with one set of NCH3/NCH2 
signals. The analysis of the 1H NMR spectra of the native complex AuL23 in acetone-d6, confirmed 
the same behaviour recorded for IT01, with the minor species irreversibly interconverting into the 
major one over time, leading to its almost complete disappearance (Figure 1.10A and 1.10B). The 
same behavior was observed also in CDCl3 and CD2Cl2 (data not shown) whereas no interconversion 
occurred in either CD3OD (data not shown) or DMSO-d6 over 24 h (Figure 1.10C and 1.10D), 
confirming the crucial role played by the solvent. 
Chapter 1. Design, synthesis and characterization of gold(III) peptidomimetics
 
Figure 1.10: 1H NMR spectrum of complex 
and in DMSO-d6 (C) soon after dissolution and (D) after 24 h.
Figure 1.11: [1H,13C] HMBC spectrum of complex 
 
The two forms were isolated by preparative layer chromatography and characterized by 
1H-NMR spectroscopy (Figure 
dithiocarbamato derivative AuL23
analysis (Figure 1.13). The minor species 
bridging dithiocarbamato ligands are bound to both gold(III) centers whose coordination sphere is 
completed by two trans-bromides, as suggested by the ab
Br−Au−Br stretching vibrations in the far
 
47 
AuL23 over time in acetone-d6 (A) soon after dissolution and (B) after 24 h, 
 
1 in acetone-d6 (dotted arrows indicate long
1.12). The major species was identified as the expected gold(III)
-1 depicted in Figure 1.9, whose structure was confirmed by X
AuL23-2 is consistent with a gold(III) dimer in which two 
sence of both the symmetric S
-IR spectrum (Figure 1.12).  
 
 
 
-range 1H-13C couplings). 
FT-IR and 
-
-ray 
−Au−S and 
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Figure 1.12: detail of the 1H NMR (in CD2Cl2) and IR spectra of (A) native raw complex 1, and (B) the major and (C) 
the minor forms as isolated by preparative layer chromatography. 
 
Single crystals of compound Aul23-1 allowed the resolution of the 3D structure of the compound, 
reported in Figure 1.13A (for further details see Appendix 1). 
 
Figure 1.13: (A) X-ray crystal structure with atom numbering scheme for [AuIIIBr2(dtc-Sar-OCH3)] (1), with thermal 
ellipsoids drawn at 30% probability. (B) Crystal packing of 1 with Au−S (2)'' and Au−Br(1)' distances (Å) (symmetry 
codes: ' = 1+x; y; z, '' = 1-x; y; z). The corresponding crystallographic data as well as a list of selected bond lengths and 
angles are reported in Table S1 and Table S2, respectively. 
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Going back to our gold(III)-peptidomimetic compounds IT01-IT05, the thermal behaviour of the 
synthesized complexes have been studied by thermogravimetric (TG) and differential scanning 
calorimetry (DSC) techniques in a dynamic atmosphere of air, in order to establish the different 
decomposition processes and to confirm the proposed stoichiometry. The experimental data agree to 
a good extent with the ones obtained by other spectroscopic techniques, and the results of such 
analysis summarized in Table 1.4, indicate a good correlation between calculated (to metallic gold) 
and found weight loss values for all the investigated compounds. 
 
Table 1.4: Thermogravimetric (TG) and differential scanning calorimetric (DSC) data. 
Compound 
Weight loss (%) DSC 
Found Calculated Peak temperature [°C] (process*) 
IT01 67.95 69.61 158.0 (endo); 499.4 (exo) 
IT02 67.90 69.61 151.0 (endo); 469.4 (exo) 
IT03 72.00 71.38 113.7 (endo); 439.7 (exo) 
IT04 71.89 71.38 178.0 (endo); 436.7 (exo) 
IT05 73.82 72.61 122.6 (endo); 493.7 (exo); 542.1 (exo) 
*endo/exo=endothermic/exothermic 
 
The thermal degradation of all the complexes is likely to occur in two major steps, the first TG step 
corresponding to the pyrolysis, the decarboxylation and reduction elimination Au(III)→Au(I), thus 
leading to [Au(SCN)] as the residue, a commonly discovered intermediate in the thermal 
decomposition of metal dithiocarbamates124. The removal of the remaining ligand atoms at higher 
temperature is followed by complete degradation leading to metallic gold125,126.  
After the purification of the gold(III) dithiocarbamato complexes, the crystals of two complexes were 
grown, in particular for the racemate [AuIIIBr2(dtc-L/D-ProAibOtBu)] (IT03/IT04) and [AuIIIBr2(dtc-
SarAibOTEG)]⋅(IT05). 
By exploiting the Wallach rule127 ("racemates pack better"), a racemal mixture of [AuIIIBr2(dtc-L,D-
Pro-Aib-OtBu)] was prepared to grow single crystals and to solve the crystal structure (the D-
enantiomer IT04 is shown in Figure 1.14).  
As expected, Au adopts a planar square coordination. The Au-S and Au-Br bond values, as well as 
the bond angles, are comparable to those of the few available similar crystal structures128,129. The Pro 
N atom adopts a sp2 hybridization. The values of the D-Pro and Aib φ, ψ torsion angles are 81°, –
166° and 54°, 37°, respectively (see Appendix 1).  
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Figure 1.14: molecular structure of the racemate IT04 [AuIIIBr2(dtc-L,D-Pro-Aib-OtBu)] (crystal obtained from a 
CH2Cl2/n-pentane mixture) 
 
In summary, the solved molecular structure indicate that: (i) the planar geometry of the Au(III) 
complexes is not affected by a bulky ligand (a dipeptide); (ii) Pro and Aib are folded in their typical 
conformations (semi-extended and helical, respectively).  
 
 
 
Figure 1.15. Molecular structure of [AuIIIBr2(dtc-Sar-Aib-OTEG)] (IT05). Thermal parameters are depicted at the 30% 
probability level. 
 
The molecular structures of IT05 is reported in Figure 1.15. The metal exhibits a square planar 
geometry achieved by the S,S chelate dithiocarbamate ligand and by two bromine atoms. The 
coordination environment of the metal and the coordination distances (Table A6, Appendix 1) are in 
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agreement with previously reported data for gold complexes with a dithiocarbamate ligand and two 
bromide anions (Appendix 1)129,130. The peripheral methylated triethylene glycol is folded towards the 
dithiocarbamate moiety and the three ethereal oxygen atoms, O(4)-O(6), are capping the C(2) methyl 
group of the ditiocarbamate ligand. The crystal packing shows that the IT05 molecules are irregularly 
stacked along the b crystallographic axis (Figure A3 in Appendix 1), and that the long arm of the 
ligand originating from the C(3) atom, is responsible of several C-H···O interactions (Figure A4, 
Appendix 1). In addition, there is a bifurcated hydrogen bond between the N(2)-H and the O(4)’ and 
O(5)’ atoms of a symmetry related triethylene glycol residue (symmetry code = 1/2-x; 1/2+y; z), 
d[N(2)··O(4)’] = 3.00(3) Ǻ, and d[N(2)··O(5)’] = 3.18(4) Ǻ, that is mainly responsible of the 
conformations adopted by the methylated triethylene glycol. 
To sum up, in this Chapter is reported the synthesis and the characterization of newly synthetized 
gold(III)-peptidodithiocarbamato complexes, with possible application in targeted anticancer therapy.  
The oligopeptides were prepared using liquid phase synthesis approach, and further purified by flash 
chromatography. They were subsequently functionalized by reaction in aqueous condition with CS2, 
to obtain the dithiocarbamato ligands, used in situ for the synthesis of the corresponding gold(III) 
derivative, which precipitate from solution. The synthetic procedure allowed the obtainement of the 
complexes with yields of 50-70%, depending on the substrate used. Nonetheless, the complexes were 
further purified, to separate the two isoforms obtained from the reaction crude (mononuclear and 
dinuclear gold(III) dithiocarbamato species) by exploiting the thin layer chromathography technique. 
Finally, the crystal structure of three compounds, IT03, IT04 and IT05 were obtained, confirming the 
geometry and stoichiometry proposed for the major species formed from the one-pot reaction. 
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Chapter 2 
Synthesis of AuL12 and IT03 in MeOH in anhydrous conditions 
 
So far, a general route has been followed for the synthesis of these complexes, which combined 
several steps (dithiocarbamic group formation, deprotonation and metal ion coordination) in a one-
pot reaction. The main drawback of this procedure was identified in the conversion rate of starting 
material, which often do not exceed 50%. 
Early studies focused on mechanistic details of this reaction, by using sarcosine ethyl ester (ES 
hereon) as substrate, has pointed out ester hydrolysis as the main cause of degradation of the 
substrate, together with the formation of a number of byproducts. The degradation process is favored 
by the presence of a base in aqueous solution, but these conditions also favored the establishment of 
an equilibrium between the neutral and the protonated substrate. This latter depletes the amount of 
substrate available to the dithiocarbamate conversion, by forming a cationic counterion (Figure 2.1). 
 
 
Figure .2.1: Reactions occurred during the template synthesis of ES dithiocarbamic acid. 
In addition, the efficiency of this synthetic strategy is largely influenced by the nature of the 
substrate, leading in some cases to highly limited final yields or even to total starting material 
inertness, as in the case of primary amines (for which this procedure was proved to be not suitable), 
or more complex systems, such as long oligopeptides, for which unspecific metal binding on the side 
chain can occur. In order to overcome the limitations of the technique, the attention has been focused 
on the study of the mechanistic details of the synthetic pathway. 
In this Chapter it has been reported a detailed study, mainly based on NMR spectroscopy, which has 
led to interesting results. In fact, by screening and modifying the reaction conditions, total conversion 
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of the starting material to dithiocarbamate derivative has been obtained for several substrates, leading 
to increase the final yields in Au(III) complexes in many cases. 
The variety of the investigated substrates has led to the development of a methodology for the 
synthesis of dithiocarmabates that allows the total conversion of the starting material. In particular, 
the proposed methodology has been found successful also in case of more complex substrates. 
 
Experimental section 
All the synthetic operations were performed under inert atmosphere (N2, Ar) by using Schlenk-line 
technique. A methanol solution of the hydrochloride substrate (HCl.ES, HCl.H-L-Pro-Aib-OtBu; 2 
mL, 1 eq) was cooled at 0°C. Cold carbon disulfide (CS2, 2 eq) was added to the solution, followed 
by the dropwise addition of a methanol solution of NaOtBu (2 eq, 1 mL) under continuous stirring, in 
order to neutralize the starting material. The reaction has been kept under stirring for half an hour, 
after which cold (K[AuBr4])MeOH solution (1 eq, 2 mL) has been added dropwise to the mixture, 
leading to direct precipitation of the complex. The solid was filtered-off, washed with cold water and 
finally dried in a dessicator with P4O10. 
NMR spectra in CD3OD (residual peak 3.31 ppm) have been recorded after half an hour from the 
addition of CS2, to check the progress of the substrate conversion. For each experiment, an aliquot of 
reaction crude has been withdrawn, dried under nitrogen flux and newly dissolved in the proper 
deuterated solvent. NMR spectra of final complexes were registered, according to their solubility, in 
acetone-d6 (residual peak 2.05 ppm) or DMSO-d6 (residual peak 2.5 ppm). 
 
Results and discussion 
2.1 Synthesis of Aul12 
Several substrates have been investigated with the aim to assess the applicability of the method. The 
ES has been used to obtain a promising Au(III)-based drug candidate synthesized in our lab, better 
known as AuL12. From a chemical point of view, the presence of sarcosine at the N-terminal, where 
the dithiocarbamato formation takes place, confers stability to the synthesized dithiocarbamate, as a 
hydrogen atom (N-H) is replaced by a methyl group (N-CH3). Interestingly, for several gold(III)-
dithiocarbamato complexes synthesized in our lab, promising biological activity have been exhibited 
when a Sar residue is placed at the N-terminal of the peptide moiety, pointing out an interesting 
structure/activity relationship19,107. 
 As already mentioned above, early preliminary investigations on this substrate evidenced ester 
hydrolysis as the main issue correlated with the use of the traditional methodology. To overcome this 
inconvenience, presence of water has been minimized by using freshly distilled methanol and by 
performing all the operations in an inert atmosphere; in addition, stoichiometric amounts of base have 
been used. The substrate, available as chlorhydrate form, has 
tBuONa, to make the amino group entirely available for the reaction with CS
1H-NMR spectrum in CD3OD for ES chlorhydrate shows two singlets, attributable to N
ppm) and to α-CH2 (δ 3.96 ppm) hydrogen nuclei, both considered diagnostic of the reaction 
progress, as they result the most affected by dithiocarbamate formation. In addition, the spectrum 
shows a triplet (δ 1.32 ppm) and a quartet (
of ethyl ester (Figure 2.2). Successively to the neutralization of 
developed with propyl-amine has been applied. After half an hour, the two singlets corresponding to 
N-CH3 and α-CH2 undergo considerable downfield chemical shift (
respectively) due to the formation of dithiocarbamato group (
presence of only one species, confirming the total conversion of the substrate (
Figure 2.2: 1H-NMR spectrum of the substrate
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been pre-treated with 1 equivalent of 
2.
δ 4.31 ppm) attributable to methyl and methylene groups 
the hydrochloride
δ 0.81 and 0.99 ppm, 
Table 2.1). The spectrum reveals the 
 ES (expanded view of the alkyl region). Solvent: methanol
 
 
-CH3 (δ 2.76 
, the procedure 
Figure 2.3). 
 
-d4; 200MHz. 
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Figure 2.3: 1H-NMR spectrum of the reaction between ES and CS
alkyl region). Solvent: methanol-d4; 200MHz.
 
Table 2.1: 1H-NMR spectral data for ES chlorhydrate and dithiocarbamic derivative (ESDT)
1H
*relative peak area integral
In an attempt to assess the compatibility of the new reaction conditions with the formation of the final 
gold complex, a methanol solution containing one equivalent of K[Au(Br)
to the dithiocarbamate solution. The addition has been performed inversely with respect to the 
procedure used in the template synthesis, to assess possible differences in 
case, differently from the old strategy for which 0.5 equivalents of gold precursor were used for the 
complexation of 1 equivalent of ligand, a stoichiometric amount of metal precursor has been used. 
The formation of a brownish orange precipitate is soon observed and successively isolated from the 
orange mother liquor. The two fractions were investigated 
AuL12 and IT03 in MeOH in anhydrous conditions
56 
2 in presence of base after 1/2h (expanded view of the 
 
 
-NMR ES-H+ ESDT- 
A* δ (ppm) A δ (ppm) 
O-CH2 2 4.31 q 2 4.18 
α-CH2 2 3.96 s 2 4.96 
N-CH3 3 2.76 s 3 3.57 
CH3 3 1.32 t 3 1.27 
 
4] has been added dropwise 
the formed products. In this 
via 1H-NMR spectroscopy (
 
 
Figure 2.4).  
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The spectrum in acetone-d6 for the isolated precipitate reveals the presence of two species with 
similar chemical shifts, similarly to what already described in Chapter 1 for the analogous 
compound AuL23.  
In fact, in the region of α-CH2 two singlets are detected (δ 4.78 and δ 4.81 ppm, respectively), as well 
as for N-CH3 region (δ 3.57 and δ 3.61 ppm, respectively), with a constant integral ratio of 1.5. On 
the other hand, the signals related to the ester group (δ 1.28 and δ 4.28 ppm for methyl and 
methylene, respectively) do not show duplicity and the ratio between integral values of these signals 
with respect to the integral sum of each couple of singlets found for α-CH2 and N-CH3 confirm that 
ester hydrolysis does not occur. In addition, the NMR spectrum registered in acetone-d6 on the 
residual mother liquor shows the presence of both the species, but with a different integrals ratio 
(0.5), suggesting a higher solubility of the second species in MeOH with respect to AuL12 (Figure 
2.4). 
Similarly to what reported for AuL23 (Chapter 1), these findings suggest the presence of the same 
dithiocarbamato ligand coordinated to gold ion for both the species, either with a different geometry 
with respect to the coordination plane or with different ligands in trans to the two sulfur atoms that 
do not affect the ester moiety, where the signals corresponding to the major species can be attributed 
to the desired complex AuL12. 
Moreover, NMR data collected on the reaction crude obtained by using the classical methodology 
report about the presence of the same number of additional peaks (falling at the same chemical shift) 
here described. These previous studies hypothesized the formation of a dinuclear gold species, having 
two bridging dithiocarbamato ligands and two bromide ions trans-coordinated for each gold center 
(Figure 2.5). The presence of the dinuclear species was supported by the occurrence of the 
conversion of the minor species into AuL12, observed in acetone after 24 hours: according to this 
finding the dinuclear species, upon breakage, could give rise to two AuL12 molecules. 
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Figure 2.4: 1H-NMR spectral comparison of the alkyl region for precipitate (top) and mother liquors (bottom) obtained 
by AuL12 new synthetic methodology. Solvent: acetone
 
H3C
O
EtO
Figure 2.5: Molecular structure of AuL12 and hypothesized byproducts for the reported synthesis.
 
The similar behavior assumed by the mixture obtained with the new synthesis confirms the formation 
of the same minor species formed during the 
AuL12 has been successively purified from the minor species, by means of silica gel chromatography 
(eluent, DCM:MeOH, 97:3). The minor species mainly undergoes degradation upon intera
silica. Interestingly, the final yield of AuL12 was 65% (calculated over ligand).
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one-pot synthesis as a by product. 
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1H-NMR spectrum registered in acetone-d6 confirms the purity of the compound, with the presence 
of only one signal for each diagnostic region (4.78 and 3.57 ppm for α-CH2 and N-CH3, respectively) 
together with the signals related to the ethyl ester group (1.28 and 4.28 ppm) (Figure 2.6). The values 
of the chemical shifts are in accordance with those previously found in literature100. In addition, 
elemental analyses confirmed the structure proposed for AuL12 (Table 2.2). 
 
 
Figure 2.6: 1H-NMR spectrum of purified AuL12 (expanded view of the alkyl region). Solvent: acetone-d6; 200MHz. 
 
Table 2.2: Elemental analysis data for AuL12. 
AuL12 C (%) H (%) N (%) S (%) 
calcd found calcd found calcd found calcd found 
C6H10AuBr2NO2S2 13.17 13.65 1.84 1.84 2.56 2.34 11.69 12.56 
 
Far-IR spectrum (Figure 2.7) on AuL12 showed the typical bands for Au-S stretching (384-356 cm-1 
for antisymmetrical and symmetrical, respectively) and for Au-Br stretching (249-228 cm-1 for 
antisymmetrical and symmetrical, respectively). Moreover, the band at 422 cm-1 is probably related 
to the out-of-plane bending of the 4-membered ring (C-S-Au-S) (Table 2.3). 
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Figure 2.7:1 Far-IR spectrum of purified AuL12 (nujol suspension). 
 
Table 2.3: Far-IR main values for AuL12 vibration modes. 
 
ν out-of-plane 
bending (cm-1) 
νa/s S-Au-S stretching 
(cm-1) 
νa/s Br-Au-Br 
stretching (cm-1) 
AuL12 422 384/356 249/228 
 
 
2.2 Synthesis of IT03 
The dipeptide prolyl-α-amino isobutyric tertbutyl ester (HProAibOtBu) has been then selected as 
substrate to test the methodology. The same experimental procedure was adopted also for the 
synthesis of the compound IT03 [AuIIIBr2(dtc-L-ProAibOtBu)] (Figure 2.8), for which multistep 
purification procedures were usually adopted, and low yields were normally obtained.  
 
 
 
 
Figure 2.8: molecular structure of IT03. 
 
 Also in this case, total conversion of the substrate to the corresponding dithiocarbamato has been 
observed. The 1H-NMR spectrum in CD
multiplet corresponding to α-CH (Pro) (
3.04), which are the two most affected signals by the presence of CS
recognize two groups of signals attributable to the two diasterotopic protons 
and 1.85 ppm), superimposed to γ
the tert-butyl ester signals, are all overlapped at 1.41 ppm. The 
crude, half an hour after the addition 
(Pro) (about δ 1.5 and 1 ppm, respectively) (
affected by the reaction and remain unchanged (
Figure 2.9: 1H-NMR spectrum of the substrate HProAibO
300MHz. 
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3OD (Table 2.4; Figure 2.9) of the substrate shows a 
δ 3.74 ppm) and a doublet of multiplets for 
2. In addition, it is possible to 
-CH2 (Pro) (δ 1.80 ppm). The two β-CH3 (Aib) groups, as well as 
1H NMR spectrum of the reaction 
of CS2, shows a large downfield shift for 
Table 2.4, Figure 2.10). The methyl groups are not 
δ 1.43 ppm). 
tBu (expanded view of the alkyl region). Solvent: methanol
 
δ-CH2 (Pro) (δ 
of β-CH2 (Pro) (δ 2.18 
α-CH (Pro) and δ-CH2 
 
-d4; 
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Figure 2.10:1H-NMR spectrum of the reaction between HProAibO
view of the alkyl region). Solvent: methanol
 
Table 2.4: 1H-NMR spectral data. 
1H-NMR 
α-CH 
β-CH2 + γ-CH
δ-CH2 
α-C(CH3)2 
OC(CH3)3 
 
To obtain the IT03 complex, a methanol solution of one equivalent of K
dropwise to the obtained dithiocarbamate. The spectrum of the reaction crude, recorded in acetone
d6, confirms the formation of the complex (
ppm) together with a multiplet corr
to β-CH2 (Pro) hydrogen nuclei are found at 2.60 and 2.35 ppm, respectively. Overlapped to this 
latter, the multiplet for γ-CH2 (Pro) is found (
1.43 ppm. After purification, an orange solid has been isolated and characterized by 
spectroscopy (Figure 2.11). Interestingly, upon the purification process (which is not carried out in 
inhert athmposphere) the spectrum of the purified compou
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tBu and CS2 in presence of base after 1/2h (expanded 
-d4; 300MHz. 
HProAibOtBu DTC--ProAibOtBu 
A δ (ppm) A δ (ppm) 
Pro  1 3.70 m 1 5.21 m 
2 2+2 2.18-1.80 m 2+2 2.25-1.85 m 
2 3.05 m 2 3.97 m 
Aib  6 1.41 s 6 1.43 s 
9 1.41 s 9 1.43 s 
[Au(Br)
Figure 2.11). A doublet is found for 
esponding to δ-CH2 (Pro) (δ 4.00 ppm). The two multiplets related 
δ2.30 ppm). Finally, the methyl groups are fou
nd seems to be more complicated. On the 
 
 
4] has been added 
-
α-CH(Pro) (δ 5.04 
nd at 
1H-NMR 
 basis of our previous studies, this is probably due the formation 
species, already described for similar 
minor product suggest a similar structure for both the species as already reported.
Figure 2.11: 1H-NMR spectra comparison of the alkyl region for IT03 before (bottom) and after purification (top). 
Solvent: acetone-d6; 300 MHz. 
In fact, the similar chemical shift of the t
coordination sphere for both the species. The differences between the two species affected also the 
CH3 groups of Aib, which undergo a small downfield shift. 
previous syntheses of IT03, obtained by means of the in water one pot methodology, revealed the 
same set of signals for the byproduct, which has been supposed to correspond to a dinuclear species 
of IT03. 
The mixture has been purified by means of silica 
isolate the desired complex. The final yield for IT03 is 61% (calculated on ligand). 
Elemental analyses for this compound confirmed the purity of the isolated compound (
 
Table 2.5: Elemental analysis data for mixed fraction.
IT03 
 calcd
C14H23AuBr2N2O3S2 24.43
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compound AuL23 in Chapter 1. The chemical shifts of this 
wo sets of signals suggests the presence of a very similar 
1H-NMR investigations performed on th
gel chromatography (DCM:EtOH 97:3) in order to 
 
C (%) H (%) N (%) 
 found calcd found calcd found 
 24.41 3.37 3.30 4.07 4.03 
 
of a second minor 
 
 
α-
e 
 
Table 2.5). 
S (%) 
calcd found 
9.32 9.1 
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In conclusion, a new methodology has been tested for the formation of dithiocarbamates aimed to the 
synthesis of Au(III) complexes suitable for antitumor therapy. Investigations on the secondary amine 
substrates employed were successful, exhibiting total conversion to dithiocarbamato derivative. In 
case of HCl·HProAibOtBu, the synthesis of the related IT03 complex have been performed, 
obtaining higher yields as the whole substrate was available for the reaction. Interestingly, even 
though in the new methodology the metal precursor solution is added dropwise to the substrate 
(contrarily to the traditional method) the same gold-byproducts were produced after both the 
synthetic and purification pathways. Notwithstanding, using the reaction under anhydrous conditions 
allow an increase of final yield. 
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Chapter 3 
Spectroscopic investigation of compounds' stability and reactivity in 
physiological-like conditions 
 
To elucidate the pharmacological behavior of our compounds it is of crucial importance to better 
understand the possible modifications they can undergo in physiological conditions. Moreover, it 
could be of fundamental importance for the forthcoming pharmacokinetic studies, to predict if there 
can be an interaction or a stabilization in physiological medium by carrier proteins. Indeed, for the 
upcoming in vivo experiments, it could be significant to predict if the serum components can interfere 
with drugs activity and bioavailability, as a consequence of their well known binding properties 
which made them good transporters.  
Among the gold(III) compounds under study, [AuIIIBr2(SSC-Sar-L-AlaOtBu)] (IT01) was chosen as 
a model to investigate the behavior in different aqueous systems and in presence of putative protein 
carriers.  
In particular, it is essential to analyze the interaction of serum albumins with our compounds, since 
they are the most abundant proteins in the circulatory system of a wide variety of organisms (30-50 
g.L-1, in the human serum, 52-60% of plasma protein composition)131. 
The human serum albumin (HSA) is constituted by a single polypeptide chain having 585 amino acid 
residues, characterized by low tryptophan and high cystein content. Its secondary structure consists of 
67% α-helix, 23% extended chains and 10% β-turns, having six turns and seventeen disulphide 
bridges. Under physiological conditions it assumes a heart-shaped three dimensional structure, with 
three homologous domains labeled as domains I-III. Each of these domains is further subdivided into 
two sub-domains (A and B), that consist of 4- and 6-helices, respectively. Conversely, more easily 
available bovine serum albumin (BSA) shares with HAS the 76% sequence homology, and is 
constituted by a single polypeptide chain of 583 amino acids residues, having molecular weight of 66 
kDa. Like HAS, BSA also has seventeen disulphide bridges and one free -SH group (C34), which can 
be involved in the formation of a dimer. Both proteins show the presence of a Trp in the subdomain 
IIA (W214 for HSA and W212 for BSA). The fundamental difference between HSA and BSA 
consists mainly in an additional tryptophan residue (W135) located on the surface of the BSA 
protein132. 
Albumins play a fundamental role not only in the control of the osmotic blood pressure, but also in 
the transport of various endogenous compounds such as fatty acids, hormones, toxic metabolites (e.g. 
Chapter 3. 
Spectroscopic investigation of compounds' stability and reactivity in physiological-like conditions 
66 
 
bilirubin), bile acids, amino acids and metals. In recent years, human serum albumin (HSA) has been 
emerging as a reliable and versatile carrier for therapeutic and diagnostic agents, owing to its small 
size, flexibility and high abundance in the plasma133. 
Depending on their chemical properties, drugs can bound to HAS in the bloodstream, but in most 
cases only free drug molecules can interact with therapeutic targets to produce their therapeutic 
effect. Indeed, only the unbound molecules can passively diffuse through the barriers constituted by 
endothelial cells and tissue cells into organ tissue and undergo metabolism, biliary excretion or 
glomerular filtration in kidney, or be distributed intracellularly via specific transport systems (e.g. 
receptor-mediated endocytosis, protein-mediated transport)134. 
Any injected metal-based therapeutic is expected to have some kind of interaction with albumin. For 
many drugs and prodrugs it was demonstrated that the protein plays a crucial role in their 
stabilization and transport, modulating their bioavailability and toxicity135. Accordingly, without 
exception, also platinum-based drugs bind to HSA and such reactions may be related to the 
metabolism, effectiveness, and body distribution136,137. Indeed, the protein contains six methionine 
residues (i.e. Met-87, 123, 298, 329, 446, and 548) among which Met-298 is the most surface 
accessible and thus has been speculated to be the main cisplatin-binding site138.  
Considering the pharmacokinetic and pharmacological implications, the study of the interaction 
between the compounds and BSA become of great importance. This analysis was carried out 
combining different experimental techniques, as fluorescence and UV-Vis spectroscopy, together 
with CD analysis. 
 
3.1 UV-Vis analysis of stability in physiological conditions 
Since the compounds are not per se soluble in water, all the biological assays up to now were 
performed pre-dissolving the compounds in the minimum volume of DMSO before adding them to 
aqueous medium. 
In this Chapter are in particular reported the results obtained for the compound IT01, that was chosen 
as a model for our gold(III)-peptidedithiocarbamato derivatives. 
First of all, the stability of the compound in sole DMSO (used as stock solution) was evaluated. The 
compound was dissolved in the solvent at a final concentration of 50 µM, recording UV-Vis spectra 
at 25°C in the range 190-800 nm over 24h (Figure 3.1). In this solvent the complex shows three main 
absorption bands. The first two bands, hereafter called band I and band II, are assigned from the 
literature to intraligand π*← π transitions (at nearly 260 and 310 nm) mainly located on the -NCS and 
-CSS moieties, respectively93. An intraligand π*←n transition (where n is the in-plane non-bonding 
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sulfur orbital) is expected around 340 nm, but is not discernible because overlapped to higher 
intensity bands at very close wavelength. The third detectable band of weak intensity is rather found 
at higher wavelengths (around 370 nm), and is assigned to an electron transfer of the type u←g, from 
a 4p orbital (σ symmetry) of the bromide ligands to the lowest unfilled 5d metal orbital (band III, 
Table 3.1). 
No significant modification of neither the position of the bands and their intensity was detected over 
24 h, confirming that the compound remains stable in this solvent. The only very slight variations 
registered are connected to the presence of water in the solvent, which increases over time. Indeed, 
upon water absorption by the system, partial hydrolysis of the complex takes place. The bromide 
ligands are thus substituted by one/two water molecules to form the corresponding aquo complex, 
which is still quite water soluble. This effect is also suggested by the slight shift in wavelength of the 
main two absorption bands, which move towards the band positions recorded for the complex in 
water (DMSO<5%). 
 
Figure 3.1: electronic spectra of IT01 (50 µM) in DMSO at 25°C for 24 h. 
 
Moving to aqueous systems, the behavior in pure deionized water was first evaluated, confirming the 
tendency of the complex to undergo partial hydrolysis, with slow modifications over the first 24 h 
(Figure 3.2). The main absorption bands present opposite trends, with band I and band II undergoing 
a hypochromic and hyperchromic modifications with time, respectively. Simultaneously, a band at 
nearly 380 nm increases in intensity with time. All these variations have probably to be connected to 
the formation of the aquo-complex in solution. Anyway, after nearly 10 h, an hypochromic effect of 
all the absorption bands is detected, which can be correlated to the partial precipitation of the 
dihydroxo-complex (already described for other gold(III)-dithiocarbamato derivatives) which results 
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less water soluble than the corresponding aquo complex. The compound, which precipitates as a 
yellow powdery solid, was isolated and characterized by means of elemental analysis and FT-IR 
spectroscopy, allowing the identification of the hydroxo-derivative. 
 
Figure 3.2: electronic spectra of IT01 (50 µM) in deionized water at 25°C for 24h. 
 
The behavior of the complex IT01 in saline solution (0.9% NaCl), is slightly different with respect to 
what recorded in pure water (Figure 3.3). In this case an hyperchromic effect is registered for both 
band I and band II, along with the formation of a band at nearly 380 nm due to the coordination of 
aquo groups to the gold(III) metal center.  
 
Figure 3.3: electronic spectra of IT01 (50 µM) in saline solution (NaCl 0.9%) at 25°C for 24h. 
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The hyperchromic effect recorded for both bands can be explained with the substitution of the 
bromine ligands with chlorines, as a consequence of the higher concentration of Cl- ions in solution. 
Subsequently, the substitution of one/two chloride ligands with water molecules can lead to the 
formation of the aquo-derivative, as suggested by the appearance of an absorption band at 380 nm 
(metal-to-ligand charge transfer). In this case, however, no precipitates were detected in solution over 
24h, suggesting that the hydroxo complex does not form until this time. 
Otherwise, the behavior of IT01 in PBS (phosphate buffered solution) seems to be completely 
different (Figure 3.4). After only 4 h from dissolution, the complex undergoes fast hydrolysis, 
leading to the formation of the dihydroxo complex which precipitates as a yellow powdery solid. The 
process is accelereted with respect to the trend registered in pure deionized water. The more basic pH 
of the solution (buffered at 7.4) can favor the formation of the dihydroxo derivative, along with the 
presence of the phosphato ions, which can directly interact with the metal by coordination causing 
the precipitation of the corresponding phosphato-derivative. 
 
Figure 3.4: electronic spectra of IT01 (50 µM) in PBS buffer pH=7.4 at 25°C over 4 h. 
 
Moving to more complex environments, the stability of the gold(III) complex in complete cell culture 
medium was analyzed. The electronic spectra, registered in presence of 20% complete medium 
(RPMI-1640 medium supplemented with 10% fetal calf serum) in PBS show two main absorption 
bands at 273 and 307 nm, both assignable to the IT01 complex (Figure 3.5). The main absorption 
band of the medium itself is otherwise present at 276 nm. The behavior of the complex in this 
environment is similar to that registered in PBS, even if the formation of a precipitate is not 
detectable in this case, probably as a consequence of the interaction with proteins or other medium 
components which lowers the rate of the hydroxo-derivative precipitation. Similarly to the previous 
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spectra, an intensity reduction of the bands related to the π*← π transitions, is accompanied by an 
hyperchromic effect of the band at 362 nm, correlated to the formation of a gold-oxygen bond (as 
already described above). 
 
Figure 3.5: electronic spectra of IT01 (30 µM) in RPMI-1640 mod and FCS (10%) at 25°C for 24. 
Table 3.1: main absorption bands wavelength (nm) in different solvents. 
 
λmax/nm 
 
Band I Band II Band III 
DMSO 276 316 378 
Bidistilled water 272 310 370 
Saline solution 0.9% NaCl 261 312 -- 
PBS 262 313 375 
Cell culture media + 10% bovine 
fetal serum 
273 307 362 
*
λmax determined soon after dissolution 
3.2 Interaction with BSA 
To analyze the possible interaction of the compound IT01 with BSA, different spectroscopic 
techniques were employed.  
Firstly, the compound was incubated at equimolar ratio with BSA (30 µM), and electronic spectra 
were recorded over time. The UV-Vis spectrum of BSA is characterized by two main absorption 
bands at 198 and 280 nm, which correspond to π*← π transition located on the peptide group and the 
aromatic ring aminoacids (Trp and Tyr), respectively.  
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In the UV-Vis spectra recorded soon after incubation, the main absorption bands previously 
described for IT01 are detected, with band I almost overlapping the BSA absorption band at 280 nm 
(Figure 3.6).  
 
Figure 3.6: electronic spectrum of BSA and IT01 (equimolar, 30 µM) in PBS at 25°C over 24h. 
 
Upon incubation with BSA, no stabilizing effect in reducing complex hydrolysis rate seems to take 
place, as an hypochromic effect of both band I and band II is recorded. This is accompanied by the 
the slight increase in the intensity of a band at 360 nm, probably due to the complex-protein 
interaction (through metal coordination) which can stabilize the hydrolized compound in solution 
preventing its precipitation.  
The possible interaction with BSA was analyzed also by CD spectroscopy, to evaluate possible 
modification in protein secondary structure upon incubation with the complex. The interaction of 
equimolar quantities of each component (15 µM) in PBS solution (after dissolution of IT01 in 
DMSO; final DMSO concentration < 1.5%) was monitored over time showing only slight and not 
coherent variation in protein α-helix content (data not shown). Contrarily, the CD spectra recorded 
soon after incubation of IT01 with BSA (15 µM) at different molar ratios (Figure 3.7) showed 
variations in the protein secondary structure which were significant only at IT01:BSA molar ratio of 
1 or higher. These modifications can be correlated with more extended conformation, or to an 
increase in β-sheet or random contributions to the structure. Anyway, this behavior is detectable only 
at high complex concentrations (with respect to BSA) that are far from the physiological-like 
conditions.  
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Figure 3.7: CD spectra of IT01 incubated with IT01 at different molar ratios (from 0 to 3) in PBS at 25°C. 
Further studies, aimed at elucidating the result obtained with the CD experiments, were performed 
recording fluorescence spectra at constant temperature (25°C) in the same time ranges and 
concentrations used in the CD experiments above reported.  
It is known that the intrinsic fluorescence of BSA derives from two tryptophan (Trp) residues per 
chain which are known to be excellent fluorogenic structural probes. They are characterized by 
strong emission signals at room temperature, and are very sensitive to the local microenvironment. 
The first residue is buried inside the protein where it is sheltered from energy loss or fluorescence 
quenching, thus resulting in increased fluorescence quantum yield. The second one is located on 
protein surface. The change in either fluorescence intensity or emission band position can be 
correlated to a modification of the two Trp environmental polarity or rigidity and consequently to the 
protein modifications. 
This intrinsic fluorescence can be quenched by a variety of molecules and the mechanism may be 
either through static or dynamic quenching139. Static quenching refers to quenching through 
fluorophore-quencher complex formation, and dynamic quenching refers to a process where the 
fluorophore and the quencher come into contact during the transient existence of the excited state. 
In the first experiment the molar ratio between protein and IT01 was kept constant (1:1; 15 µM), and 
the fluorescence spectra were recorded at different times, starting from incubation, over 24 h. 
As we can see from Figure 3.8-3.9, there is a progressive quenching of BSA fluorescence intensity 
with time. The quenching phenomena may account for a direct interaction of the metal compound 
with the protein fluorophores or for an increasing amount of endogenous quenchers such as water 
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molecules or oxygen approaching the site of fluorescence. In the recorded spectra, only slight 
modifications in the fluorescence intensity of the emission bands are recorded, but the position of the 
emission bands are not affected, thus suggesting that no changes in the polarity of the Trp sites take 
place. 
 
Figure 3.8: fluorescence spectra of BSA (1.5 µM) in presence of IT01 (1.5 µM) in PBS at 25°C over 24h. 
 
Figure 3.9: intensity fluorescence at the λem maximum (349 nm) of BSA (alone, ) incubated with IT01 as a function of 
time (, 0-6h) 
The same exeriment was repeated changing the molar ratio of BSA and IT01, and recording the 
fluorescence spectra soon after incubation at the constant temperature of 25°C (Figure 3.10). In this 
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case it was detected a decrease in the fluorescence intensity that was proportional to the increase of 
IT01/BSA molar ratio (the DMSO content was kept constant for each sample).  
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Figure 3.10: fluorescence spectra of BSA (1.5 µM) in presence of IT01 at different molar ratios (from 0 to 3) soon after 
mixing, in PBS at 25°C. 
 
Figure 3.11: intensity fluorescence at the λem maximum (349 nm) of BSA (alone, ) and incubated with IT01 at different 
IT01/BSA molar ratios (From 0.3 to 3; ) 
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The decrease in fluorescence intensity may be correlated either to the direct interaction of 
Trp134/213 with the metal based compound, or to interactions with other sites of the protein which 
can modify the overall BSA structure. In fact, as before stated, each fluorophore may undergo a small 
structural change upon interaction of the complex with different sites of the protein, resulting in a 
different local environment at molecular level and thereby justifying the decrease of the quantum 
yield. 
From the analysis of the spectra reported in Figure 3.10, it is evident that only slight modifications 
are recorded for IT01:BSA molar ratios equal or lower than 1, suggesting that only weak interaction 
take place between the gold(III) complex and the protein. 
To sum up, the stability of the model compound IT01 was firstly evaluated under physiological-like 
conditions, to analyze their reactivity for the subsequent biological tests. It was shown that the 
compound (previously solubilized in DMSO) behaves differently depending on the conditions used. 
Indeed, it was shown that the compound undergoes hydrolysis both in pure water and in saline 
solution, by exchanging the bromido ligands with water molecules.  
Conversely, upon dissolution in PBS, rapid formation of the hydroxo-derivative (not water-soluble) 
was detected. The precipitation of a yellow powdery compound was connected to the precipitation of 
the dihydroxo derivative or either to the formation of the corresponding gold(III)-phosphato 
compound, formed by the coordination of the phosphato anion to the metal center.  
Anyway, when considering the cell culture medium, the precipitation of the hydroxo-derivative is 
likely reduced, probably thanks to the interaction of the compound with biomolecules and proteins 
present in the medium.  
This behaviour reflected the results recorded for the interaction of the gold(III) compound with BSA 
in PBS. Considering the informations collected from the CD and fluorescence analysis, it can be 
concluded that IT01 does not significantly modify the secondary structure of the protein when 
incubated at low molar ratio (representative of the physiological-like condition). The slight 
modifications in the overall secondary structure might be due to weak secondary interaction with the 
complex, which can account for slight stabilizing effect that make BSA, almost in principle, a 
possible carrier for our compounds in vivo. 
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Chapter 4.  
Evaluation of the in vitro and in vivo antiproliferative activity, 
and ex vivo toxicological effects 
 
As reported in the Introduction, "first generation" complexes were already tested for their 
anticancer activity both in vitro and in vivo, showing outstanding antiproliferative 
properties.  
In this work we carried out the screening for the newly synthesized compounds IT01-
IT05 (belonging to the "second generation" of gold(III)-peptidedithiocarbamato 
derivatives). Firstly, they were tested in vitro for their cytotoxic activity toward different 
human cancer cell lines. Subsequently, the compounds were tested on MDA-MB-231 
human breast cancer xenografts, to check their capability to induce tumor growth 
inhibition in mice.  
The toxicity of selected compounds representatives of the "first" and "second generation" 
complexes was also assayed, comparing the obtained results to the reference drug 
cisplatin. Finally, the complexes were tested ex vivo on rat tissues of different organs 
(liver, colon and kidney) excised from healthy animals, in order to preliminary determine 
their toxicological profile without using living animals during the compounds' 
administration. These experiments were performed at the Groningen Research Institute of 
Pharmacy of the University of Groningen (Groningen, The Netherlands) under the 
supervision of Prof. A. Casini. 
 
 
Experimental 
Cell lines and culture conditions 
Human non-small cell lung carcicoma A549 cells, human embryonic kidney HEK cells 
and human breast adenocarcinoma MCF-7 cells (ATCC) were cultured in DMEM 
(Dulbecco's Modified Eagle Medium, Life Technologies), while human ovarian cancer 
A2780 cells, A2780cisR (A2780 cells made resistant to cisplatin), human large cell lung 
cancer H460 cells and non-small cell lung cancer H1975 cells (ATCC) were grown in 
RPMI-1640 (Roswell Park Memorial Institute, Sigma Aldrich). Human breast cancer 
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MDA-MB-231 cells (ATCC) were instead grown in DMEM/F12 1:1 medium enriched 
with 1 mM sodium pyruvate and 10 mM HEPES. Each media was further supplemented 
with 10% Fetal Calf Serum (FCS) and 1% penicillin and streptomycin (Invitrogen). Cells 
were incubated at 37°C in the presence of 5% CO2 and moisture-enriched atmosphere.  
 
In vitro cytotoxicity 
Cells were seeded at a concentration between 3.0-5.0 x 104 cell mL-1 (depending on cell 
line) in either 96-well flat-bottomed microplates or 24-well culture plates, and incubated 
in standard conditions for 24h to allow cells adhesion. Afterwards, the medium was 
discarded and replaced with fresh new medium containing the test compounds at different 
concentrations. Gold(III) derivatives were previously dissolved in DMSO and added to 
each well at a maximum final DMSO concentration of 1%. Otherwise, cisplatin (Sigma-
Aldrich), micellar and vesicular formulations of the gold(III) complexes were dissolved in 
saline solution (0.9% NaCl). Cells were incubated with the compounds for either 24 or 72 
h (depending on the experiment) and the induced cell growth inhibition was assayed by 
MTT or by Trypan Blue Exclusion assay. The final GI50 (µM) (i.e. concentration of the 
test compound that induce a reduction of cells viability equal to 50%) were calculated 
from data collected from almost three independent experiments. 
 
Human breast xenograft tumor experiments 
Seven-week-old Female athymic nude mice were purchased from Harlan Laboratories 
(Horst, The Netherlands) and housed in accordance with protocols approved by the 
ethical committee of University of Groningen. Human breast cancer MDA-MB-231 cells 
suspended in 0.1 mL of serum-free DMEM/F12 cell growth medium were inoculated 
subcutaneously (s.c.) into the right flank of each mouse. When tumors reached sizes of 
around 115 mm3, the mice were randomly allocated in three groups of seven mice per 
group, and treated by daily s.c. injection of either vehicle [1:1:1 v/v PBS, DMSO, 
Cremophore/ethanol (1:4)] or medium containing 1.0 mg/kg of IT03. Tumor length (L) 
and width (W) were measured every other day using a caliper, and tumor volumes were 
evaluated according to the standard formula (π·L·W2)/6. Mouse weights were monitored 
twice a week. Mice were sacrificed after 27 days of treatment when control tumors 
reached ~ 1,800 mm3. The tumors were collected and weighed.  
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Toxicity studies on animals 
Male Wistar (HsdCpb:WU) rats were purchased from Harlan (Horst, The Netherlands). 
Rats were housed in a temperature- and humidity-controlled room on 12h light/dark cycle 
with food (Harlan Chow no. 2018 or standard RMH Chow, Hope Farms, Woerden, The 
Netherlands) and tap water ad libitum. All the experiments were conducted with the 
approval of the Ethical Committee of the University of Groningen (NL). 
 
Preparation of precision-cut colon, liver and kidney rat slices 
Krebs-Henseleit buffer (KHB), 3% agarose solution and University of Winsconsin organ 
preservation solution (UW) were prepared as described elsewhere140. 
After influxing the rats with isofurane/N2/O2 anesthesia, the liver and colon of the animal 
were excised and conserved in oxygenated ice-cold UW solution. Liver and kidney cores 
of 8 mm diameter were obtained using a mechanical drill (Metabo), while colon was 
excised in ca. 2 cm long pieces, washed with UW solution and filled with agarose. The 
cores obtained from each organ were than fitted in supports and sliced with a Krumdieck 
tissue slicer (ARD), obtaining slices of ca. 300 µm and 10-15 mg for liver and kidney, and 
300 µm and 2 mg for colon.  
Liver and kidney slices were preincubated for 1h in 12-well plates containing 1 mL/well 
of WME (Williams Medium E, Invitrogen) enriched with D-glucose (2.75 mg.mL-1) and 
gentamicine (50 mg ml-1). The slices were then transferred to 12-well plate containing the 
compounds at different concentration dissolved in complete medium, and incubated for 
24 h. Control slices were collected soon after slicing, after 1 h preincubation and after 24 
h incubation in complete medium only.  
Colon slices were directly incubated after slicing for 5 h in medium containing the test 
compounds at different concentrations. In addition to D-glucose and gentamicine, as 
previously reported, also amphotericine B (250 µg ml-1) was added to WME. Control 
samples for colon were collected both after slicing and after 5 h incubation in sole 
complete medium. 
Each sample was quickly frozen in 1 mL Sonop solution140, and stored at -80°C. 
 
ATP determination assay 
ATP content of the samples was determined using the ATP Bioluminescence Assay Kit 
CLS II (Roche), following producer instructions. The slices stored in 1 mL Sonop solution 
were homogenized with a Minibeadbeater (BioSpect Products) for 45 seconds after 
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addition of glass beads, and the homogenates were centrifuged for 2 min at 4°C and 
13000 rpm. All the samples were stored in melting ice during all the procedure. For each 
sample 5 µL of supernatant solution were diluted in a 96-well black plate with 45 µL of 
100 mM Tris-HCl buffer containing EDTA (2 mM). Different dilutions of an ATP 
standard solution in Tris/EDTA buffer were prepared for calibration, and ATP content 
was determined reading the luminescence of each sample after addition of 50 µL/well of 
Luciferase reagent (Roche). Each sample of the assay was prepared in duplicate, and final 
ATP content expressed in (nmol.ml-1). 
 
Protein determination assay 
The protein content of each sample was determined using the BIO-rad DC Protein Assay 
based on Lowry method (BIO-rad), following the manufacturer's protocol. The 
homogenized samples prepared for the ATP determination were dried overnight and 
incubated with 200 µL of 5N NaOH at 37°C in shaking water bath. After dilution with 
800 µL milliQ water, the samples where homogenized again with a Minibeadbeater 
(BioSpect Products) for 40 s. Calibration curve was prepared using different dilution of a 
BSA standard solution, at final concentrations between 0 and 1,2 mg.mL-1. The samples 
or either the standards were then added to a 96-well clear plate, together with 25 µL of 
reagent A and 200µL of reagent B (BIO-rad DC Protein assay). The plate was gently 
shaken for 1 min and, after 15 min of incubation in the dark at r.t., the absorbance at 650 
nm was read with a ThermoMax Microplate Reader (Molecular Devices). The protein 
content of each sample was calculated on the bases of the calibration curve made with 
BSA, and expressed as concentration of mg.mL-1. 
 
 
Results and discussion 
4.1 In vitro cytotoxic activity on human cancer cells  
The compounds were tested on a broad panel of cancer cells to assess their cytotoxic 
activity on different tumor types. The GI50 values were calculated for each compound 
after 72h incubation, and the number of viable cells was evaluated by MTT test (or 
Trypan Blue Exclusion assay, were indicated). The results are summarized in Table 4.1. 
All gold(III) complexes belonging to the "second generation" of compounds show quite a 
similar activity on the same cell lines, with the exception of IT05 on MCF-7 and H1975, 
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which seems to be less effective than the other compounds of the series. These results can 
be probably connected to their different solubility and steric hindrance properties (due to 
the presence of either -TEG or -OtBu functions). 
Among the tested complexes, IT03 and IT04 resulted the most active with GI50 values 
comparable to the antiprolferative data recorded for cisplatin on the same cell line. 
In particular, the tested compounds present higher cytotoxic activity towards A2780 cell 
line, with GI50 values lower than 0.50 µM, 10 times more effective than cisplatin.  
Good results were obtained also on H1975 cells, with GI50 in the submicromolar range. 
The cytotoxicity of the compounds on breast adenocarcinoma MCF-7 cells seems to be 
promising as well, with GI50 values 5-fold higher than that obtained after cisplatin 
treatment.  
Generally, even if comparable, their antiproliferative activity resulted slightly lower to the 
"first generation" compound AuL12 on all the cell lines tested. 
 
Table 4.1: GI50 ± st.dev. (µM) on A549 (human non-small cell lung carcinoma), HEK (human embryonic 
kidney) and MCF-7 (human breast cancer), A2780 (human ovarian carcinoma cells) H1975 (human non-
small cell lung cancer) and H460 (human large cell lung carcinoma), A431 (human epidermoid carcinoma) 
cells calculated after incubation for 72 h for the compounds IT01, IT02, IT03, IT04, IT05, AUL12 or 
cisplatin. Viable cells were determined via MTT test or via Trypan Blue dye exclusion method. 
 GI50±st.dev. (µM) 
 IT01 IT02 IT03 IT04 IT05 AUL12 Cisplatin 
A549 20.04±2.80 26.62±3.20 10.28±3.31 9.06±2.14 13.5±1.56 12.27±1.62 8.00±0.50 
HEK 5.88±1.44 4.17±1.25 7.07±2.58 4.52±1.03 5.20±0.69 2.85±0.95 11.00±2.90 
MCF-7 3.44±0.93 4.30±0.80 4.00±0.70 3.2±1.6 8.50±0.85 6.40±0.70 20.00±3.00 
A2780 0.59±0.16 0.32±0.17 0.44±0.11 0.21±0.12 0.46±010 0.40±0.08 5.20±1.90 
H1975 a 0.56±0.13 0.57±0.19 0.71±0.10 0.66±0.06 5.78±1.30 0.158±0.008 0.99±0.09 
H460 a 3.83±2.13 3.38±0.40 3.63±0.51 2.99±0.64 4.25±0.22 2.15±0.260 0.76±0.11 
A431 a 16,10±3,90 14,01±2,52 8,37±2,57 10,07±1,91 13,51±2,62 9,59 ± 2,53 3,22± 0,50 
avalues calculated with Trypan Blue dye exclusion method. 
  
Moreover, the cytotoxic activity of the compounds IT03 and IT04 was determined after 
24 h incubation on large cell lung cancer H460 cells, to analyze the GI50 time-
dependence. Interestingly, the obtained values (Table 4.2) highlight how the complexes 
are able to exert a cytotoxic effect already after shorter incubation times. Cisplatin, on the 
contrary, normally induces good inhibitory effects on cells proliferation only for 
incubation times of 72 h (data not shown). 
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Table 4.2: comparison between cytotoxicity values calculated on H460 cells after 24 h and 72 h incubation 
with IT03 and IT04. 
 
IC50 ± st.dev. (µM) on H460 cells 
 
 
24 h 72 h 
IT03 10,45 ± 3,97 3,63 ± 0,51 
IT04 10,01±3,08 2,99±0,64 
 
Generally, the compounds differing only for the stereochemical configuration (D, L 
entantiomers) of the second aminoacid of the dipeptide ligand, show similar cytotoxic 
activity. This highlights that probably there is no correlation between the stereochemical 
features of the compounds and their cytotoxic activity and/or transporter recognition. In 
particular this is evident on A549 cells, known to overexpress PEPT2 transporter. Both 
IT01 and IT02 (similarly to IT03 and IT04) exert the same cytotoxic activity on this cell 
line, even if, almost in principle, the transporters would be more selective in the L-isomer 
recognition.  
Nevertheless, the selectivity for L-configuration derivatives is recognized for naturally 
occuring aminoacids or oligopoetides, but since PEPTs are responsible also for the 
transport of peptido-mimetics which resemble the main features of their physiological 
substrates, it is possible that similar recognition occurs for both the gold(III) isomers, 
despite their chirality.  
Anyway, deeper studies about the overexpression of PEPTs by selected cell lines will be 
performed to analyze if differences in the internalization rates the two gold(III) 
configurational isomers can be detected. 
 
 
4.2 Preliminary in vivo studies 
Preliminary studies on human xenografts were performed to determine the capability of a 
selected compound IT03 to induce tumor growth inhibition in in vivo conditions. The 
compound was in particular tested towards a breast cancer cell line MDA-MB-231, which 
is known to be highly metastatic and invasive.  
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Figure 4.2: tumor growth inhibition on human xenografts treated with IT03 with respect to the controls 
treated only with vehicle. 
 
In vitro tests on the MDA-MB-231 cells were preliminarily done to determine the 
cytotoxicity of the compound on this tumor cell type. After 24h incubation of cells with 
different concentrations of IT03, MTT test was performed to calculate cell viability, 
obtaining a GI50 value of 10.3±0.7 µM.  
The in vivo experiment was performed on athymic nude mice inoculated subcutaneously 
with human breast cancer cells MDA-MB-231, and then treated with 1 mg.kg-1 of IT03 
every day.  
The tumor volume was measured every other day both in control animals and in treated 
animals. As we can see from Figure 4.2, the tumor growth in the mice administered with 
IT03 is inhibited by almost 60% after 19 days of treatment, without any evident sign of 
suffering or weight loss in the animals administered with the gold compound. 
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4.3 Ex vivo studies 
The toxicity of selected complexes was 
tested on different organ tissues 
exploiting ex vivo experiments that 
consist in the incubation of drugs or 
other compounds with small slices of 
tissue derived from organs excised from 
healthy rat. This method allows the 
study of drug metabolism and toxicity in 
intact tissues, with great advantages with 
respect to both in vitro cell culture and 
in vivo animal testing. The use of slices 
permit to reduce the number of animals 
used for the experiments, since a large 
number of slices can be obtained from 
the same organ (about 80–100 slices 8 
mm thick or 200–250 slices 5 mm thick 
can be obtained from 10 g of rat liver), 
allowing the testing of more than one 
compound at different concentrations in 
parallel. Moreover, although being an 
in vitro experiment, it has the advantage of using intact tissues where enzyme systems, 
cofactors and transporters are present in their physiological levels, resulting in a reliable 
model for the in vivo conditions141. The slices used in the experiments are easy to prepare 
and to process and can be obtained (with slight modifications of the method) from a large 
variety of different organs as liver, intestine, kidney and lungs. 
From the in vitro tests carried out on different cancer cell lines, it emerged that the 
compound IT03 was one of the most promising for its antiproliferative activity on all the 
tested cell lines, and was thus selected for the ex vivo toxicity experiments.  
The toxicity of IT03 on healthy tissues was preliminarily determined on rat liver and 
colon slices, since these two organs are generally mainly involved in drug metabolism. 
Afterwards, toxicity of the compounds on kidneys was also tested, since they are usually 
Figura 4.1: upper part: procedure adopted to obtain 
liver cores (a-b) and liver slices (c-f), that are 
subsequently incubated with different test compounds 
for toxicological studies (a-g); lower part: preparation 
of colon cores (a-j) and obtainment of colon cores (h-j) 
suitable for slicing (k-l). 
Chapter 4. 
Evaluation of the in vitro and in vivo antiproliferative activity and ex vivo toxicollogical effects. 
85 
 
strongly affected by cisplatin treatment. The slices, characterized by both similar size and 
weight, were freshly prepared on the day of the experiment from excised organs140.  
Cylindrical liver and kidney cores were cut from each organ with the use of a mechanic 
drill (for liver) or manual cutter (for kidney), while intestine was first washed and flushed 
with UW solution and then filled with 3% solution of agarose, in order to obtain 
cylindrical sections with dimensions comparable to those obtained for the liver (Figure 
4.1). Both cores were subsequently sliced with a Krumdieck tissue slicer (ARD), adjusting 
knife speed and position to obtain slices with the final desired characteristics. 
Previous studies were aimed at establishing the viability of incubated slices as a function 
of time, so to assess the best incubation times for each experiment type. Since the slices 
are obtained from normal tissues with no further modification, their viability with time 
decreases fast, with rates depending on tissue type.  
It was found that soon after slicing the ATP content is low, with values depending on the 
time they are preserved cold, and it rises again to higher viability values after 1 to 3 h 
incubation in medium at 37°C. For liver and kidney slices it was noticed that ATP level 
remains in the range between 10-12 nmol.mg-1 for almost 72 h. Thus, after slicing, 1h 
preincubation in WME is necessary to allow viability recover and to eliminate debris and 
other residues from the tissue before the experiment. 
The viability of colon slices decreased faster with respect to liver and kidney (with ATP 
values that go from 3-4 nmol.mg-1 to about 1 nmol.mg-1 after only 24 h), so the 
experiments should be carried out during the first 8 hours following the slicing. Unlikely 
from liver and kidney, colon slices should be stored in ice cold KHB instead of UW 
solution which allow a better preservation, and no preincubation is needed before starting 
the experiment.  
The viability after incubation with the test compounds was thus evaluated after 24 h for 
liver and kidney slices, and after 5 h for colon slices. These times were chosen as the best 
compromise for the determination of possible toxic effects of the compounds on tissues 
while maintaining constant the viability of non treated slices.  
The viability was expressed as a function of their ATP levels, with values normalized by 
their total protein content to eliminate the differences deriving from slices of different 
weight and dimensions. 
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The compounds to test were previously dissolved in DMSO, and then diluted in complete 
medium to the desired final concentrations ranging from 1 to 100 µM (final DMSO 
content. < 1%).  
In each experiment, control samples were also incubated with medium containing the 
maximum concentration of DMSO, so to determine any intrinsic toxic effect of the 
solvent on the slices. On none of the organ tissues the concentration of DMSO added to 
the samples resulted toxic, with values of tissue viability comparable to the control 
samples incubated with sole medium. 
Each experiment was performed almost in triplicate and the viability of each slice was 
expressed in terms of moles of ATP per grams of protein, while the toxicity was 
expressed in terms of TC50 values (toxic concentration, defined as the concentration of 
compound that decreases viability of the slices by 50%). 
 
Table 4.3: TC50  and st.dev. for IT03, AUL12 and cisplatin on liver, colon and kidney slices. 
Organ 
TC50±st.dev. (µM) 
IT03 AuL12 Cisplatin 
Liver 36.6±7.1 43.5±6.4 16.92±8.7 
Colon 38.3±8.7 51.1±10.2 >100 
Kidney 42.6±9.2 52.6±8.8 39.1±3.7 
 
As we can see from the values calculated in Table 4.3, the toxicity of compound IT03 on 
liver, colon and kidney is quite similar, with 36.6, 38.3 and 42.6 µM respectively. The 
standard deviations for the mean values of toxicity are sometimes quite high, but we have 
to take in account the great different responses that may arise from the individuality of the 
treated animals with the same compound. 
The toxicity values determined for AuL12 on the same tissues are quite similar, but they 
result in both cases less toxic than the reference drug cisplatin. Only exception is colon, 
where cisplatin seems to be much less toxic than the gold(III) dithiocarbamato complexes 
screened. 
The toxicity values measured on colon slices resulted comparable to those detected in the 
other organs, even if shorter incubation times were adopted in these sets of experiments.  
The values of TC50 obtained for the gold(III) compounds on the other organs were 
anyway improved, even if slightly, when compared to cisplatin. This is more evident in 
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particular on liver, where IT03 displays a toxicity that is 50% lesser with respect to 
cisplatin treatment.  
From the results reported in this Chapter we can conclude that the newly synthesized 
compounds show outstanding antiproliferative activity on all the tested human cancer cell 
lines, proving to be particularly promising towards the ovarian cancer cell line A270 and 
breast cancer cell line MCF-7. Their antiproliferative activity was confirmed in vivo, by 
the preliminary experiment on the breast cancer cell line MDA-MB-231 inoculated into 
immunodepressed mice. After only 19 days of treatment the reduction of the tumor mass 
was about 60%, with no evident signs of suffering detected in the animals. 
Subsequently IT03, choosen as a model for the "second generation" compounds, was 
tested ex vivo on precision-cut slices of different organs to determine its toxicity, in 
comparison with AuL12 and the reference drug cisplatin. 
The results highlighted how the two gold(III) compounds have similar toxicity on the 
tissues tested (liver, kidney and colon), resulting less toxic than cisplatin in particular on 
liver. 
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Chapter 5 
Targeting and delivering of gold(III) complexes through the 
encapsulation into vesicular and micellar systems 
 
As previously assessed, our gold(III) dithiocarbamato complexes were proved to be very 
promising for their biological activity as antiproliferative agents, but are characterized by 
very low water solubility. Indeed, they dissolve in isotonic saline solution to a lesser 
extent than cisplatin, which is clinically i.v. administered in the presence of sugars, such 
as mannitol and dextrose142, to improve its solubility.  
Efficient carriers can be thus used to enhnce the properties of drugs which exhibit poor 
solubility, undesired pharmakokinetics and low stability in physiological environment, 
furthermore increasing their circulation times143. 
For the delivery of our gold(III) dithiocarbamato complexes we explored different 
approaches, based on the encapsulation in supramolecular aggregates. This allowed to 
avoid the use of organic solvents, normally exploited to solubilize the compounds for the 
biological tests, excluding additive toxic effects.  
In particular, the internalization of our gold(III) complexes was carried out in either 
micellar or vesicular systems to improve both their solubility and their bioavailability in 
physiological conditions. Moreover, micellar functionalization with a targeting moiety, as 
the cholecystokinin octapeptide CCK8, was performed to obtain tumor-selective delivery, 
thus further improving the chemotherapeutic index of our compounds (which is defined 
as the ratio between the lethal dose (LD50) and the effective dose (ED50) of a drug).  
An important feature to consider when selecting nanocarriers for drug delivery are the 
dimensions of the aggregates, since variations in the nanoscale range strongly affect 
blood circulation times and the bioavailability of the particles within the body144.  
In particular, it was proved that the encapsulation of drugs in micelles can diminish their 
extravasation into normal tissues and provide for a passive drug targeting to tumors via 
the enhanced permeability and retention (EPR) effect145. Indeed, being unable to 
penetrate through tight endothelial junctions of normal blood vessels, the concentration of 
the drug-loaded systems can build up in the plasma increasing their half-lifes. More 
importantly, they can selectively extravasate in tumor tissues due to their abnormal 
vascular nature and escape renal clearance. Overtime the tumor concentration of drug will 
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increase reaching values several-folds higher than those found in the plasma, due to lack 
of efficient lymphatic drainage in solid tumor, thus becoming an ideal application for 
EPR-based selective anticancer nanotherapy146.  
For pharmaceutical applications, the preferred size range goes from 10 to 100 nm. 
Particles ranging from 10 to 70 nm in particular, are known to offer effective distribution 
in certain tissues and are preferred to obtain faster drainage from the site of 
injection147,148. Particles smaller than 100 nm can also be accommodated in endocytotic 
vesicles, allowing the entrance into target cells via endocytosis149. Particles going from 70 
to 200 nm demonstrate the most prolonged circulation times150. However, the use of 
particles with higher diameters, likely more than 200 nm, are not recommended since 
they are frequently sequestered by the spleen as a result of mechanical filtration151, 
followed by eventual removal by the phagocyte system of the cells. On the other hand, 
small particles with diameters less than 5-10 nm are rapidly removed through 
extravasation and renal clearance144. 
The polymer-based nanotechnology is becoming one of the most attractive and fast 
growing area of the pharmaceutical research. The main nanoscale sized materials which 
are used as delivery agents for not water soluble compounds are polymeric micelles, 
polymer-DNA complexes ("polyplexes"), nanogels and liposomes, and are commonly 
referred to as nanomedicines145. These polymeric molecules can be thus specifically 
arranged to efficiently and safely deliver drugs, genes, antigenes and imaging 
molecules143. 
For the delivery of our gold(III)-dithiocarbamato complexes two different types of 
dispersing systems were employed; the first is based on the self-assembly of DPPC 
(dipalmitoylphosphatidylcholine) molecules to form vesicular structures, the second 
exploits the formation of micellar structures based on the aggregation of the Pluronic 
F127 amphiphilic polymer. 
 
DPPC vesicles 
The first dispersant system was chosen among the class of lipid nanosystems which, 
because of their high degree of biocompatibility, have been used to improve the 
pharmacological profiles of various anticancer drugs, otherwise discarded because of 
their low water solubility, poor bioavailability or either rapid biotransformation.  
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Liposomes are synthetic phospholipid vesicles with sizes ranging from approximately 50 
to 1,000 nm that can be loaded with a variety of drugs152. As for micelles, liposomes used 
for delivery purposes have several advantageous properties such as biocompatibility, 
biodegradability, low toxicity and capacity to modify the pharmacokinetic profile of the 
loaded drug, which can help in the preferential delivery of a drug to a desired target 
tissue. Although liposomes have attracted extensive attention during the past 30 years as 
pharmaceutical carriers, the currently available marketed liposomal formulations are not 
capable of selectively target cancer cells at a molecular level153. The introduction of PEG 
functionalizations was widely used to increase liposomes longevity in the circulatory 
system, since the presence of the polymer sterically hinders the interaction of blood 
components with the liposome surface, reducing the binding to plasma proteins154,155 and 
their interaction with opsonins (molecules that act as a binding enhancers for the process 
of phagocytosis) subsequent to capture by the RES (reticuloendothelial system)156. 
Thus so far, four formulations based on liposomes have been just clinically approved: 
Doxil® (Caelyx® in Europe), Myocet®, DaunoXome® and DepoCyt®157. The first two 
formulations include respectively PEGylated and non-PEGylated liposomes 
encapsulating doxorubicin which, at therapeutic concentrations, has severe cardiotoxic 
effects which limits its dosage when administered in a standard formulation. 
DaunoXome® is a non-PEGylated liposomal formulation of daunorubicin1580,159, while 
DepoCyt® is the commercial name of a non-PEGylated liposomal cytarabine160, a 
hydrophilic chemotherapeutic drug. 
In addition to the previous formulations on the market, a huge variety of antineoplastic 
liposomes are still under clinical evaluation. 
Most recently, the concept of “stimuli-sensitive” nanocarriers has been developed within 
the field of drug delivery. Such nanocarriers bear site-specific targeting ligands which are 
expected to be released in targeted tissues or cell compartments when exposed to certain 
internal or external stimuli, such as low pH161, elevated temperature162,163, magnetic 
field164,165 or altered redox potentials166, thus greatly increasing the drug’s efficacy. 
The choice of lipid composition is also crucial for maintaining the stability of liposomes 
in the circulatory system. The correct choice of lipids can indeed reduce the binding of 
serum proteins167 or stabilize the drug formulation, diminishing the rate of drug leakage. 
In fact, liposomes characterized by particular compositions have shown more rapid RES 
uptake increasing their size168.  
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The effect of surface charge on liposome clearance was demonstrated using 
eggPC/cholesterol (PC=phosphatidylcholine) liposomes with anionic lipids added in a 
1:10:5 ratio (anionic lipid/eggPC/cholesterol)169. It was found that liposomes containing 
phosphatidylglycerol (PG), phosphatidic acid (PA), and phosphatidylserine (PS; 
PS>PA>PG) were cleared more rapidly than neutral liposomes. Addition of ganglioside 
GM1 or phosphatidylinositol (PI) resulted in longer circulation times. 
 
Pluronic micelles 
The second dispersant system was chosen among the Pluronic amphiphilic molecules, a 
class of tri-block copolymers characterized by an A-B-A architecture of polyoxyethylene-
polyoxypropylene-polyoxyethylene (PEOx-PPOy-PEOx) units. Pluronics are a class of 
surfactants available in a wide range of molecular weights and PEO/PPO ratios. They are 
usually identified with an alphanumeric code, the first letter indicating the physical form 
at room temperature (with "L" stating for liquid, "P" for paste and "F" for flakes). The 
next two (or three) numbers give information about the composition and molecular 
weight of the compound, since the first number (or two numbers, in case of three number 
codes) multiplied by 300 gives the approximately molecular weight of PPO, while the last 
one, by a factor 10, gives the weight percentage of PEO in the structure. 
For the encapsulation of our gold(III) dithiocarbamato complexes, the Pluronic F127 was 
chosen. It is characterized by a PEO98-PPO57-PEO98 (Figure 4.1) structure with an 
average molecular weight of 12600 g mol-1. Above the critical micelle concentration 
(2.8·10-6 M at 37 °C, pH 7.4)170 it self-assembles in solution, giving rise to spherical 
micelles (Figure 5.2). 
 
Figure 5.1: structure of Pluronic F127 triblock copolymer. 
 
These types of structures are characterized by two well-defined regions: a central core 
which has hydrophobic properties and can incorporate lipophilic substances and an 
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like water (Figure 5.2).  
The hydrophobic core of Pluronic
studied for biomedical applications and demonstrated a good solubilization capability for 
our compounds. Regarding the biocompatibility, it is worth emphasizing that this class of 
organic carriers remains metabolically intact until renal clearance and has proved to be 
little or not toxic171.  
 
 
 
 
 
 
 
 
 
Figure 5.2: schematic representation of Pluronic
 
The use of Pluronic F127 for different clinical applications is already reported in 
literature, since it was first
an anticancer compound) in a mixed formulation named SP1049C, which contains two 
different types of Pluronic, F127 and L61
biodistribution of Dox encapsul
administration of the free drug, there was a more efficient accumulation of Dox into the 
tumor site, with delayed peak levels and prolonged residence time of the drug
Dox, but also other anticancer drugs as Paclitaxel and Carboplatin were encapsulated in 
this type of nanocarriers and tested 
activity, being furthermore capable to overcome multidrug resistance (MDR) in cancer 
cells145. Even if the polymers used for drug delivery were usually considered as 
biologically inert components, that have only the role to protect 
prolong the exposure of tissues to drugs and enhance the transport into cells, it was 
demonstrated that in some selected cases they can 
responses143.  
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Experimental 
Materials 
Protected Nα-Fmoc-amino acid derivatives, coupling reagents and Rink amide p-
methylbenzhydrylamine (MBHA) resin were purchased from Calbiochem-Novabiochem 
(Lafelfingen, Switzerland). The Fmoc-21-amino-4,7,10,13,16,19-hexaoxaheneicosanoic 
acid (Fmoc-Ahoh-OH) was purchased from Neosystem (Strasbourg, France). The N,N-
dioctadecylsuccinamic acid was synthesized according to published methods174. A tri-
block copolymer, containing ethylene oxide (EO) and propylene oxide (PO) groups, with 
the trade name Pluronic® F127 (PF127) and an approximate formula of 
PEO98PPO57PEO98 (average molecular weight of 12600 g mol-1) was obtained from 
BASF Svenska AB (Helsingborg, Sweden). All other chemicals were commercially 
available by Sigma-Aldrich (Bucks, Switzerland) or LabScan (Stillorgan, Dublin, Ireland) 
and were used as received unless otherwise stated. Snake skin dialysis tubing 3.5 K 
MWCO was purchased by Pierce Protein (USA). All solutions were prepared by weight 
with bidistilled water. Solid phase peptide synthesis was performed on a 433A Applied 
Biosystems automatic synthesizer (Carlsbad, California). Analytical LC-MS analyses 
were performed by using Finnigan Surveyor MSQ single quadrupole electrospray 
ionization (Finnigan/Thermo Electron Corporation San Jose, CA) column: C4-
Phenomenex eluted with H2O/0.1% TFA (A) and CH3CN/0.1% TFA (B) from 20–80% 
over 20 min at a flow rate of 0.8 mL/min. The crude peptide was purified by RP-HPLC 
on a LC8 Shimadzu HPLC system (Shimadzu Corporation, Kyoto, Japan) equipped with 
a UV lambda-Max Model 481 detector using a Phenomenex (Torrance, CA) C4 (300 Å, 
250 x 21.20 mm, 5 µ) column eluted with H2O/0.1% TFA (A) and CH3CN/0.1% TFA (B) 
from 20–80% over 20 min at a flow rate of 20 mLmin-1. UV-Vis measurements were 
performed on a UV-Vis Jasco V-5505 spectrophotometer (Easton, MD) equipped with a 
Jasco ETC-505T Peltier temperature controller with a 1-cm quartz cuvette (Hellma).  
 
Peptide Synthesis 
(C18)2-PEG1000-G-CCK8 amphiphilic peptide was synthesized by using standard solid-
phase 9-fluorenylmethoxycarbonyl (Fmoc) procedures. The Rink amide MBHA resin 
(substitution 0.65 mmol g-1) was used as the solid-phase support, and the synthesis was 
performed on a scale of 0.1 mmol. The peptide Gly-CCK8 was prepared by sequential 
condensation of Fmoc-AA-OH using PyBOP/HOBt/DIPEA (1/1/2) as coupling reagents 
Chapter 5.Targeting and delivering of gold(III) complexes through the encapsulation into 
vesicular and micellar systems. 
95 
 
in DMF in pre-activation mode. All the reactions were performed twice for 1 hour, by 
using an excess of 4 equivalents for the single amino acid. Fmoc deprotection was carried 
out by 30% solution of piperidine in DMF after the coupling of each amino acidic 
residue. When completed the Gly-CCK8 synthesis, the Fmoc N-terminal protecting group 
was removed and three residues of Fmoc-Ahoh-OH hexaoxoethylene linker and the N,N-
dioctadecylsuccinamic acid were sequentially condensed as previously reported174,175. 
Then, the amphiphic peptide was fully deprotected and cleaved from the resin with TFA 
and 2.5% (v/v) water and 2.5% (v/v) TIS as scavengers, at room temperature, and then 
precipitated with ice-cold water, filtered, dissolved in H2O/CH3CN mixture, and 
lyophilized. The crude peptide derivative was purified by RP-HPLC. Purity and identity 
were assessed by analytical LC-MS analysis.  
(C18)2-PEG1000-G-CCK8. Rt=17.26 min; MS (ESI): m/z: 2724 calcd. for 
C136H226N15O37S2; [M+2H]2+= 1363.0 
 
Synthesis of AuL12 
[AuIIIBr2(SSC-Sar-OEt)] (Sar=N-methylglycine, Et=ethyl; AuL12) was synthesized and 
fully characterized according to our procedure, reported elsewhere93.  
 
Stability studies by UV-Vis spectrophotometry  
Stability of the compound AuL12 or IT01 alone (pre-dissolved in DMSO) in saline 
solution at a final concentration of 100 µM was studied recording several electronic 
spectra over 24 h at 25 °C between 240 and 450 nm. The stability of AuL12 loaded in 
either targeted or non-targeted PF127-based micelles, and of IT01 in non-targeted ones, 
was evaluated by UV-Vis spectrophotometry over 72 h acquiring spectra in the 
wavelength range 210÷500 nm. Other experimental settings were: scan speed (300 
nm/min), spectral bandwidth (2.0 nm), average time (0.100 s) and data pitch (0.5 nm). 
 
Determination of logP 
The determination of the partition coefficient (P) was performed dissolving the gold(III) 
compounds at a concentration of 5 mM in 50 mL n-octanol. The solution was mixed with 
50 mL bidistilled water in a separating flask, and equilibrated for 2h. After the 
equilibrium was reached, the two non miscible solutions were separated, and the 
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concentration of compound in n-octanol was determined before and after equilibration via 
UV-VIs spectroscopy, obtaining indirectly the concentration of complex in water. 
 
Micelles formulation 
Pure micelles of PF127 were prepared by dissolving copolymer at 2% w/w in aqueous 
solution at the physiological conditions. Mixed PF127/(C18)2-PEG1000-G-CCK8 
micelles were prepared by adding 4% w/w of the CCK8 amphiphilic peptide with respect 
to PF127. Briefly, the two amphiphile compounds were dissolved in a small amount of 
MeOH/CHCl3 (50:50); subsequently a thin film was obtained by evaporating the solvent 
by slowly rotating the tube containing the solution under nitrogen flux. Lipid film was 
hydrated in physiological solution (1 mL) for 5 min by vortex, sonicated for 10 min and 
used without further treatment. Concentrations of CCK8-containing solutions were 
determined by absorbance on a UV-Vis Jasco (Easton, MD) Model 440 
spectrophotometer with a path length of 1 cm using a molar absorptivity (ε280) of 6845 M-
1
 cm-1 for CCK8. This value was calculated according to the Edelhoch method175, taking 
into account contributions from tyrosine and tryptophan present in the primary structure, 
which amount to 1215 and 5630 M-1 cm-1, respectively176.  
 
AuL12 and IT01 micelles loading 
Loading of either AuL12 or IT01 compounds in PF127 pure micelles and of AuL12 in 
PF127/(C18)2-PEG1000-G-CCK8 mixed micelles was performed via film method177. 
Briefly, after lipid film preparation previously described, AuL12 or IT01 (0.35 mg or 
0.36, respectively, in 20 mg of PF127) were dissolved in chloroform/methanol (50/50) 
mixture. Organic solvent was then evaporated under nitrogen flux and saline solution 
added as previously described. Subsequently, unloaded AuL12/IT01 was removed using a 
Sephadex G50 column pre-equilibrated with a NaCl 0.9% w/w aqueous solution.  
The AuL12 concentration (0.5 mM) and drug loading content (DLC), defined as the 
weight percentage of Au complex encapsulated in the micelles, was quantified by using 
ICP-AES analysis (Inductively Coupled Plasma Atomic Emission Spectroscopy) after 
subtraction of the amount of AuL12/IT01 removed from the column from the total 
amount of AuL12/IT01 loaded. 
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AuL12 release from PF127 micelles 
Non-targeted AuL12-containing aggregates (lyophilized) were dissolved in 1 mL of 
water. The solution was then transferred into a dialysis bag (MW cutoff = 3500 Da) 
which was placed into 15 mL (hereinafter, V0) of saline solution and incubated under 
stirring for 72 h at 37°C. At different time points, 2 mL (VD) of the dialyzed solution 
were withdrawn to evaluate the released drug amount over time; such volume was 
immediately replenished with fresh saline solution. It was assumed that the crossing of 
gold species through the dialysis membrane occurred quickly, and that the overall release 
of AuL12 from micelle vehicle to the dialysis bag medium was the rate determining step 
process.  
The extent of gold complex released was evaluated by ICP-AES analysis (AuI λem= 
242.795 nm) as ratio of the concentration of released metal (CJ) to the total metal 
previously loaded into the micelles. In particular, CJ is the released concentration 
immediately after drawing of each sample (labelled as J) and refilling of the removed 
volume VD. In Equation 1 defines CJ (wherein the subscript a stands for "analyzed") and 
the first term takes into account the effects of both drawing (system resulting in a volume 
of 13 mL=VR) and dilution (system volume =V0) whereas the second term considers all 
the 2 mL aliquotes related to the Jth drawing and the ith previous aliquotes, α and β being 
VR/VD and VD/V0, respectively. The second term could be neglected only if VD<<V0 
which is not our case.  
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Then, we analyzed the overall release kinetics from the micelles via experimental data 
fitting, assuming a first-order dissociation process178. Equation 2 describes that AuL12 is 
released from the supramolecular aggregates owing to two parallel dissociation events 
(not identified yet). The parameters a1 and a2 are the maximum amount of gold compound 
released by means of the first or the second event, respectively. The parameters k (s-1) are 
the overall experimental rate constants which correspond to the combination of single 
microscopic rate constants associated with the unloading processes from the micelle 
hydrophobic core of the different AuL12 isoforms (present in the sample).  
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By fitting the CJ vs. t profile with Eq. 2, the following parameters were obtained: a1= 
3470 ± 26 ppb; a2 = 1730 ± 57; k1 = (6.7 ±0.3) · 10-4s-1; k2  = (8.7 ±0.8) · 10-6s-1. 
 
 = (1 − ) + (1 − )																																	(2) 
 
Vesicles formulation and AuL12 and IT01 loading 
Vesicles based on dipalmitoylphosphatidylcholine (DPPC, Sigma Aldrich; 
CMC=0.46nM) containing either IT01 or AuL12 were prepared dissolving phospholipids 
(3.8 mg) and test compound (0.35 or 0.38 mg respectively) in chloroform/ethanol. The 
solvent was slowly evaporated under a gentle N2(g) flux in a flask, obtaining an 
homogeneous DPPC/AuL12 or DPPC/IT01 thin film, that was dried overnight at reduced 
pressure to eliminate any trace of solvent. The thin layer was then rehydrated above the 
critical temperature of the phospholipids Tc (about 50°C) with 1 mL of saline solution 
(NaCl 0.9% aqueous solution). The suspension was stirred for 30 min and then submitted 
to 5 cycles of quick freezing/defreezing in liquid nitrogen and 37°C water bath to obtain 
large unilamellar vesicles (LUV) with heterogeneous dimensions. The solution was then 
extruded through a porous membrane of polycarbonate with mean pores diameter of 100 
nm, to obtain small unilamellar vesicles (SUV). The solutions before and after extrusion 
were analyzed by means of DLS analysis to assess the dimensional properties of the 
vesicles. The extruded vesicles were then dialyzed for 2 h against saline solution to 
eliminate gold(III) complex and phospholipids not entrapped in the vesicles system.  
 
DLS (Dynamic Light Scattering) Analysis 
Mean diameter was measured using a ZetasizerNano-S (Malvern Instruments, 
Westborough, MA) at 25 °C using disposable sizing cuvettes. DLS samples were 
prepared at 2.0·10-4 M in saline solution NaCl 0.9% and centrifuged at room temperature 
at 13,000 rpm for 5 min. For each batch, hydrodynamic radius and size distribution were 
the mean of three measurements and final values were calculated as the mean of three 
different batches.  
 
ICP-AES analysis 
ICP-AES measurements were carried out by ICP-AES spectrometer (ICP SPECTRO 
Arcos with EndOnPlasma torch; Spectro Analytical, Kleve, Germany) equipped with 
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capillary cross-flow nebulizer. Analytical determinations were carried out with a plasma 
power of 1.4 kW, a radiofrequency generator of 27.12 MHz and an argon gas flow with 
nebulizer, auxiliary, and coolant set at 0.8, 0.8 and 13 L·min-1, respectively. 
Samples were diluted with 5% aqua regia (HCl/HNO3 3:1 v/v) in bidistilled water. The 
extent of gold complex release was evaluated by ICP-AES analysis [λem(AuI)= 242.795 
nm] through external calibration method. 
 
Cell Lines and cultures 
A431 cells (human epidermoid carcinoma) and H460 (human large cell lung cancer) were 
obtained from American Type Culture Collection (ATCC). Cells were grown in a 
humidified atmosphere containing 5% CO2 at 37°C in either Dulbecco Modified Eagle 
medium (DMEM, Sigma Aldrich) supplemented with D-glucose (final concentration 4.5 
g/L, Sigma; A431) or RPMI-1640 (Roswell Park Memorial Institute, Sigma Aldrich; 
H460), both supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen), 
100 U.mL–1 penicillin (Sigma), 100 µg.mL−1 streptomycin (Sigma) and 0.25 µg.mL−1 
amphotericin B (Sigma). The human epidermoid carcinoma cell line A431 overexpressing 
the CCK2-R by stable transfection, kindly provided by Dr. L. Aloj (Istituto Nazionale 
Tumori, Fondazione G. Pascale, Napoli, Italy), was cultured as exponential growing 
subconfluent monolayer on 100-mm plates in DMEM supplemented with 10% FCS 
(Fetal Calf Serum), 2 mM L-glutamine, and 250 g/mL neomycin analog G418 (Gibco 
BRL) in a humidified atmosphere containing 5% CO2 at 37°C.  
 
In Vitro cytotoxicity assays 
A431, A431-transfected and H460 cells (3·104 cells mL-1) were seeded into each well of 
24-well cell culture plates. After 24 h incubation, the medium was discarded from the 
plates and replaced with an equal volume of fresh medium containing the test complexes 
at different concentrations. Then, cells were incubated for 72 h. A DMSO solution of 
either AuL12 or IT01 was added for the tests in amounts of organic solvent not exceeding 
the 0.4% v/v per well. Cisplatin (Sigma) was stocked in saline solution (0.9% w/w NaCl 
in water) at a concentration up to 4 mM. The formulations of micelles or vesicles loading 
either AuL12 or IT01 were likely hydrated in saline solution, at a final stock solution 
concentration of 5.0.10-4 M. The Trypan Blue dye exclusion assay was performed to 
determine cell viability. Cytotoxicity data were expressed as GI50 values (µM), i.e. the 
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concentration of test compound inducing 50% reduction in cell number compared to 
control cultures. Control samples of F127 and DPPC vesicles were furthermore tested to 
confirm the absence of intrinsic toxicity due to the carriers. 
 
Results and discussion 
5.1 Determination of the partition coefficient P 
Before loading the gold(III)-dithiocarbamato compounds into micelles or vesicles, the 
lipophilic properties of the analyzed complexes were defined through the determination 
of their partition coefficient (P) between water and n-octanol, usually expressed in the 
logarithmic form, logP (Equation 3). The value of P is defined as the ratio between the 
concentrations of a compound in a mixture of two immiscible solvents at equilibrium. 
)3(][
][loglog tan
water
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complex
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In particular, the partition of the complexes was evaluated between a hydrophobic solvent 
such n-octanol, and a hydrophilic one, like water, which are immiscible. In medical use, 
this parameter is evaluated to achieve information about the network of inter- and 
intramolecular forces affecting drug transport through lipid structures as well as drug's 
interactions with target proteins. Indeed, at the organism level, lipophilicity and 
hydrophilicity are important factors defining the pharmacokinetics and 
pharmacodynamics of a drug substance179. 
In this case, since the scarce solubility of our compounds in water, the evaluation of the 
partition coefficient was carried out determining the concentration of the complexes in a 
n-octanol solution before and after the mixing with a well-defined volume of water 
(Table 5.1).  
 
Tabella 5.1: logP values measured for the three complexes AuL12, IT01 and IT03. 
 log P 
AuL12 0.13 
IT01 0.51 
IT03 0.87 
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Positive values for the logarithm of P have to be correlated to a more lipophilic character 
of the compounds. The determination was performed both for the "first generation" 
reference compound AuL12 and for the "second generation" dipeptide derivatives, IT01 
and IT03. The determination on the correspondent IT02 and IT04 isomers was not carried 
out, since they differ from the above mentioned compounds only for the configuration of 
the chiral aminoacid, property which does not affect the chemico-physical behaviour of 
the compounds, neither their solubility. 
In all cases, the compounds showed higher affinity for hydrophobic environments, with 
values of logP increasing from the more hydrophylic AuL12 to the more hydrophobic 
IT03.  
For the further solubilization studies, which include two different types of dispersant 
nanosystems, IT01 was chosen as a model upon the peptido-functionalized gold(III)-
dithicarbamato complexes while AuL12 was taken as a reference compound.  
In the first case we exploited the encapsulation of the gold(III) compound in the 
hydrophobic core of Pluronic F127 non-targeted and targeted micelles. In the second 
case, the complexes were loaded in hydrophobic corona of DPPC-based vesicles (Figure 
5.3).  
 
Figure 5.3: schematic representation of Pluronic F127 monomer (x=z=98, y=57) and the corresponding 
micelle architecture (left) and of phospholipid DPPC and the corresponding vesicular system upon 
surfactant organization in solution (right). 
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5.2 Targeting and delivery of AuL12 with Pluronic-based micelles 
The gold(III)-dithiocarbamato complex AuL12 (Figure 5.4A, compound 2) was selected 
among the "first generation" compounds due to its good antiproliferative rates recorded 
both in vitro and in vivo2,180. Such gold(III) derivative was loaded in two types of self-
assembling supramolecular aggregates, namely consisting of Pluronic® F127 (PF127, 
Figure 5.4B) or its combination with the amphiphilic peptide (C18)2-PEG1000-G-CCK8 
(Figure 5.4C), thus yielding the formation of either non-targeted and targeted micelles, 
respectively.  
In fact, upon self-assembling, the second type of drug carrier is characterized by the 
presence of the octapeptide CCK8 bound to the external hydrophilic corona of the 
resulting micelles (Figure 5.4D). 
 
 
Figure 5.4: Chemical drawing of cis-diaminodichloroplatinum(II) (cisplatin) (A-1), dibromo[ethyl N-
(dithiocarboxy-kS,kS’)-N-methylglycinato]gold(III) (AuL12) (A-2), non-ionic surfactant Pluronic® F127 
with n=98 and m=57 (B), (C18)2-PEG1000-G-CCK8 (C) and schematic representation of AuL12 loaded in 
PF127/(C18)2-PEG1000-G-CCK8 targeted micelles (D). 
 
The targeting peptide CCK8 belongs to the family of cholecystokinin (CCK) peptides 
whose receptors181,182 are normally present on the cell surface and are known to be up-
regulated after malignant transformation. Two different receptor types, called CCK1-R 
and CCK2-R, recognize CCK and mediate its action183. Both are located predominantly in 
the gastrointestinal tract and in the central nervous system184. The CCK1-R was found 
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overexpressed in a number of pancreatic adenocarcinomas and in gastro-entero-pancreatic 
neuroendocrine tumors (38%), in meningiomas (30%) and in some neuroblastomas 
(19%), while the CCK2-R in stromal ovarian cancers (100%) and it was shown to be up-
regulated in a high percentage of medullary thyroid cancers (92%), in astrocytomas 
(62%) and in small-cell lung cancers (57%)182-185. Also the octapeptide amide-CCK8 
(amino acid sequence: Asp26-Tyr27-Met28-Gly29-Trp30-Met31-Asp32-Phe33-amide) binds 
with nanomolar affinity both receptor subtypes, also when modified on its N-terminus 
with chelating agents or alkyle chains186. In fact, it has been successfully used to deliver, 
in a selective way, contrast agents for nuclear medicine applications187 or supramolecular 
aggregates carrying gadolinium complexes and/or anticancer drugs.  
In this work the amphiphilic CCK8-functionalized surfactant (C18)2-PEG1000-G-CCK8 
(Figure 5.4C) was synthesized by solid-phase methods on a Rink-amide resin. After 
CCK8 assembling, a Gly residue, three units of Fmoc-Ahoh-OH and N,N-
dioctadecylsuccinamic acid were subsequently condensed step by step. After cleavage 
and purification, the amphiphilic peptide derivative was obtained in high yield and purity. 
The preparation of both AuL12-loaded PF127 non-targeted micelles and PF127/CCK8 
targeted micelles was carried out exploiting the thin film hydration method188. Briefly, a 
homogeneous lipid layer has been obtained by dissolution of the amphiphilic monomers 
[0.020 g of PF127 alone or along with 0.0008 g of (C18)2-PEG1000-G-CCK8] and 
AuL12 (0.00035 g) in a small volume of chloroform/methanol (50/50) mixture, followed 
by evaporation of the solvent under a mild nitrogen flow. Afterwards, the layer was 
hydrated by addition of aqueous solution (10 mM HEPES at pH 7.4, 10 mM PBS at pH 
7.4 or saline solution at 0.9% w/w NaCl pH=5.0), resulting in a suspension containing 2% 
of PF127 with respect to water weight, which was then vortexed until obtaining a clear 
solution. 
Dynamic Light Scattering (DLS) measurements were performed to assess the dimensions 
of the two, empty or filled, self-assembled systems. As previously reported, the mean 
hydrodynamic diameter of PF127 micelles at 2% w/w and 25 °C is 25 nm, accordingly to 
literature data189,190, and no significant variation occurs after loading of AuL12 at 0.035 
% w/w (diameter=26 nm). A slight increase in size was observed for mixed, empty or 
filled, targeted micelles (mean diameter values calculated from DLS were 34 and 32 nm, 
respectively, Table 5.2).  
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Table 5.2: Structural parameters (mean hydrodynamic diameters, polydispersity indexes and diffusion 
coefficients) determined from dynamic light scattering measurements for the studied systems. 
 
Systems 
Micelle diameter± 
SD (nm) P.I.± SD 
diffusion coefficient 
[m2s-1]х10-12 
PF127 25±14 0.23±0.01 20±11 
AuL12-PF127 26±13 0.23±0.01 19± 10 
PF127/CCK8 34±11 0.43±0.02 15± 5 
AuL12-PF127/CCK8 32±12 0.48±0.01 15± 6 
Electronic spectra of free AuL12 in saline solution (Figure 5.5) and AuL12-loaded 
micelles in different solution systems (Figure 5.6) were recorded to assess the stability of 
the metal complex over time (until either 24 or 72 h). The wavelength range 210-500 nm, 
wherein only the gold(III) complex shows significant absorption bands, was explored. In 
saline solution, the electronic spectrum of AuL12 alone (previously dissolved in DMSO 
at 0.5% v/v) displays two strong absorption bands at around 270 (band I) and 312 (band 
II) nm, ascribed to the transition already described for IT01 complex (see Chapter 3). 
As can be observed in Figure 5.5, the compound undergoes partial hydrolysis, as shown 
by the appearance of a band at 380 nm assignable to the coordination of water molecules 
to the metal center. 
 
Figure 5.5: UV-Vis spectra of AuL12 dissolved in DMSO collected over time in saline solution (NaCl 
0.9%) at 25°C.  
 
However, the spectral features varitions reported for AuL12 differ from those of IT01 
recorded in the same experimental conditions (Chapter 3). This different behaviour can 
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be explained with different solubility properties and hydrolysis rates for the two 
complexes. Nevertheless, deeper and more accurate evaluations will be performed to 
elucidate this subject.  
Considering the AuL12-encapsulating micelles, the UV-Vis spectrum recorded soon after 
their re-suspension in PBS shows a slight change in the values of λmax for band I and band 
II (258 and 312 nm; Figure 5.6A) with respect to those recorded for the complex alone in 
saline solution. However, a strong hypochromic effect accompanied by a bathochromic 
shift is detected over time for both bands, together with the appearance of a new band at 
380 nm (band III), thus highlighting the reactivity of the compound in this medium, in 
agreement with literature data106.  
On the contrary, no notable changes in terms of spectral features (e.g., intensity, λmax), 
have been observed in the kinetic trend recorded for the AuL12-loaded micelles prepared 
in saline solution (Figure 5.6B), pointing out a higher stability of the compound in such 
an aqueous medium. On the whole, the position of the bands (270 and 313 nm) is 
basically unchanged with time, indicating that the gold center remains in the +3 oxidation 
state due to the stabilization effects played by the chelating dithiocarbamato ligand106,191.  
 
Figure 5.6: UV-Vis spectra of AuL12/PF127 micelles collected over time in: (A) 10 mM phosphate 
buffered saline and (B) saline solution.  
 
The slight changes in spectral intensity (hypochromic and hyperchromic effect for band I 
and II, respectively) have been ascribed to the progressive hydrolysis of gold(III)-bound 
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bromide ions, leading to the formation of an aquo complex (as already described for IT01 
in saline solution, Chapter 3). The changes in spectral intensity (hypochromic and 
hyperchromic effects for band I and II, respectively) have been attributed to the 
progressive hydrolysis of gold(III)-bound bromide ions, resulting in the formation of the 
corresponding water-soluble aquo-complex81,82 (as already described for IT01 in saline 
solution, Chapter 3). 
Furthermore, the band III (M→L charge transfer involving the M nd orbitals and the 
dithiocarbamato π* system)192,193 intensity increase at about 385 nm may be explained 
considering the effects of the Br/OH substitution on the transition dipole moment and, 
hence, on the transition probability.  
Based on the higher stability of the formulation in saline solution compared to PBS, all 
subsequent studies were carried out in the first medium. 
 
The drug release from the micelle carriers was evaluated using a dialysis membrane 
(MWcutoff = 3500). Figure 5.7 shows the release profile obtained at 37 °C over 72 h. The 
amount of released complex was evaluated by ICP-AES analysis (Inductively Coupled 
Plasma Atomic Emission Spectroscopy) as percentage of released gold(III) complex on 
the total compound previously encapsulated in the aggregates. It is worth noting that most 
of the drug (around 73%) is released after 72 h and that the process takes place quite 
quickly as after 30 min the 35% of the compound is out of the micelles, with 56% release 
reached after 12 h. 
 
Figura 5.7: Gold concentration (CJ, according to equation 1) evaluated over 72 h in saline solution at 37 
°C, namely AuL12 release from non-targeted micelles (%, with respect to total compound previously 
encapsulated in the aggregates). Error bars were determined by means of the error propagation equation. 
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The antiproliferative activity (Table 5.3, Figure 5.8) was evaluated on two tumor cell 
lines, namely A431 (epidermoid carcinoma) and A431 overexpressing the CCK2 receptor 
(CCK2-R) by stable transfection (kindly provided by Dr. L. Aloj, Istituto Nazionale 
Tumori, Naples, Italy). AuL12 dissolved in DMSO (AuL12-DMSO) and AuL12-
encaspulating non-targeted micelles (AuL12-PF127) display similar GI50 values on both 
tumor cell lines.  
 
Table 5.3: In vitro antiproliferative activity of AuL12 dissolved in DMSO (AuL12), encapsulated in non-
targeted micelles (AuL12/PF127) and in CCK8-receptor targeting micelles (AUL12/Pf127-CCK8). GI50 
data are calculated as average value of at least three experiments ± S.D.  
 
 
Samples 
GI50 (µM) 
A431 CCK2-R transfected A431 
AuL12* 9.50± 2.00 9.50± 2.40 
AuL12/PF127 9,01 ± 0.70 6.80 ± 1.90 
AuL12/PF127-CCK8 7.50 ± 2.10 0.75±0.08 
Cisplatin 4.00± 1.80 6.00± 2.10 
*dissolved in DMSO 
 
 
Figure 5.8: Barchart related to Table 5.3 cytotoxicity values of the tested formulation with respect to 
Ciplatin, on A431 and CCK2R transfected A431 cells (A431-tr). 
 
Anyway, cisplatin remains the most potent compound against A431 cells, showing a 
cytotoxic effect about 2-fold higher than the two AuL12 micellar formulations, and only a 
slightly higher effect on A431 CCK2-R-transfected cells. However, when AuL12 is 
loaded in the peptide-conjugated micelles (AuL12-PF127/CCK8), the GI50 value 
determined on A431 CCK2-R-transfected cells decreases of one order of magnitude with 
respect to those of cisplatin, AuL12-DMSO and AuL12-PF127. Thus, in agreement with 
the release data, it is possible to suppose that the endocytic process occurs faster (in the 
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order of minutes) with respect to the rate of AuL12 released from the micelles, thus 
allowing tumor cell targeting and cell internalization before the loss of active gold(III) 
complex from the supramolecular aggregates. 
To sum up, one of our poorly water-soluble gold(III)-based complexes (AuL12) has been 
loaded in the lipophilic core of PF127-based micelles. Overall, here we have 
demonstrated that: 
 AuL12 encapsulated in micelles proved to be stable in saline solution up to 72 h. 
 the studied supramolecular aggregates have proved to be good carriers, thus enhancing 
the water solubility together with keeping or increasing the antiproliferative activity of 
the model compound (compared to the DMSO vehicle). 
 the release from the micelle systems into the aqueous medium was shown to occur 
very fast, reaching 50% after 2 h. 
 if a targeting moiety is present on the hydrophilic shell of micelles, the designed 
supramolecular scaffold, besides being a vehicle, it also acts as a targeted bullet. In 
fact, on passing from A431 cells to CCK2-R-transfected counterparts, the cytotoxicity 
of the loaded AuL12 compound is 10-fold increased.  
In conclusion, loading of metal-based antiproliferative compounds in labeled micelles of 
Pluronic® seems to be a winning approach both to increase water solubility and to favor 
tumor selectivity in a single strategy. Based on these preliminary promising results, we 
evaluate the loading of some gold(III)-peptidomimetics into Pluronic® aggregates to 
enhance their bioavailability in the prospect to enter phase I clinical trials101. 
 
 
5.3 Delivey of IT01with Pluronic micelles and DPPC vesicles 
IT01-loaded micelles and vesicles were prepared by using the thin film hydration 
method194, as above reported. After resuspension of the lipidic film in saline solution 
NaCl 0.9%, a heterogeneous mixture of large unilamellar vesicles (LUV) was obtained. 
To control liposomes dimensions, the samples were thus extruded through a 
polycarbonate membrane of 100 nm porosity (as described in the Experimental Section of 
this Chapter). By mechanically forcing the LUVs to pass through the pores of the 
membrane, vesicles reorganize in smaller homogeneous systems (SUV, small unilamellar 
vesicles) of mean diameter comparable to the membrane pore dimension employed. 
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Dynamic Light Scattering (DLS) measurements were performed to assess the dimensions 
of the loaded or unloaded systems (Table 5.4). The mean hydrodynamic diameter of 
PF127 at 2% w/w and 25 °C is 25 nm, accordingly to literature data189,190, and no 
significant variation occurs after loading of AuL12 at 0.035 % w/w (diameter=26 nm). 
Hydrodynamic diameters of nearly 80 nm were obtained for vesicles, slightly smaller 
than expected since a membrane porosity of 100 nm diameter was used for the extrusion. 
It is worth noting that even in this case, no significant structural changes were detected 
passing from the loaded to the unloaded systems. 
 
Table 5.4: Structural parameters (mean hydrodynamic diameters, polydispersity indexes and diffusion 
coefficients) determined from dynamic light scattering measurements for the studied systems. 
 
Hydrodynamic diameter 
± st.dev (nm) P.I.± SD 
diffusion 
coefficient 
[m2s-1]х10-12 
Au content 
(x10-4M) 
F127/IT01 22 ± 4,7 0.45±0.12 18±3 5.00±0.06 
F127/AuL12 26±13 0.23±0.01 19± 10 5.00±0.10 
F127 control  25±14 0.23±0.01 20±11 -- 
DPPC/IT01 81 ± 16 0.60±0.22 5.3±0.3 4.37±0.30 
DPPC/AuL12 100 ± 40 0.34±0.23 4.4±0.1 4.30±0.20 
DPPC 
control 
83±20 0.64± 0.18 5.6±0.4 -- 
 
Each sample was then analyzed via ICP-AES analysis to determine the content of 
gold(III) complex encapsulated in the two different systems. As reported in Table 5.4, the 
amount of gold internalized in the liposomes is slightly lower than the amount found in 
the Pluronic micelles. This can be probably due to the multistep procedure used to obtain 
the complex-loaded liposomes, if considering in particular that the process of extrusion 
through the polycarbonate membrane can determine a loss of compound, as a 
consequence of the possible adsorption of the complex on the membrane itself. 
The stability of the IT01/DPPC and IT01/F127 systems was evaluated through UV-Vis 
analysis of the sample in saline solution NaCl 0.9% (final IT01 concentration 50.0 µM) at 
37°C for 24 h. From the analysis of the electronic spectra recorded for the IT01-loaded 
pluronic system (Figure 5.9), it can be noticed that the main absorption bands of IT01 
undergo a hyperchromic effect with time, accompained by a slight shift in λmax for the 
π
*
← π transition (from 264 to 271 nm). Contrarily, the position of the π*← n transition 
does not change with time, while an absorption band of low intensity appears at nearly 
360 nm.  
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This situation is coherent with the release of the compound from the micelles, since 
hydrolysis of the complex could take place upon release from the hydrophobic core to the 
aqueous saline solution. Indeed, the position of the bands after 24 h is similar to those 
recorded in saline solution for the compound alone (added form a DMSO solution, 
Chapter 3).  
 
 
Figure 5.9: UV-Vis spectrum of IT01-loaded (50 µM) Pluronic F127 micelles recorded at 25°C over 72h. 
 
Differently, for IT01-loaded DPPC vesicles in saline solution NaCl 0.9%, a hyperchromic 
effect on all the absorption bands is recorded without significant shift of their λmax 
(Figure 5.10). This behaviour can be explained as the effect of an increase in scattered 
light due to the formation of larger aggregates in solution. This was furthermore 
confirmed by DLS analysis of the sample after 72h, which shows that the vesicles 
dimensions (in terms of hydrodynamic diameter) after 72h incubation at 37°C varies from 
82±16 to 1868±520 nm, assessing the tendency of the vesicles to aggregate in solution. 
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Figure 5.10: UV-Vis spectrum of IT01-loaded (50 µM) DPPC vesicles recorded at 25°C over 72h. 
The DPPC and Pluronic F127 systems loading either the compound IT01 or AuL12, were 
subsequently tested on H460 human cancer cells, to check whether their cytotoxicity is 
maintained after the encapsulation in the two different dispersant systems. As we can see 
from Table 5.5, the activity of both the IT01- and AuL12-loaded vesicles and micelles is 
comparable to the cytotoxic activity of the compounds alone (administered to cells from a 
DMSO solution).  
 
Table 5.5: in vitro cytotoxic activity of IT01- and Aul12-loaded in Pluronic F127 micelles and DPPC 
vesicles on H460 cells after 72h. 
 
 GI50 ± dev.st.(µM) 
DPPC/IT01 3.20 ± 1.93 
F127/IT01 2.89 ± 1.62 
IT01 3.83 ± 2.13 
DPPC/AuL12 3.51 ± 0.48 
F127/AuL12 2.13 ± 0.13 
AUL12 2.15 ± 0.26 
 
The toxicity of pure DPPC and Pluronic F127 on H460 cells was also checked, to assure 
the absence of any contribution to the decreased cell viability deriving from the intrinsic 
effect of the carrier. DPPC did not exhibit any cytotoxic effect on H460 cells even at 
concentration 2-fold higher then the highest concentration employed for the cytotoxicity 
studies with AuL12- or IT01-loaded liposomes ([DPPC]max=2.47.10-4M). Otherwise, 
Pluronic F127 showed a slight decrease in cell viability while increasing its administered 
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concentration. At the maximum concentration used for cytotoxicity test of the gold(III) 
derivatives ([F127]max=2.89.10-5M) it was shown that it determined a cell viability 
decrease of 17% with respect to the reference control (83% cell viability), which 
approached the 30% with Pluronic concentration of 4.00.10-5M.  
Concluding, in this section we evaluated the possibile encapsulation of the new gold(III) 
complexes in biocompatible carrier systems, in order to enhance their stability in 
physiological conditions and thus increase their bioavailability for the forthcoming in vivo 
studies. The results obtained for both the Pluronic F127-based micelles and for the DPPC-
based liposomes were promising. In both cases the stability of the gold(III) complexes 
was enhanced, and the cytotoxic activity was maintained in comparison with that of the 
compound previously dissolved in DMSO.  
With respect to DPPC liposomes, the Pluronic F127 formulations should be preferred if 
considering the simpler and faster procedure adopted for their preparation. Anyway, the 
intrinsic toxicity (even if low) of Pluronic F127 and the lower stabilization of the 
complexes, with respect to the liposomal systems, must be taken into account when 
considering their application to forthcoming in vivo experiments.  
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Chapter 6 
Insights into the mechanism of action of gold(III)-
dithiocarbamato derivatives 
Considering the good cytotoxic properties of our compounds on human cancerous cells in 
vitro and the promising antiproliferative activity verified in vivo, it resulted of peculiar 
importance to obtain more details about the mechanism of action of our compounds. 
In this context, the interaction with biomolecules already identified as putative targets for 
other anticancer metallodrugs have been explored. 
In particular, we focused on the evaluation of selected gold(III) compounds interaction 
with different macromolecules, as DNA, proteasome, thioredoxin reductase and PARP 
enzymes.  
As already mentioned, the most known metallodrug used in cancer chemotherapy is 
cisplatin. Even if its antiproliferative activity was discovered in 1969 and more than 30 
years passed since its approval by FDA (Food and Drug Administration), its effective 
mechanism of action is still not fully understood yet. It is generally accepted that DNA is 
its principal target. As already described in the Introduction, cisplatin is activated 
intracellularly by the substitution of one or two chlorido ligands with water molecules, 
and it is known to subsequently covalently bind to DNA, forming DNA adducts. This 
activates various signal-transduction pathways, for example those involved in DNA-
damage recognition and repair, cell-cycle arrest and programmed cell death/apoptosis195.  
It is also well known that only 5% of the internalized drug reaches the nucleus, and there 
are extensive evidences that it can interact with other molecules in the cells. Indeed at the 
basis of resistance occurrence to cisplatin therapy, there are increased levels of 
cytoplasmic thiol-containing species, such as tripeptide glutathione and metallothioneins, 
which are rich in sulphur-containing amino acids cystein and methionine, and cause 
detoxification due to the high affinity of platinum for sulfur atoms. 
The evaluation of the action mechanism of gold(III)-dithiocarbamato compounds started 
from the assessment of their stability and reactivity under physiological conditions. 
Since the physiological environment is generally reducing, the potential reduction of 
gold(III) compounds to the less active gold(I) counterparts could result a major drawback 
for the pharmacological development of gold(III)-based anticancer agents. 
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The high stabilization of the +3 oxidation state due to the presence of the dithiocarbamato 
chelating moiety was demonstrated by the lower redox potentials registered for 
[AuIIIBr2(ESDT)2] (AuL12) in physiological-like solution by cyclic voltammetry. It was 
shown that AuL12 undergoes irreversible stepwise reduction to gold(I) dinuclear species, 
[AuI(ESDT)2], at ca. -180 mV (vs. saturated calomel electrode, SCE), which resulted 
significantly lower than the typical reduction potential for Au(III)/Au(I) of the 
corresponding KAuX4 (X=Cl, Br) precursor (+1.29 V). Concerning their solution 
properties, the gold(III) complexes hydrolyze in physiological-like environment 
delivering two moles of halide per mole of starting complex, leading to the corresponding 
Au(III)-diaquo counterparts within 30-40 min. The hydrolyzed species were proved to be 
reasonably stable in physiological-like solution, and reduce to gold(I) species only after 
12-24 h. 
With reference to the interaction with DNA, experimental results highlighted that there is 
a dramatic inhibition of both DNA and RNA synthesis in a non-dose-dependent way, 
whereas cisplatin promoted a strong inhibition of DNA without significantly affecting 
RNA synthesis, as expected. In addition, gold (III) dithiocarbamato complexes showed 
extremely fast rates of DNA binding (100% to calf thymus DNA after 3h), with respect to 
cisplatin (51% after 24h) under the same experimental conditions. They were also proved 
to form intrastrand cross-links with a faster kinetics than cisplatin, but they were unable to 
induce DNA-protein cross-links196.  
This ability of Au(III)-dithiocarbamato derivatives to bind DNA to a greater extent than 
cisplatin, seems to be a consequence of their higher reactivity toward isolated biological-
relevant macromolecules, rather than undoubtedly assign DNA as their ultimate target195. 
As the mechanism of action of our gold(III)-compounds differs from that of the classical 
platinum(II)-based anticancer drugs and DNA seems not to be the only and/or the major 
target, interaction with other biomolecules were explored. 
 
 
Thioredoxine reductase  
The thioredoxine system, along with the glutathione one, is one of the main machineries 
involved in the cellular control of the thiol redox state. 
In particular, the enzyme thioredoxine reductase (TrxR) has been recently described as 
potential target for some gold anticancer compounds197. 
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Trx is a small ubiquitary protein (12 kDa) expressed in cells in two isoforms, the 
cytosolic Trx1 and the mithocondrial Trx2. Both human isoforms keep the active site, 
characterized by the sequence {Cys-Gly-Pro-Cys} unmodified, and it is highly conserved 
in other species as {Cys-X-X-Cys}. It plays different roles in cells, comprehending 
reduction of ribonucleotide reductase enzyme during DNA synthesis, and activation of 
ROS (reactive oxygen species) scavengers through reduction of peroxiredoxine enzyme 
(Prx). Moreover it was demonstrated that it can activate, by reduction, different 
transcription factors involved in the regulation of different aspects of cellular proliferation 
and differentiation (AP-1, SP-1), cellular migration (NF-κB) and apoptosis (p53)77. 
The cytosolic form is overexpressed in many human carcinomas, and its cellular levels 
are linked to the tumor aggressiveness and inhibition grade of the apoptotic processes. It 
was so often identified as possible target for the pharmacological development of new 
anticancer drugs.  
TrxR was found to be a potential target for gold(III) complexes, as well. It is a 
homodimeric selenoenzyme which controls the redox state of thioredoxine. In mammals, 
its catalytic site {Cys-Val-Asn-Val-Gly-Cys} is highly conserved, and the presence of a 
selenocystein in the C-ter is fundamental for the redox catalytic process.  
Since gold compounds are known to have high affinity for selenium residues, TrxR 
results a good target candidate for these compounds, also considering that the redox 
center of the enzyme is located on a flexible chain exposed to the solvent and reactive to 
electrophilic agents197. 
TrxR was proved to be inhibited by a number of gold derivatives, thus triggering 
alterations of the mitochondrial functions and inducing severe oxidative stress, eventually 
leading to cell apoptosis. Our gold(III)-dithiocarbamato complexes were proved to induce 
cancer cell death through both apoptotic and non-apoptotic mechanisms, and to inhibit 
TrxR activity129.  
For some first generation gold(III)-dithiocarbamato complexes, it was hypothesized that a 
potential mechanism of action involves the deregulation of the Trx/TrxR system through 
the inhibition of both the cytosolic and mithocondrial forms of TrxR, allowing 
uncontrolled ROS production and modification of some mitochondrial functions (for 
example: alteration of membrane potential, induction of mitochondrial swelling without 
modifying the respiratory chain), ultimately causing cell death. 
Gold(III) complexes presumably inhibit TrxR by covalently irreversible binding to its 
active site, avoiding the possibility for the enzyme to act as a mediator in the active 
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transport of electrons from nicotinamideadenindinucleotide phosphate (NADPH) to Prx, 
thus determining the increase of ROS concentration levels in cells. Deregulation of 
Trx/TrxR system activates other pathways in cells, as the one connected to the 
dissociation of the Trx-ASK-1 (Trx-apoptosis signal-regulating kinase 1) complex, with 
consequent activation of MAPK (mitogen-activated protein kinase) system. High levels 
of ROS, along with activation of MAPK system, induce a persistent presence of 
phosphorylated ERK-1 and ERK-2 (Extracellular signal-Regulated Kinases-1(/2)), which 
induces cell death. (Figure 6.1). 
Nonetheless, phosphorylation of ERK-1 and consequent cell death, can be prevented 
through the action of an antioxidant agent as L-NAC (N-acetyl-L-cysteine) which, by 
keeping Trx in the reduced form, can prevent the dissociation of the Trx-ASK-1 complex. 
On the contrary, the antioxidant Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid) is not able to prevent cell death, since does not interact with thiols but 
only with free radicals, like peroxo species129. 
 
 
Figura 6.1: molecular mechanism of apoptotic death induction through Trx/TrxR system inhibition by 
gold(III)-dithiocarbamato complexes (adapted from129). 
 
Thus, it was hypothesized that the persistent activation of ERK-1/2 by ROS, followed by 
the deregulation of ASK-1, can be responsible for cell death through both apoptotic and 
non-apoptotic processes (as demonstrated by the % of PARP (poly-(ADPribose)-
polymerase) cleavage, known to be an apoptotic marker129. 
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High levels of Trx and TrxR (with respect to those observed in healthy cells) were 
detected in many cancer types198,199, including prostate cancer200, and were proved to be 
connected to the insurance of platinum201 and docetaxel resistance202 in this cancer type.  
For this reason, gold(III) complexes were tested in vitro on two human cancer cell lines 
androgen-resistant (namely PC3 and DU145)2. In particular, [AuIIIBr2(ESDT)] (AuL12) 
showed lower GI50 values on PC3 and DU145 cell lines than cisplatin. Moreover, the 
results were comparable to those registered on the PC3 cisplatin-resistant counterpart, 
PC3-R. In that case, it was demonstrated that the compound inhibits the activity of TrxR 
in PC3 cells, inducing ROS formation and depolarization of the mitochondrial membrane, 
activating preferentially the intrinsic mitochondrial apoptotic pathway2. 
 
 
Proteasome 
Also proteasome was recently identified as possible target for our gold(III) complexes. 
The proteasome 26S is a large protease complex (>2400KDa) constituted by different 
subunits (19S and 20S), present both in the cellular nucleus and cytosol. It is a 
fundamental part of the ubiquitin-proteasome system (Figure 6.2), which plays an 
important role in the proteolytic degradation processes in eukaryotic cells and is essential 
in controlling the concentration of many intracellular proteins, preserving the normal cell 
functions. Its role consists principally in the degradation of proteins implicated in 
processes concerning the proliferation, apoptosis, and progression of cell cycle, along 
with the degradation of abnormal proteins generated from oxidative stress or mutations.  
The degradation process is possible only after the targeting of the substrates by covalent 
binding to ubiquitin molecules. Ubiquitin (Ub) is a small protein made of 76 amino acidic 
residues which binds to substrate-proteins through the subsequent action of three distinct 
enzymes, which favor the activation (E1), conjugation (E2) and binding (E3) to the 
molecule to be degraded. 
The protein is marked by one or more ubiquitin molecules (ubiquitinated) and delivered 
to proteasome 26S, characterized by the 20S catalytic core and the two 19S regulatory 
units. These last two units are localized at the two opposite ends of the catalytic core, and 
recognize the ubiquitinated proteins regulating their entrance to 20S subunit, 
characterized by a "barrel"-like structure made of 28 subunits (14 of type α and 14 of type 
β) organized in four eptameric rings (7α-7β-7β-7α) piled to form a cylindrical structure 
with the catalytic site in the middle.  
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Figura 6.2: The ubiquitin-proteasome pathway. A target protein degraded by the ubiquitin-proteasome 
pathway is first covalently modified by multiple ubiquitin (Ub) molecules in a three-stepped, highly 
regulated enzymatic process involving an Ub-activating (E1), Ub-conjugating (E2), and the Ub-ligating 
(E3) enzymes. The ubiquitinated protein is then escorted to the 26S proteasome, recognized by the 19S cap, 
de-ubiquitinated and then degraded by the catalytic 20S core into oligopeptides. The ubiquitin molecules 
are released and recycled201. 
 
The proteolytic activity is executed in the β-subunits and comprehends chimotripsyn-like 
(cut after hydrophobic residues), caspase-like or PGPH-like (Peptidylglutamyl Peptide 
Hydrolizing-like, cut after acidic residues) and tripsyn-like (cut after basic residues) 
activity, while the two α-subunits regulate the access to the catalytic core, allowing the 
passage of only non-folded and extended substrates203. 
In some pathologies, like cancer, it has been observed an anomalous proteasome activity, 
which leads to the overexpression of some antiapoptotic proteins and the degradation of 
other pro-apoptotic ones, thus determining an uncontrolled proliferation of unhealthy 
cells and the progression of the disease.  
In the case of colorectal carcinoma, leukemia and prostate cancer, the level of proteasome 
alteration was demonstrated to be strictly connected to the grade of malignity and to 
tumor aggressiveness204,205. 
Cell cycle arrest and apoptotic death of tumor cells are thus activated in cancerous cells 
upon inhibition of the ubiquitin-proteasome system, as consequence of the accumulation 
of tumor suppressor factors and pro-apoptotic proteins206. 
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The inhibition of this system can be achieved preventing the binding of ubiquitinated 
substrates to the enzyme catalytic core, made by Thr1, Glu17 and Lys33 residues207, 
where the N-ter amino acid threonine is directly responsible for the substrate degradation. 
Around the active site of the enzyme are located binding pockets, which allow the 
recognition of the amino acids side chains which undergo to the proteolitic cleavage. The 
identification of this specific binding sites allowed the design of suitable compounds 
capable of selectively and irreversibly binding them, acting as inhibitors of the 
proteasome activity203. Nonetheless, the inactivation of the enzyme could take place also 
indirectly, for example by oxidative modification and inactivation upon exposure to free 
radical-generating systems. 
In this context, a "first generation" complex was tested as possible proteasome inhibitor, 
since it was known to exhibit high cytotoxic activity on different breast cancer cell lines. 
In particular, the compound was tested in vitro on the human breast cancer cell line 
MDA-MB-231, an highly metastatic and invasive cancer type, registering a cellular 
growth inhibition of nearly 85% (at a concentration of 5 µM), with respect to the 20% 
inhibition caused by cisplatin treatment.  
The same gold(III) compound was proved to strongly inhibit the chymotrypsin-like 
proteasomal activity on MDA-MB-231 whole cell extract, in a dose-dependent way. This 
result is particularly important since this effect is associated to the induction of cell 
growth inhibition in cancer cells, and activation of apoptotic processes208.  
Proteasome inhibition was also detected after treatment of intact MDA-MB-231 cells 
with the same compound, leading to the increase of the ubiquitinated proteins and of 
proteasome target protein, p27.  
Moreover, in vivo tests on immunodepressed mice inoculated with the same breast tumor 
type, demonstrated how the treatment with the gold compound caused a significant 
reduction of tumor mass, by 49% with respect to non-treated mice, accompanied by 
proteasome activity inhibition.  
It is important to underline that after 29 days of treatment with daily 1 or 2 mg.kg-1of 
gold(III) compound, the mice have not shown signs of prostration, anorexia of weight 
loss209. 
All these results identify the proteasome as primary target for our gold(III) complexes, 
without anyway excluding the possible affection of the Trx/TrxR system.  
Indeed, our gold(III)-dithiocarbamato complexes are known to cause a consistent 
production of ROS in cells. This can hence favor the production of high levels of 
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persistent phosphorylated ERK-1/2, which can affect the TrxR/Trx system. But, at the 
same time, the increase in ROS concentration levels can oxidize and thus inactivate the 
proteasomal activities.  
This process was indeed recently reported also for Bortezomib, the first and only 
proteasome inhibitor recently approved by FDA for the treatment of multiple myeloma, 
which can induce apoptotic death in treated cells through either direct or indirect 
inactivation of the enzyme functions.  
 
 
PARP-1  
Exploring the possible targets responsible for the cytotoxicity of our class of compounds 
on cells, also the DNA damage repair route was taken into account.  
As above reported, the results of direct interaction of our gold(III) compounds with DNA 
show that, even if the compounds have a great affinity for DNA purified molecule, it does 
not seem to be in vivo a major target. Nonetheless, enzymes involved in the repair and 
regulation mechanisms of DNA can be affected by the action of the gold(III) 
dithiocarbamato complexes. 
In particular, our investigation focused on the interaction of the compounds with PARP-1 
(poly-adenosine diphosphate (ADP)-polymerases-1), a zinc-finger protein essential for 
DNA repair and also relevant in activation of resistance mechanisms to cisplatin in cancer 
cells210.  
Among the PARP family, PARP-1 enzyme is one of the most studied and well-
characterized211, playing a central role in the repair of subtle DNA damages caused for 
example by alkylation, oxidative stress or single-strand breaks principally via the base 
excision repair pathway212.  
The human homologue of PARP-1 (hPARP-1) is a highly conserved nuclear enzyme of 
113kDa, characterized by the presence of three major domains213:  
• the amino-terminal DNA binding domain (DBD), which contains two zinc-finger 
motifs (ZnF1 and ZnF2) that are sensitive for DNA-damage and bind to it 
specifically; 
• the auto-modification domain, which binds to poly-ADP-ribose (PAR)214; 
• the C-terminal catalytic domain, containing the third zinc finger motif (ZnF3). 
Among the three zinc finger domains, ZnF2 has the strongest affinity for DNA breaks, 
while ZnF1, with the cooperation of ZnF3, is responsible for PARP-1 activation215,216. 
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Any damage in the DNA structure activates PARP-1, which breaks nicotinamide-
adenine-dinucleotide (NAD+) in ADP-ribose and nicotinamide. Subsequently, ADP-
ribose unites are linked together to form long chains of poly-ADP-ribose (PAR) which 
covalently attaches to acceptor proteins as PARP-1, histones, and other DNA-repair 
proteins. This long negatively charged polymer located closely to the damaged DNA site 
acts like a scaffold, recruiting other proteins that are involved in the BER/SSB (Base 
Excision Repair/Single Strand Break) mechanism and resulting in the repair of the 
damaged DNA. On the other end, the over-activation of PARP-1 may cause a depletion of 
NAD+ pools, which conversely activates the necrosis response of the cell. Upon PARP-1 
inactivation, a cascade of signals that promote apoptosis is started, preventing both the 
repair of DNA damages and the activation of necrosis caused by huge consumption of 
NAD+. The overexpression of this enzyme, both at mRNA and protein expression levels, 
was detected in a variety of cancer types. In particular, nuclear levels of PARP-1 in breast 
cancer (especially in triple-negative tumors) have been directly correlated to the level of 
progression of the malignant transformation, representing a parameter to predict poor 
prognosis in operable invasive breast cancer217. The connection between PARP-1 
overexpression and cancer progression has not been fully elucidated yet. Nonetheless, it is 
known its contribution to the regulation of important transcription factors as NFkB218,219, 
which overexpression is connected to the tumor progression and malignancy220,221, being 
also directly involved in the angiogenenic process, important for cancer development222. 
In the past, cellular dysfunctions in the DNA repair were exploited to cause irreversible 
DNA modification that couldn't be recognized by DNA repair enzymes, and ultimately 
led to cell death. Today an alternative approach has been evaluated, and compounds were 
designed to specifically target components involved in the DNA damage repair process, 
as topoisomerase or PARP enzymes222.  
The importance of targeting PARP enzymes arises mostly from their ability to act as 
initiators of a signal cascade that lead to cell death through an apoptotic mechanism. 
In the last decades compounds capable to inhibit PARP-1 emerged as potential anticancer 
drugs, either to be used alone or in combination with other well-established drugs which 
cause DNA damage, thus amplifying their cytotoxic effect223. 
PARP enzymes, in particular, are playing a dual role in the DNA damage response, acting 
not only as DNA damage sensors but also as signal transducers to down-stream effectors.  
Many compounds have been developed in the last years to specifically target PARP-1 or 
PARP-2, and are now in the early stages of clinical trials224. One of them, Olaparib 
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(AstraZeneca), showed an IC50 value of 0,005 µM for the inhibition of PARP-1 enzyme 
in the in vitro screenings, and is now in clinical phase studies for the treatment of ovarian, 
breast and colon rectal cancer225.  
 
Experimental section 
Analysis of the proteasomal activity on purified 20S proteasome 
The purified human 20S proteasome (0.5 nM) was incubated in triplicate with three 
different proteasomal fluorogenic substrates (20 µM) and the compound (IT03) 
(previously dissolved in DMSO) at various concentrations ranging from 0.1 to 10 µM, or 
an equivalent volume of solvent DMSO as control in 100 µL assay buffer [20 mM Tris-
HCl (pH 7.5)]. After 1 hour incubation at 37°C, inhibition of each proteasomal activity 
was measured recording the fluorescence of the hydrolyzed AMC groups by means of a 
Wallac Victor3 1420 multilabel counter (Perkin Elmer, excitation wavelength = 355 nm, 
emission wavelength = 460 nm, measurement time 0.1 s). 
 
PARP-1 inhibition assay on purified protein 
The ability of the test compounds to inhibit PARP-1 enzyme was evaluated on the pure 
protein using the HT Universal Colorimetric PARP Assay Kit (Trevigen). The assay is 
based on the detection and quantification of biotinylated-poly(ADP-ribose) linked onto 
histone proteins in a 96-well strip plate. PARP-1was purified after expression from E.Coli 
containing recombinant plasmid harboring the human PARP gene. The protein is 
generally quantified in Units, defined as the amount of enzyme incorporating 10 fmol of 
NAD+ onto 5 µg of immobilized histones in 30 minutes at room temperature.  
The compounds dissolved in DMSO (with exception of cisplatin, dissolved in saline 
solution containing 0.9% NaCl) were diluted in water and incubated with 0.5 U of 
recombinant human PARP-1 in PARP Buffer (Trevigen) to different final concentrations 
and then incubated with 0.5 U for 1h at room temperature (final DMSO content per 
sample < 0,1%). Samples not containing PARP-1 were used as negative controls for 
reading the background absorbance, while positive controls containing only PARP-1 
solution were used as reference for determine the 100% of enzyme activity.  
After the incubation with the compounds, the amount of active PARP-1 was evaluated by 
adding Streptavidine-HRP to the samples in presence of a mixture of NAD+, biotinylated-
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NAD+ and activated DNA. The Streptavidine-HRP-biotine conjugates so formed were 
subsequently quantified incubating the samples with TACS-Sapphire for 30 min in the 
dark226. The absorance for each well was then recorded at 630 nm using a 
ThermoMaxMicroplate Reader (Molecular Devices). 
 
 
Results and discussion 
 
6.1 In vitro inhibition of proteasome 20S 
The second generation compound IT03, one of the most active gold(III)-
peptidedithiocarbamato complexes screened, was tested for the inhibition of all the three 
principal proteolitical activities present in the proteasome core 20S (Table 6.1), and the 
results were compared to those recorded for the first generation compound, AuL12.  
In particular, IT03 inhibitory activity resulted significative especially for the 
chimotripsine-like function, which is known to be strongly connected with the activation 
of apoptotic response. Its inhibitory potency seems to be slightly improved if compared 
with the test compound AuL12. The IC50 values are anyways still higher than the values 
obtained for the reference proteasome inhibitor Velcade® (Bortezomib, N-acyl-dipeptidyl 
boronic acid; Millennium Pharmaceuticals, Figure 6.4). 
 
Table 6.1: IC50 values for inhibition of proteasome activities by selected gold(III) dithiocarbamato 
compounds, with respect to the activity of the reference proteasome inhibitor Velcade. 
 
 
IC50 (µM) 
 
IT03 AuL12 Velcade 
Chimotrypsyne-like (CL) 0,68 1,13 0,002 
Trypsine-like (TL) 1,7 - 
 
Peptidyl-glutamyl-peptide-hydrolysis-like 
(PGPHL) 
0,77 - 
 
 
Up to now Velcade® is the only proteasome inhibitor approved by the Food and Drug 
Administration (FDA) and is currently used for the treatment of relapsed multiple 
myeloma and mantle cell lymphoma18.  
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Figure 6.4: molecular structure of Velcade® (Bortezomib). 
 
It consists in a small boronic acid dipeptide molecule that binds reversibly to the subunit 
of the 20S catalytic cavity, responsible for the chimotrypsine-like activity of the enzyme. 
In particular, the compound binds through the boron atom (that shows Lewis acidity 
properties) to the oxygen of an N-terminus threonine sited in the catalytic pocket of the 
enzyme18. 
The mechanism of action of our gold(III) dithiocarbamato complexes towards proteasome 
is not fully understood yet, and different pathways can be correlated to the final inhibitory 
outcome. At least two (or three) mechanisms could be responsible for the inactivation of 
proteasome by our compounds in vivo. These include direct binding to the active site, 
redox processes involving Au(III) and sulfur containing biomolecules, as for example 
glutathion (GSH), and ROS production. So, apart from the direct inactivation or 
oxidation, also secondary redox effects can take place, emphasizing the enzyme inhibition 
effect.  
Therefore, the mechanism of proteasome inhibition of gold(III) dithiocarbamato 
complexes seems to be different from the one hypothesized for bortezomib, and the 
evaluation of IT03 inactivation in vitro describes only partially the situation that could 
occur in vivo, where secondary effects could participate to the effective inactivation of the 
enzyme. In fact, contrary to bortezomib, IT03 affects all the three principal proteasome 
activities presented by the 20S core, as shown in Table 6.1.  
 
 
6.2 In vitro inhibition of PARP-1 enzyme 
PARP enzymes are essential proteins involved in cancer resistance to chemotherapies. 
They play a key role in DNA repair by detecting DNA strand breaks and catalyzing 
poly(ADP-ribosylation), and consequently PARPs have been referred to as “the guardian 
angels” of DNA. PARP-1, in particular, is activated by mild to moderate genotoxic 
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stimuli, which facilitates DNA repair by signaling cell cycle arrest and by interacting with 
DNA repair enzymes. Severe DNA damage may even induce hyperactivation of PARP, 
which ultimately leads to apoptosis210. The initiation of the apoptotic process is 
characterized by the activation of caspases (cysteinyl aspartate specific protease), causing 
the cleavage of multiple targets in cells. PARP, being a specific substrate for caspases 3 
and 7, is recognized as a marker for apoptosis. Studies regarding "first generation" 
compounds have shown how, upon treatment of cells with gold(III) compounds, the 
levels of cleaved PARP were not dose-dependent, thus highlighting that also other cell 
death mechanisms can be involved (i.e. necrosis).  
Since it is known that PARP-1 can be a pharmacological target for some anticancer 
compounds213, the direct inhibition of the enzyme by our gold(III) complexes was 
investigated. For other gold(III) compounds it was indeed demonstrated that the metal can 
inhibit the enzyme by directly binding to the zing-finger domain, thus competing with 
Zn(II) for the binding site210. 
 
 
Figure 6.5: inhibition of PARP-1 activity by test compounds at different concentrations (from 10 to 0.01 
µM). For the assay each compound was incubated for 1 h with 0.5 U of purified protein. 
 
Our gold compounds were tested as inhibitors of PARP-1 purified protein, using a 
universal colorimeter PARP assay (Trevigen), and the values were compared to the those 
obtained for other gold(III) compounds210 and for drugs now in clinical trials as specific 
PARP-1 inhibitors. 
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The inhibitory activity of the model compound IT03 and the first generation compound 
AuL12, obtained after 1 h incubation with the purified enzyme, are shown in Figure 6.5. 
The corresponding IC50 values were correlated to those obtained for cisplatin, the PARP-
inhibitor Oliparib and the gold(I) antiartritic drug auranofin (calculated after 24h 
incubation), and are reported in Table 6.2 only for comparative purposes. 
 
Table 6.2: inhibitory activity of selected compounds on purified PARP-1. IC50 values and st.dev. (µM) are 
the result of data collected in three independent experiments. 
 IC50 ±st.dev (µM) 
IT03 0,017±0,006 
AuL12 0,019±0,004 
cisplatin 12,3±2,0¥ 
auronofin 0,079±0,009¥ 
oliparib® 0.00500±0,00001¥ 
¥ evaluated after 24h incubation 
 
As we can see from the data shown above, our gold(III)-dithiocarbamato compounds 
result as good inhibitors of the purified PARP-1, with IC50 value in the nanomolar range.  
The inactivation of PARP-1 by AuL12 was evaluated not only on the purified protein, but 
also on the total cell extracts.  
 
Figure 6.6: inhibition of PARP-1 from cell extracts. 
 
The cultured cells were detached, centrifuged at 10,000 g/min at 4°C for 10 min and then 
resuspended in lyses buffer (Trevigen). After 15 min on ice, lysates were centrifuged 
obtaining a pellet of cellular debris, while the supernatant was removed. 
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The total protein content in each sample was determined by using the DC Protein Assay 
Kit (BIO-Rad). For each sample, 50 µg of cell extracts was then incubated with the gold 
compounds at fixed concentration. Non treated samples were also collected as controls. 
Preliminary experiments with AuL12 were performed on MCF-7, A2780, A2780cisR and 
HeLa cells (Figure 6.6). 
Also the results obtained for the cell extracts show an inactivation of PARP-1 by our 
compound, with higher values in particular on A2780 and HeLa cells. It is interesting to 
notice how the inactivation of PARP-1 from A2780cisR cell extracts with respect to 
normal A2780 is relevantly different (Figure 6.6). 
Moreover, comparing the PARP-1 inactivation with compounds' cytotoxicity on cell 
lines, we can notice that apparently there is no direct correlation between cytotoxic 
activity and PARP-1 inactivation. Indeed, MCF-7 and HeLa cells, which are similarly 
sensitive to the tested compounds, show very different values of PARP-1 inactivation 
from the cell extracts.  
The reported results are representative only of a preliminary study that we are currently 
performing on the gold(III)-oligopeptide dithiocarbamato derivatives as well. Further 
investigation should be done on cell extract deriving from cultured cells incubated with 
the compound for 24 h. 
To sum up, the model compound IT03 was chosen among the newly synthetized 
compounds, to achieve more insights into their mechanism of action.  
Two enzymes involved in two different pathways of apoptotic activation, known as 
targets for other anticancer drugs, were selected for leading the preliminary assays in 
vitro. The results demonstrated that the "second generation" compound is able to inhibit 
all the three proteolytic functions of 20S proteasome and affects PARP-1 activity with 
IC50 values in the nanomolar range. Nevertheless, further experiments on intact cells 
should be carried out to achieve more information about the effective targets in vivo. 
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Chapter 7 
Real-time cell growth inhibition profile analysis and Au uptake 
kinetic studies 
 
From the results presented in the previous Chapter, we continued the investigation of the 
mechanism of action of our gold(III)-peptidedithiocarbamato complexes through the 
evatution of the kinetic cellular response upon their administration to cancer cells.  
In particular, the inhibitory effect of our compounds on cell proliferation was monitored 
real-time through an electronic device which provides also informations about 
morphological changes and cell adhesion variations.  
Interestingly, it was demonstrated that the analysis of the cellular growth inhibition 
profiles with time results diagnostic for the discrimination of different mechanism of 
action exerted by drugs on cells. 
As shown in Figure 7.1, cells exposed to selected compounds were dynamically 
monitored over 70 h, using real-time electrical impedance as a measure of viable cell 
number. Using this methodology, five well-characterized cytotoxic compounds were 
found to have different kinetics responses. Digitonin (Figure 7.1A), a mild detergent, and 
tamoxifen (Figure 7.1E), a Ca2+ influx stimulator, were fully cytotoxic to HepG2 cells 
after only 10 min of exposure. Potassium dichromate (Figure 7.1B) and doxorubicin 
(Figure 7.1D), both DNA-damaging agents, demonstrated a slower onset of activity and 
induced complete cytotoxicity only after 35 h of exposure. Finally, cycloheximide 
(Figure 7.1C), a protein synthesis blocker, inhibited cell proliferation but did not 
decreased cell number below the amount present at the time of addition227. 
All these results highlight how, almost in principle, it is possible to discriminate between 
drugs having different mechanisms of action, by comparing their time-dependent cell 
growth inhibition profiles. Similarly, for new drugs it can be possible to achieve more 
insights into their mechanism of action by correlating the experimental data to the profiles 
recorded for well characterized drugs. 
Lastly, the data obtained from the analysis of the cellular growth and adhesion profiles 
over time, were subsequently correlated to the results obtained for kinetics experiments 
which evaluate the kinetics of gold uptake by cells after treatment with the complexes 
(determined via ICP-AES analysis). 
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Figure 7.1: Kinetics of cytotoxicity responses for digitonin (A), potassium dichromate (B), cycloheximide 
(C), doxorubicin (D), and tamoxifen (E) in HepG2 cells monitored by the RT-CES system. 10,000 
cells/well were plated in 16-well strips for the RT-CES cytotoxicity assay. ↓, time of compound addition. 
Different compound concentrations are indicated by different colors. Data are normalized to the time of 
compound additionat 22–24 h of cell culture227. 
 
 
Experimental section 
 
Cell inhibition growth profile with time 
Human non-small-cell lung carcinoma A549 cells (ATCC) were cultured using the same 
conditions described in Chapter 4. Cell attachment and proliferation was continuously 
monitored for 96 h in 16-microtiter plates (E Plate 16, Roche), characterized by well 
bottoms covered with gold microelectrodes. The cell-sensor impedance measured at each 
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well was expressed in arbitrary units called Cell Index, defined as (Rn-Rb)/15 where Rn 
is the cell-electrode impedance of the well when it contains cells and Rb is the 
background impedance of the well with the media alone. The Cell Index can be than 
normalized setting the Cell Index value at treatment to 1. Before the cytotoxicity 
experiments, the cell proliferation pattern was followed for 24 h in order to determine the 
optimum number of cells to seed. Cells were seeded at a concentration of 5000 cell.mL-1 
in 100 µL of media and Cell Index values were collected every 15 minutes. After 24h 
from seeding, each well was supplemented with the compounds dissolved in 100 µL of 
medium, to obtain the final desired concentrations. Gold(III) complexes were dissolved in 
DMSO prior addition to the medium, while cisplatin was dissolved in 0.9% NaCl water 
solution. Cells were also treated with only vehicle, corresponding to 1% DMSO in 
medium, as control. 
 
Kinetic experiments of gold dithiocarbamato complex uptake 
 
Materials 
Nitric acid 70% v/v and hydrochloric acid 37% for ultratrace analysis were purchased 
from Sigma Aldrich, and the standard Au solution (concentration of 1000 µg mL-1) from 
Inorganic Ventures. ICP measurements were carried out using ICP SPECTRO Arcos with 
the same equipment and experimental condition described in Chapter 5. All solutions 
were prepared with final aqua regia content of 3% v/v.  
 
Method 
Human large cell lung cancer H460 cells (ATCC) were grown in RPMI-1640 (Roswell 
Park Memorial Institute, Sigma Aldrich) further supplemented with 10% Fetal Calf Serum 
(FCS), 1% penicillin and streptomycin (Invitrogen). Cells were incubated at 37°C in 
presence of 5% CO2 and moisture-enriched atmosphere. For the experiment, cells were 
seeded in 4 mL Petri dishes (1,25.105 cell.mL-1) and incubated for 48 h to allow cells to 
attach and grow.  
After 48 h from seeding, the medium was removed and replaced with fresh new one. In 
the first experiment the uptake kinetics was followed in time, and all the samples were 
incubated with the compound IT01 at the concentration of 20 µM, with exception of 
control samples. For the experiment of uptake kinetics at different concentration of 
compound, each Petri dish was incubated with gold(III) compound at different 
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concentrations (ranging from 10 to 100 µM) for two hours. In both experiments, each 
sample was collected following the same procedure: the medium was removed and 
collected in a Falcon tube, while attached cells were washed with 2 mL saline solution 
(0.9% NaCl) and incubated with 2 mL trypsin to allow cell detachment. Cells in trypsin 
solution were put in a Falcon tube and collected with 2 mL saline solution used to wash 
the Petri dish. 100 µL of solution were withdrawn from each sample to determine the cell 
number. Cell suspensions were then centrifuged for 5 min at 5000 rpm, the solution 
discarded and cells washed again with 2 mL saline solution. Death or detached cells were 
also collected from the medium and gathered to the ones detached from the dishes, after 
careful washing/centrifuging with saline solution to eliminate possible contaminants 
coming from the medium. Samples were stored at -20°C. Before ICP-AES analysis, cell 
pellets were transferred in Pyrex vials and mineralized with aqua regia, to obtain samples 
at final acidic concentration of 3% v/v. 
 
 
Results and discussion 
7.1 Real-time cell proliferation profile after treatment  
To achieve more insights into the mechanism of action of our gold(III) compounds, the 
cellular growth inhibition induced by the treatment with our compounds was followed 
real-time.  
The most common methods used for establish the cytotoxicity of compounds on cells are 
based on assays which use optical detection methods, that usually involve multi-step 
protocols. These protocols normally comprehend significant manipulation of the samples 
in order to obtain detectable species that are related to the percentage of viable cells. 
Moreover, these methods allow only the determination of the cell viability at a precise 
time for each experiment, with no information about the development of the system up to 
that time. 
To monitor the real-time proliferation and viability of adherent cells, we exploited the 
xCELLigence system (ACEA Biosciences and Roche). This apparatus allows the 
determination of viable cells in situ through an electronic device that is based on the use 
of 200 µL/well microplates with bottoms covered with gold electrodes, which allow the 
measurement of the impedance at the base of each well (Figure 7.2). 
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Figure 7.2: detection of cell growth/adhesion modification on gold
with reference compound. Impedance is measured as a function of time in every well, giving a curve with a 
trend that for cisplatin, could resemble the one reported in this picture.
 
When only medium is in contact with the electrode a stated value of impedance is 
measured, that is usually taken as the zero
well bottom, the measured impedance changes by a value that is proportional to the area 
of the electrode that is modified. The impedance difference from the zero
measured with time and could arise from a change in cell number, efficiency of adhesion, 
changes of size or morphology. This method allows the real growth or morphology 
change after the addition of a cytotoxic compound to the cells.
As we can see from Figure 7
the treatment of A549 cells with different concentrations of either AuL12 or cisplatin. In 
the case of cisplatin the cytotoxic effect is evident only after 24
a progressive decrease of cell adhesion correspondent to cell death and detachment.
For the compound AuL12, instead, the recorded cellular growth profile is completely 
different with respect to cisplatin, showing a dramatic lowering of Cell
first 3 hours after the addition of the compound. This fast modification
to a change in the morphology of the cells, which acquire a more rounded shape, as 
shown in Figure 7.4.  
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Figure 7.3: profile of cell adhesion/growth after treatment of A549 cells with AuL12 (A) or cisplatin (B) at 
different concentrations compared to non-treated cells. 
 
 
 
Figure 7.4: photos of A549 cells after 3h from the treatment with AuL12 (A) with respect to the control 
cells at the same time (C); A549 cells after 24h after treatment with AuL12 (B) with respect to the control 
cells (D). 
 
The different cellular growth inhibition profile recorded for the two compounds can be 
presumably correlated to a different mechanism of action of the two compounds in 
(A) 
(B) 
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inducing cell death and allows, almost in principle, to differentiate between compounds 
acting on different cellular targets and pathways.  
As reported in Figure 7.5, compounds as Etoposide and Methotrexate, which are both 
known to be involved in mechanisms of DNA damage, show similar effect on cells 
proliferation to the one recorded for cisplatin (Figure 7.3B), which is known to have 
DNA as an ultimate target.  
 
Figure 7.5: Real-time monitoring of apoptosis using the xCELLigence System. HeLa cells were treated 
with different drugs for which are recognized different mechanisms of action. Cell Index values were 
monitored continuously for 72 hours. 
 
Otherwise, compounds as Azelastine, Methiothepin and Amlodipine present very fast 
effects in cellular growth/adhesion profiles since they exert their cytotoxic effect at a 
membrane level, acting or different receptors. Indeed, Azelastine is a well known 
Chapter 7. Real-time cell growth inhibition profile analyisis and uptake kinetic studies 
136 
 
histamine antagonist, Methiothepin acts as a dopamine and seratonine antagonist, while 
Amlodipine interferes with Ca2+ transporters.  
The curve shape recorded for AuL12 highlights how the mechanism of action for our 
gold(III) compounds is completely different from the one recorded for cisplatin and 
resembles the curve shapes characteristic for the above reported drugs Azelastine, 
Methiothepin and Amlodipine. 
From these data it can be deduced that our compounds interfere (upon direct binding or 
indirect perturbation) with proteins and receptors present on the cell membrane double 
layer. This is suggested by the very fast response detected in the variation of Cell Index 
(CI) which can be correlated to a rapid shape modification (cell rounding within the first 
3h) upon the incubation of cells with the compounds, thus resulting in a lowered cellular 
adhesion to the culture plate bottom. These alterations can be actually due to membrane 
interactions, which activate cell death processes after few hours from compound 
administration.  
For the second generation compound IT01 similar trends with respect to AuL12 were 
predictably recorded (Figure 7.6), even if at the same concentration the effect on cell 
growth inhibition was lower. This is consistent with the higher value of GI50 calculated 
for IT01 on A549 cells with respect to AuL12 (20.0 µM and 12.3 µM) respectively (See 
Chapter 4). 
 
 
Figure 7.6: profile of cell adhesion/growth after treatment of A549 cells with IT01 at different 
concentrations (from 1 to 20 µM) compared to non-treated cells. 
 
As we can appreciate from the curves recorded after both AuL12 and IT01 treatment, the 
cells present their maximum cytotoxic effect after nearly 24 h from compound 
administration and following tend to recuperate their viability. To assure that the recovery 
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in Cell Index was not due to secondary effec
gold(0) species on the culture plates bottoms, the effect of the sole compounds in 
complete cell culture medium was tested. The compound was dissolved in culture 
medium solution and added to the wells, in abs
over time to detect possible variations in the registered inductance. As reported in 
7.7B, it can be seen that no contributions to the Cell Index derive from the effect of 
possible degradation products derivi
Moving beyond, to prevent the effect of regained viability after 24
administration, cells were treated with AuL12 again after 24
we can see from Figure 
completely inhibited and complete cell death is reached after 72h even for the lower 
concentration of compound used. This result is encouraging if taking into account that in 
the in vivo experiments the compound is administered every day or on alternate days, so 
complete tumor growth inhibition can predictably be achieved by administration of 
consequent even not lethal doses of the gold(III) cytotoxic compounds.
 
Figure 7.7: (A) profile of cell a
concentrations (from 1 to 20 µM)
in complete cell culture medium in absence of cells.
 
For comparison purposes, we 
experiments with a ruthenium(III)
tested in the same experimental conditions (
(A)                                                                                                                          
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Figure 7.8: profile of cell adhesion/growth after treatment of A549 cells with α-[RuIII2(pdt)5]Cl at different 
concentrations compared to non-treated cells (from 1 to 20 µM). 
 
The selected Ru(III) compound was chosen among the series synthesized in our 
laboratory for its encouraging antiproliferative properties, since it was found to be active 
on human non-small cell lung cancer cells H1975 with GI50 values of 0.059 µM19. In this 
case, the shape of the recorded curves is completely different from the characteristic 
curves obtained for our gold(III) complexes. Since the compounds share the same type of 
ligands attached to the metal center, the different mechanism of action can thus be related 
to the different properties of the metal itself, or to its different geometrical and 
coordinative properties. 
 
 
7.2 Kinetic studies of cellular gold uptake  
To gain more information about the rapid morphological changes recorded on cells after 
treatment with the gold(III) complexes, as reported in previous section, kinetic 
experiments of cellular uptake upon their administration to cancer cells was evaluated, 
setting up two different types of experiments. In the first one, the uptake of the gold(III) 
compound IT01 (chosen as reference) was evaluated over time. Cells were incubated with 
a fixed amount of IT01 complex (20 µM). At certain time point after compound 
administration (from 5 minutes to 8 h), the cellular pellets were collected, following the 
procedure described in the Experimental Section of this Chapter.  
The gold content in each sample was thus determined by means of ICP-AES (Inductively 
Coupled Plasma-Atomic Emission Spectroscopy) analysis, after their mineralization with 
aqua regia (nitric acid hydrochloride; final acid concentration of 3% v/v).  
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Figure 7.9 shows the amount of gold detected in the collected cell samples as a function 
of the incubation time with the gold(III) compound IT01. The gold content is expressed 
as the nanograms of gold detected in one million of cells. The choice to normalize the 
gold content with the number of cells per sample was suggested by the variability on cell 
number between the different culture plates employed for the experiment, which depend 
not only on varition deriving from the seeding procedure itself, but also on the intrinsic 
variation in cell number due to the different cell proliferation with time in the different 
samples. Surprisingly, the highest amount of gold internalized by cells have been found 
right after administration to the cell cultures (5 min), while the gold concentration per 
cells decreases over time, reaching a plateau after nearly 4 h (Table 7.1).  
 
Figure 7.9: amount of Au in cells treated with IT01 (dissolved in DMSO), expressed as nanograms of Au 
per million of cells (nmol/106 cells), at different time points after compound administration to cell culture. 
 
These results are consistent with the data obtained from the xCELLigence experiments, 
since the maximum modification in cell adhesion/viability detected through the 
xCELLigence curves (Figure 7.6) coincides with the time interval in which the maximum 
amount of gold is internalized by the system (Figure 7.9). After few hours, when the gold 
measured inside the cells reaches its minimum, no further increase in cell proliferation is 
detected, highlighting that the antitumor effect is activated by the compounds in the very 
first hours after internalization. 
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Figure 7.10: amount of Au in cells treated with IT01-loaded F127 micelles, expressed as nanograms of Au 
per million of cells (nmol/106), at different time points after compound administration to cells. 
 
The results achieved after administration of cells with IT01-loaded Pluronic F127 
micelles (Figure 7.10) were very similar to those obtained after treatment of cells with 
IT01 dissolved in DMSO. This suggests that the release from the micelles is very quick 
(as already reported for AuL12/F127 systems, Chapter 5) also for the IT01-loaded 
micelles, and that the uptake mechanism is the same for both the systems. 
 
 
Figure 6.11: amount of Au in cells treated with IT01-loaded DPPC vesicles, expressed as nanograms of Au 
per million of cells (nmol/106), at different time points after compound administration to cells. 
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A different behavior was instead recorded when IT01-loaded DPPC vesicles were used 
(Figure 7.11). Even if in this case the data reported are only preliminary, the 
concentration of gold determined in the cell pellets increases during the first hour, but 
then remains almost constant over the following time. This probably suggests a different 
release rate of the compound from the liposomal system (in particular with respect to the 
micelles) or a different mechanism of cellular uptake of the compound when it is 
encapsulated in the vesicles, possibly mediated by the vesicular system itself.  
 
Table 6.1: quantity of Au present in cellular pellets after incubation of cell with IT01 μM for different 
times, expressed as nanograms of gold per 1 million cells. 
 
 mean ±error (ng of Au/106 cells) 
Time (min) IT01/DMSO IT01/F127 IT01/DPPC* 
0 0,301±0,05 0,023±0,004 4,93±1,03 
5 137,60±22,03 125,08±20,02 26,20±4,72 
60 189,02±30,26 124,89±20,00 60,64±11,02 
120 80,80±12,93 68,41±10,98 34,82±5,97 
180 64,43±10,31 78,06±12,49 40,77±6,58 
240 99,19±15,89 52,08±8,42 59,76±9,57 
360 20,56±3,29 75,24±12,09 43,88±7,07 
480 40,33±6,45 23,56±3,77 44,46±7,26 
1440 29,40±4,71 4,24±0,72 - 
*preliminary data 
 
 
In a second set of experiments, the effect of different concentration of the test compound 
IT01 was evaluated after incubation with cells for a fixed time. The cellular uptake of 
gold by cells was determined after 2 h from the administration of the compound either 
dissolved in DMSO or loaded in F127 micelles or DPPC vesicles. After the selected 
incubation time, cell pellets were collected following the same procedure above 
described, and the samples were prepared for gold content determination via ICP-AES 
analysis.  
The choice of the incubation time was in particular suggested by the analysis of the cell 
growth inhibition curves previously determined by xCELLigence analysis, which 
highlighted that a significant effect in cell growth inhibition/adhesion is detectable just 
after 4 h from the compound administration. It can be noticed that the higher the amount 
of compound administered to cells, the higher the gold content measured in the cells 
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pellets, thus the maximum uptake of gold is in this range of concentrations is only 
dependent on the amount of administered gold(III) complex to cells, and this behaviour 
can be found for every of formulation tested. As an example, the amount of gold detected 
after 2 h incubation of cells H460 with IT01 loaded in Pluronic micelles at different 
concentrations is reported in Figure 7.12. 
 
Figure 7.12: amount of Au in cells treated with IT01-loaded F127 micelles, expressed as nanomoles of Au 
per million of cells (nmol/106), after 2h incubation of different amounts of compound with cells. 
 
In conclusion, the real-time proliferation curves recorded for the A549 cells after 
treatment with the selected compound in different formulations, remark the completely 
different mechanism of action exerted by our gold(III) complexes, with respect to 
cisplatin. In particular, the gold(III) dithiocarbamato complexes were demonstrated to 
strongly affect cell adhesion and cell viability during the first 4-5 h form the treatment, 
with curve shapes very similar to those obtained for drugs acting as modulators of 
calcium transporters. Combining these results to those obtained from the kinetic studies 
of compound internalization, a mechanism of action involving the inhibition of membrane 
receptors or other biomolecules at a membrane level was hypotesized. 
The gold uptake kinetic experiments carried out by ICP-AES measurements confirmed 
that the interaction of the compounds with cells is very fast and occurs in the first hours 
after treatment. 
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Appendix 1 
Crystallographic data for crystals of AuL23 
The gold(III) complex adopts a distorted square-planar geometry achieved through the bidentate 
dithiocarbamato ligand and the two cis-bromides. The four donor atoms and the metal center lie on a 
plane and the distortion from the ideal geometry is a consequence of the small bite angle of the 
dithiocarbamato moiety (ca. 75°). The Au−S distances (2.294(4) and 2.310(4) Å) are approximately 
0.1 Å shorter than those of Au−Br (2.428(2) and 2.421(2) Å). The dithiocarbamato nitrogen atom is 
functionalized with an N-methyl group (C(2)) and a methyl ester residue, the latter lying in a plane 
which is approximately perpendicular to the coordination plane (ca. 88°). 
The crystal packing is composed of layers in which the molecules are arranged in an alternate way. 
Each molecule on one side approaches a symmetry-related one with a methyl group, a sulfur and a 
bromine atoms whereas, on the other side, couples of molecules approach each other with the methyl 
ester moieties. By inspecting the packing along the a crystallographic axis, the metal ion is interposed 
at a non-interacting distance between a sulfur and a bromine atoms of two symmetry-related 
molecules. 
 
Table A1. Crystallographic data and refinement details for [AuIIIBr2(dtc-Sar-OCH3)]. 
 [AuIIIBr2(dtc-Sar-OCH3)]  
Empirical formula C5H8AuBr2NO2S2 
Molecular weight 535.03 
Color, habit Orange, block 
Temperature [K] 293(2) 
λ [Å] 0.71073 
Crystal system Triclinic 
Space group P-1 
a [Å] 4.846(3) 
b [Å] 9.200(5) 
c [Å] 14.521(8) 
α [deg] 74.464(7) 
β [deg] 84.119(7) 
γ [deg] 85.989(7) 
V [Å3] 619.5(6) 
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Z 2 
ρ (calc) [mg m-3] 2.868 
µ [mm-1] 18.633 
θ range [deg] 1.46 to 27.45 
No. of rflcn/unique 6605/2788 
GoF 1.009 
R1 0.0551 
wR2 0.1096 
R1 = Σ||Fo|-|Fc||/Σ|Fo|. 
wR2 = [Σ[w(Fo2-Fc2)2]/Σ[w(Fo2)2]]½, w = 1/[σ2(Fo2) + (aP)2 + bP], where P = 
[max(Fo2,0) + 2Fc2]/3. 
 
Table A2. Selected bond lengths (Å) and angles (°) for [AuIIIBr2(dtc-Sar-OCH3)]. 
Au−S(1) 2.294(4) 
Au−S(2) 2.310(4) 
Au−Br(1) 2.421(2) 
Au−Br(2) 2.428(2) 
C(1)−S(1) 1.72(2) 
C(1)−S(2) 1.74(1) 
C(1)−N(1) 1.28(2) 
S(1)−Au−S(2) 75.1(1) 
S(1)−Au−Br(1) 93.7(1) 
S(2)−Au−Br(2) 96.8(1) 
Br(1)−Au−Br(2) 94.43(8) 
C(1)−S1−Au 88.6(5) 
C(1)−S2−Au 87.8(6) 
S(1)−C1−S(2) 108.5(9) 
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Crystallographic data for crystals of IT03 and IT04 racemate 
 
Refinement data for IT03 and IT04 racemate crystals whose structure was reported (for IT04) in 
Chapter 1 was not sufficiently resolved, even if connectivity assignment was undoubt. 
 
Crystallographic data for crystals of Z-L-ProAibOtBu 
 
Figure A1: molecular structure of Z-L-Pro-Aib-OtBu 
 
Table A3. Crystal data and structure refinement for Z-L-Pro-Aib-OtBu. 
Identification code  Z-L-Pro-Aib-OtBu  
Empirical formula  C21 H30 N2 O5  
Formula weight  390.47  
Temperature  293(2) K  
Wavelength  1.54178 Å  
Crystal system  Orthorhombic  
Space group  P 21 21 21  
Unit cell dimensions a = 10.050(2) Å α= 90°. 
 b = 10.460(2) Å β= 90°. 
 c = 21.305(3) Å γ = 90°. 
Volume 2239.6(7) Å3  
Z 4  
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Density (calculated) 1.158 Mg/m3  
Absorption coefficient 0.674 mm-1  
F(000) 840  
Crystal size 0.50 x 0.35 x 0.20 mm3  
Theta range for data 
collection 
4.15 to 59.97°.  
Index ranges -1<=h<=11, 0<=k<=11, 
0<=l<=23 
 
Reflections collected 2158  
Independent reflections 2121 [R(int) = 0.1078]  
Completeness to theta = 
59.97° 
99.9 %  
Max. and min. transmission 0.8770 and 0.7293  
Refinement method Full-matrix-block least-
squares on F2 
 
Data / restraints / 
parameters 
2121 / 4 / 250  
Goodness-of-fit on F2 0.992  
Final R indices 
[I>2sigma(I)] 
R1 = 0.0611, wR2 = 0.1612  
R indices (all data) R1 = 0.0774, wR2 = 0.1735  
Absolute structure 
parameter 
-0.1(5)  
Largest diff. peak and hole 0.258 and -0.174 e.Å-3  
 
Table A4. Bond lengths [Å] and angles [°] for Z-L-Pro-Aib-OtBu. 
C01-C02 1.39 
C01-C06 1.39 
C01-C07 1.491(5) 
C02-C03 1.39 
C03-C04 1.39 
C04-C05 1.39 
C05-C06 1.39 
C07-OU 1.421(5) 
OU-C0 1.335(5) 
C0-O0 1.231(5) 
C0-N1 1.325(5) 
N1-C1D 1.456(6) 
N1-C1A 1.464(5) 
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C1A-C1 1.523(6) 
C1A-C1B 1.528(6) 
C1B-C1G 1.480(8) 
C1B-C1G' 1.487(8) 
C1G-C1D 1.499(8) 
C1G'-C1D 1.497(8) 
C1-O1 1.230(5) 
C1-N2 1.345(5) 
N2-C2A 1.444(6) 
C2A-C2B2 1.519(6) 
C2A-C2B1 1.536(6) 
C2A-C2 1.536(6) 
C2-O2 1.204(5) 
C2-OT 1.335(5) 
OT-CT1 1.481(5) 
CT1-CT2 1.501(8) 
CT1-CT4 1.501(8) 
CT1-CT3 1.507(8) 
C02-C01-C06 120 
C02-C01-C07 122.4(3) 
C06-C01-C07 117.6(3) 
C01-C02-C03 120 
C02-C03-C04 120 
C05-C04-C03 120 
C04-C05-C06 120 
C05-C06-C01 120 
OU-C07-C01 109.0(3) 
C0-OU-C07 116.0(3) 
O0-C0-N1 124.8(4) 
O0-C0-OU 123.3(4) 
N1-C0-OU 111.8(3) 
C0-N1-C1D 122.1(4) 
C0-N1-C1A 122.6(4) 
C1D-N1-C1A 112.3(3) 
N1-C1A-C1 110.3(3) 
N1-C1A-C1B 102.9(3) 
C1-C1A-C1B 112.2(4) 
C1G-C1B-C1A 106.7(5) 
C1G-C1B-C1G' 28.6(7) 
C1A-C1B-C1G' 103.9(5) 
C1B-C1G-C1D 107.9(6) 
C1D-C1G'-C1B 107.6(6) 
N1-C1D-C1G' 103.9(5) 
N1-C1D-C1G 100.9(5) 
O1-C1-N2 122.6(4) 
O1-C1-C1A 122.6(4) 
N2-C1-C1A 114.9(3) 
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C1-N2-C2A 123.3(3) 
N2-C2A-C2B2 111.3(4) 
N2-C2A-C2B1 108.1(4) 
C2B2-C2A-C2B1 109.4(4) 
N2-C2A-C2 112.0(3) 
C2B2-C2A-C2 109.9(4) 
C2B1-C2A-C2 106.0(3) 
O2-C2-OT 124.9(4) 
O2-C2-C2A 123.1(4) 
OT-C2-C2A 111.8(3) 
C2-OT-CT1 120.8(3) 
OT-CT1-CT2 109.8(4) 
OT-CT1-CT4 108.3(5) 
CT2-CT1-CT4 115.2(6) 
OT-CT1-CT3 102.1(4) 
CT2-CT1-CT3 110.7(6) 
CT4-CT1-CT3 109.9(5) 
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Crystallographic data for crystals of IT05 
 
 
Figure A2. Ortep drawing of IT05⋅pentane. Thermal parameters are depicted at the 30% probability level. 
 
Table A5. Summary of X-ray crystallographic data for IT05·pentane. 
Empirical formula C20H39AuBr2N2O6S2 
Formula weight 824.44 
Colour, habit Yellow, block 
Crystal size, mm 0.07x0.04x0.04 
Crystal system Orthorhombic 
Space group Pbcn 
a, Å 22.15(2) 
b, Å 9.599(9) 
c, Å 25.88(2) 
α, deg. 90 
β, deg. 90 
γ, deg. 90 
V, Å3 5503(8) 
Z 8 
T, K 293(2) 
ρ (calc), Mg/m3 1.990 
μ, mm-1 8.440 
θ range, deg. 1.82 to 20.75 
No.ofrflcn/unique 9221 / 2636 
GooF 1.028 
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R1 0.0877 
wR2 0.1774 
R1 = Σ||Fo|-|Fc||/Σ|Fo|, wR2 = [Σ[w(Fo2-Fc2)2]/Σ[w(Fo2)2]]½ , w = 1/[σ2(Fo2) + (aP)2 + bP], where P = [max(Fo2,0) 
+ 2Fc2]/3 
 
 
Figure A3: Crystal packing of IT05⋅pentane viewed along the b crystallographic axis.  
 
Table A6. Selected bond lengths (Å) and angles (°) for IT05⋅pentane. 
Au-Br(1) 2.429(4) C(1)-N(1) 1.32(3) 
Au-Br(2) 2.431(5) C(4)-O(1) 1.27(3) 
Au-S(1) 2.310(9) C(4)-N(2) 1.33(3) 
Au-S(2) 2.306(9) C(8)-O(2) 1.21(4) 
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C(1)-S(1) 1.78(3) C(8)-O(3) 1.36(4) 
C(1)-S(2) 1.71(3)   
    
Br(1)-Au-Br(2) 94.0(2) S(1)-C(1)-S(2) 108(2) 
S(1)-Au-S(2) 75.7(3) C(1)-S(1)-Au 87(1) 
Br(1)-Au-S(1) 96.1(2) C(1)-S(2)-Au 89(1) 
Br(2)-Au-S(2) 94.1(2)   
 
 
Figure A4: Depiction of intermolecular contacts between two symmetry related molecules of IT05⋅pentane. Symmetry 
code ’ = 1/2-x; 1/2+y; z. 
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Final remarks  
The development of new anticancer therapies is nowadays focusing on compounds designed to show 
both strong antiproliferative effects on cancerous cells and low or even absent toxicity on healthy 
tissues. In other words, to selectively target tumor cells without affecting healthy tissues is a goal of 
paramount importance. In this context, the complexity of neoplastic physiology and the peculiarities 
of different cancer types and subtypes make this aim not so trivial to achieve. From the molecular 
point of view, targeted therapies have been exploiting biomarkers, transporters and receptors, 
normally present on the cell membrane, which become up-regulated upon malignant transformation. 
These overexpressed membrane biomolecules promote carcinogenesis and tumor growth. 
Remarkably, their inhibition or channel/pocket stoppage may result in a slowdown in cancer 
proliferation by interfering with intracellular downstream pathways. 
In this work, we selected specific peptide transporters named PEPTs, known to be overexpressed in 
several neoplasias, and exploited them as targets for the site-specific delivery of an antitumor “cargo” 
(viz, a properly stabilized transition metal center as gold(III)). Five new gold(III)−dithiocarbamato 
peptidomimetics of the type [AuIIIBr2(dtc-AA1-AA2-OR] (AA1= Sar, L/D-Pro; AA2 =L/D-Ala, Aib; 
R = OtBu, TEG) have been synthesized, characterized and studied from the biological point of view, 
with the final aim of obtaining complexes with enhanced bioavailability and tumor selectivity with 
respect to the our previously studied gold(III)-dithicarbamato derivatives of aminoacids. In particular, 
the dithiocarbamato moiety was functionalized with selected esterified dipeptides, differing for either 
the aminoacidic sequence or the configuration of the chiral aminoacid. 
Taking into account their application as anticancer compounds, their stability was first analyzed 
under physiological-like conditions by means of UV-Vis spectrophotometry. In these studies, our 
poor water-soluble compounds were previously solubilized in DMSO (organic solvent normally used 
as a vehicle for biological in vitro tests) prior to addition to different investigated aqueous media 
(pure water, saline solution 0.9% w/w, PBS). It was shown that the model compound undergoes 
hydrolysis both in pure water and in saline solution, by exchanging the bromido ligands with water 
molecules. Conversely, upon dissolution in in PBS, a rapid formation of the hydroxo-derivative (not 
water-soluble) was detected. The presence of the phosphate anion in solution may further interfere 
with the stability of the complex since, following coordination to the metal center, can lead to the 
precipitation of the corresponding gold(III)-phosphato derivative. When considering more 
complicated environments, such as the cell culture medium, the formation of the hydroxo-derivative 
may take place, but its precipitation is likely prevented by the interaction of the compound with the 
biomolecules, including proteins, present in the examined aqueous medium. Indeed, when we 
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investigated the interaction of the model gold(III) compound with BSA in PBS, secondary stabilizing 
weak interactions were hypothesized to establish, thus suggesting a role of BSA as a carrier under 
physiological conditions. 
The antiproliferative activity of all complexes was tested in vitro on different human cancer cell 
lines, showing encouraging results, in particular on A2780 and MCF7 cell lines, with GI50 values up 
to 10-fold lower than the reference metallodrug cisplatin. Since IT03 was proved the most cytotoxic 
compound against all the studied cell lines, it was selected for preliminary in vivo studies on human 
breast MDA-MB-231, highly aggressive and metastatic tumor, subcutaneously inoculated into nude 
mice. After 19 days of treatment, a tumor xenograft growth inhibition of 60% was recorded, with no 
sign of suffering or weight loss in the treated animals.  
Preliminary toxicity studies were performed ex vivo on healthy rat tissues of liver, colon and kidney. 
The toxicity profiles recorded for the two tested gold(III) compounds were very similar and toxic 
concentration evaluated on each organ was slightly improved if compared to cisplatin. This result 
was more evident on liver, wherein IT03 was 50% less toxic than cisplatin. In this context, it should 
be highlighted that previous toxicological experiments performed in vivo with the gold complex 
AuL12 ("first generation") assessed that neither accumulation of the metal nor tissue damage were 
detected in the examined organs. 
To overcome the poor water-solubility of our compounds, micellar and vesicular systems 
encapsulating the gold(III) complexes IT01 and AuL12 were prepared, characterized and tested on 
cancer cells in vitro, in order to both avoid the use of organic solvents as a vehicle for biological 
testing and improve their therapeutic index under physiological conditions. After determination of the 
logP values for the gold(III) compounds, Pluronic F127 micelles and DPPC vesicles were loaded 
with the gold(III)-peptidodithiocarbamato compounds, pointing out that the cytotoxic activities are 
maintained also upon encapsulation in the two supramolecular aggregates. Moreover, the loading of 
the "first generation" compound AuL12 into micellar systems based on Pluronic F127 functionalized 
with the cholecystokinin octapeptide CCK8, has been carried out to obtain tumor-selective delivery, 
thus further improving the chemotherapeutic index of our compounds. The treatment of the CCK2-R-
overexpressing cells with CCK8-functionalized micelles showed a 10-fold increase of the AuL12 
antiproliferative activity with respect to the AuL12-loaded non-functionalized supramolecular 
counterpart against the same tumor cell line. These results are very encouraging and led us to plan 
new in vivo experiments with our gold(III) compounds encapsulated in functionalized nanosystems. 
To gain further insights into the mechanism of action of the investigated compounds, some inhibition 
assays were performed in vitro on purified selected enzymes. It was demonstrated that the compound 
IT03 is able to inhibit all the three proteolytic functions of 20S proteasome and affects PARP-1 
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activity, which is involved in mechanisms of DNA repair and activation of apoptosis, with IC50 
values in the nanomolar range. 
The real-time proliferation of tumor cells by an innovative technique was then analyzed, showing our 
compounds to be able to affect cell adhesion in the first 4-5 h treatment. In addition, in agreement 
with literature data, the shape of the recorded curves were directly correlated to well-known 
mechanisms of action of some clinically used anticancer drugs. The curves observed for our 
compounds were very similar to those obtained for drugs acting, for example, as modulators of 
calcium transporters. 
The very fast response detected in cell adhesion variations and cytotoxic effect was furthermore 
confirmed by gold uptake kinetic experiments carried out by ICP-AES measurements. 
Considering all the obtained results, it can be concluded that treatment with our compounds leads to 
cell death by a mechanism of action which is completely different from the one exerted by the 
reference drug cisplatin, for which DNA is the major known target. Indeed, our gold(III) complexes 
could more likely cause an effect at the cell membrane level, for instance either by bonding to the cell 
surface or by internalization after a few minutes from the incubation. 
The encouraging antiproliferative results collected so far (mainly regarding the in vitro and in vivo 
antiproliferative tests and the preliminary ex vivo toxicological studies) make our compounds good 
candidates for the conclusion of the preclinical phase studies. Moreover, micellar and vesicular 
formulations will be employed in in vivo experiments aimed at assessing the drug pharmacokinetics, 
thus paving the way to the possibility to study the antiblastic activity of our complexes upon 
intravenous administration. 
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